var title_f41_14_42208="Linear granuloma annulare";
var content_f41_14_42208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 56 year-old presented with this solitary, semi-annular plaque of granuloma annulare that slowly expanded anteriorly over 3 years. The reason this lesion did not expand in a more typical ring is unknown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42208=[""].join("\n");
var outline_f41_14_42208=null;
var title_f41_14_42209="Bipolar sterilization";
var content_f41_14_42209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bipolar electrodesiccation of laparoscopic sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tube is grasped for first electrodesiccation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42209=[""].join("\n");
var outline_f41_14_42209=null;
var title_f41_14_42210="Membranous VSD subcostal parasagittal 2D still frame";
var content_f41_14_42210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Membranous VSD subcostal parasagittal 2D still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VpKKKAHDGDk89qOMZzz6U2igBxxxg02iigApRjucUlFABSjrzxSUUAOAGeTx60gxnk8UlFAC8ZPNFJRQAUUUUAOOAeDkUDGDk8+lNooAdgbevPpQMbevPpTaKAFONoOefSkpcc4Xmnxxl2I6YoAaoBzk49KCMZ5FWEhUfe+apoj5ZwoUL9MmgCnHDJIfkQn8Kk+zMMh/lI7VqLLEqZO5j7niqbOHZsDjNAFdIAeWbA7VOYYFHyGRifwoooAiMCZ+82KckaIxPX61JtfshP0p3lScfIRmgBvy9kX8qaVU9VAH0qQxNnimlHAJKjb65oAbsVR8uPypCinr1HQ06igBDGjHJHP0o2KTk446cUtFAAMD+FT+FBCnqgoooAj8hP7xFJ9nT+8alooAiMCAgFm59qabcdn/AEqwAWPA4x1oUZHB59KAKbxFXCg5z0pDG4P3SeccVpwx4kPmJx25q6IF8sbEYY/WgDngOM5H0pOevauie2jeLEsa57YFZk9tGpYKSB6GgDPoqVoXXnGR6io8HGcHFACUUtJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFSJEz47D1oAjp4QlSwHAqWKHrvFTouAAuaAKohc444qdIkXtn6075tx5+XHSlzQAYAPAA+gowB0GKKKAClHrjIpKmiRmwCmRQBEAScKhOfSlYYbBUg+lWgBHIFBUN71YEYcNtRmYdzwKAMxlbcoRCR3JqVIDvIZgPSpLkqu0O+0jqB0qIx+ZJnlffNAGhBaDy+XJJ6DFRXEb2zfOmB67s/pU0NrJLGpVyVH8QPFLJab0YlipHGBHz+dAGWzeZllyRTGG5cHOKsiBowFBBHbjFPWz3PlpdnsKAKajAwAcCnMuyPcx59hWla2qrKQZ41Gesjda0Rp9vKgLXtumOcBv/rUAcyCCMgjnpS1o3lkqMfKubeQ89DzWcBggEkkdT2NACOSFyoJOaM5GR36ZqXzgPlVDn+9TCSRgnigBm8dMjNKobaTICD2296lScKMSInp1odwzDAxjpQA5N7BRgKPU01l+YneBjjgc1aV3jKqynnuozTzCZXI+TJ7HigCOzjLEl85HQMea0LOAq7Mwymf73I/CprDECkF2LA8KwrTiWS4BZYUlA/ij4cf4igDOuZ4tmEKqc/xpWTdRM+543Rh9a2LxJIpdskC9M8jr+Hasi9Rcq0aiNu4XoRQBQ6Drk+npTSOD0pzeoGBSfxY+XHueaAGGMMoB4+lV3iZT6j1FWz1NI4Y4wcGgCmyMpwwptXmAYEHpUbwKR8pwaAKtFSGJxkkcDvUdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUiRlsZ+VT3NADMGpVgYgE4Ganjtl2ht25T0p59KAIBBhgc8VN9KKKAClAYAleo9aAQDknGO9SQttXcy7g3T3oAWL/VksPm+lQsRknoPerkkz7dpCBfQ08W8bRbtuB/tf0oAoquTkd6VVLMRUirI7qkW3aD0xUwhZickLjuaAIxCgBJc8dsVchO5Mx8Y7U2C3MrNvVnHetjTNMjnkUZXOcgDk0AZ8Gnrdt5jIw9SD1rUg0xY7fLxO+7gBRXZaRpGnJj7ferHnszAEf4Vuw3ng/Sw3S6IOD5eW3fU8UAeT3uirGP3sbgj5gq9qp2+kXBkMwRxF6NxXpGreNdNVimk6PBGV4Bkk3FvfFcjqfiK+1DEcyRx7uqhdoH4UAPt4luYNpleADg7RxUF1ptoqkQyzNIO7ZOfwqK2vIVUKzu/OMR9K6CFGurcLAnmjuSfu0Aci1tFb4kZTnPPHFQzSRckIhOfWt2800G4JmmU7eQuDt/wqpcW2V5hRF9VoAxHnJ3eZhVA4wKaJRswiAj164q9LDbRqdwRT6gZJ+uaSSyQ4LGPZ164oAy5Pk6qWBPQU4rBKSq7g2KnuNsEhKJndxkHNVxlCCDn29KAIyuw7fSkHI45pxGQWPBJpqHBOBjFAAV5ztGaRs7Ttxn3pyPzyhHvTsEtleaAJEuW2bS43EURTsJE80gIP1+ppDbkoGKrx3FJHE8owoJ20Aek+HLiOSACSC3cDtjP61rzwWTjMdobQt1dSSPrivNLGV7dMrKF7EE/4VPHqupWswe2kkVT3DEj8qAPQJ9IVbUlJ0uU64kHzCuC121iSU4QpnOdpyK1ovE6z26R3zPFL2lj+XmszVL6KUgSYuAf49u1vxxQBzrQ7VOCcCoiAeSo/EVbuyp+WJmyRwpHSq3IQBj8woAbRQrEE4HT9aVmLc4z7CgBKKKKABWAfBHaomjWQFl+XnFTDoeeaRUOPlHFAFSSJkGTj8KjrQKhhgDPqKieBSeDj6UAVKKfIuxiOoplABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFLQAlPVGZsAVJDF3cfgasBSW+QAk+tAEaRKo5GTVm1hknBDA+g7CmKrecIyo3kZxnirtnDK6uUTEQ4Yk9P/AK1AFe6iit2WNXzKo5A6YquM55GB2q6ttCqbY2LnPzHtmqzqVY7mUqOu3kD6UAMopQCe3HUY9KVMBufzoASMbgfMHT071ZitnniGEZUBz71HkLzxUv8AaEoVUTag9hQBLa20Rc+fkqOenSrEiQkfuImA9SSaisXWeT94S2D164/CrtzKsxKRWrEd2PGKAKlpbs8rZOJOgA61ZtYFtroyXEeccFi3FJHcw2YDIGaQ8fLSXFy10d2xRgYAx0oAtXd1D5w8mIoP4vmNQJqDLLiBlhTvt4zVFdrPhmw46jNSqpkZYo4QWJ64zigB7pLcP+8YsCD827GfqO9W7JpIQVAkIAwSMjI9Oamg09kKF0Jf0Ucj866GztZS0ZkjVICOfODEn6CgDCiWzt8O9lvA5A3YqwlzBen5LYRIozhUy35mtubR4bmUx2kcj46oik/oOlSaZo32fzY7wJCrcDfkAUAc1KI3LG2gVVUclj1NS6beeSmY1AI6qmcGugg8OiaVkF7EEJ42k4NTWHh2Gzvwt1cvNag4ZYIy5H1FAGPJOsvP2dRIecZz/PgVEJtjsUjbB6jcGH/1q9C1HQrL7Kq6YLiaRhkJLtjH61z15pT26hHiaOY9uCP0oA5OcGVHFrbAE8kgZP61jXEJSYrJubPBXbxXaXul+RCChdn6kJxj61kz2sjxhWt5M+qnOfxoA5a4UKSQGVQO4qGGNCm7fg1r6jZsq7idhx90nNZKxYTMqgk9AvagBkiDkKSe+TUK7QASnJ9auogiByR+eagl2swK4x2oAj68ElfrSNEDgFjn2OKlw5jDtGCc9M0mMruKqD065oAdFG0O9fM3A8gg5FSWl6YptpC59aaiosZKBQf7tNaJXcAJhuufSgDp9MfTZQxuraWMnq8TYqXUtOURGSxkM8B7KRuH4VzaSPbkEEjPBycirIuD5BZJlJ/u0AVL7yxGQwyB/e4NUlkxGQo5zgEHNWJJPNlO8g5PAx0pJOFxtHJoAjUONrM+T3pC6kkEkk81KUIGT0PamRBRITIoA6ZoAYuAeeaVlieL5GIYHNOcKrgKpIIyDinFl2Z2gnvQBCcdc4HvQASCaVlR34X5akTrjcMdqAIaUBsZGaUL+8KnOPUU754n5GB2FADeeDtZT6nvTands/ePFRsRnGPxoAYACeSAPeo2iQ54/KrARGxkbvrSSLtJGKAM4gjsaSr5AIweRVaaLbll6enpQBDRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRU0cJJBbgdaAGCNihYCrEMewZP3qkHA44ooAKmhhllbcgOBwcUyOMO2GbAx0HWti2lSAAQQsxPc9j70AMhs1tolmvgVBOAi8tJ+PaoL/AFJp1WJQsMS8JEp7VJdmSYGS5kVX6bQeKqWkYml557Mx64oAVUeWLksqDsO/1qa2gQdhgD8B+FW5ikRW3thubgE06TTysZM8uwddvp9T/SgDJJUO5TB5wTjiocDec9K0roWwQR2wZ27kjA/LtWcYwEBUgjPUUAIW3EFQePWnK2QScUuySMc8imRISWbJK+mM0AT2peNtx7nqBjFdHaTh4hFDtXcPmdjWXpFhNeON5JXPHy4x9ankggtZyZpiFzjaF4oAXUYxgFPL8scA45b8az0djlVjZs9ge/1q7fann5YY1I6EkY49qrpIGjVlOwf7vNAE1tYTMd7xhPQMeR+XNb2i2rBvNkEfuBx/OubM8qblWUKp4OFrqfCFgLpsyhpSmOSwVB9SaAOlsV+YSGBCD2AB/U1rvNZsuWtb24lX7zyHCAewHWltNLSfB+1W+O6x/dGP9o10M2q6NpummF1gJC8tuJJ/xoAzdG0oXbGW2jeCF/4XbYuffvitzSPBsc9866nq9tFH1CQRF+PrXJXXjDTb+ONbKwRJFGA6IxLCrOkm/vJ92nxy279Cxdjn6Z4oA9Ej8MWMUbi1gluYwPlkaURDNY9zawWkh8m5itJE+/5JD8+571NBoer31usc1+3mMMsJM8e5PSrM3hb7PBHHdapDIOh8mIEt7cUAY8XiCS0gb7SsN/ZkEPLJKFcfQVnwXenSI5tLS/j3c4GHH51f1nwvYEK6yvC6nkSWzPn6HoKztMt9QspGNvds1sOgQA5+uaAIoEtPNYi0mAbgmRc7vxqvq3hU3mJl8u3T+46FR+dXJWtJbhpZboSkHDRHgj/dArotG1zw1JAba9t7lNvH70cH6UAeG+KND+wFlRRIM9UO4j8+1cgd4bDAADugyDXt/wAQtI08hrnTzMI5B1wSBXjl9avazEF1ZDyCD1/CgDJADysvJJOfu4oldEKAgAj2rSFuWUum1DjsQDVaSLau5+/Qnk0AQFxjAzzTEJI2rt4PJxUrRhU3biRRFkAiKMMp/WgCO4Q5DRnJHUDin+cd4G3HvVk26rGGkdBn+HmoAuE3EYyeC1ADriJvKLKRjrkgmqqYKDCduvTNTyPNDj97uX+4FyahfMgzGGVj/f6UAId2CAmCe9Cq6nJxTmT9z8gZieOtARFJ3B8+1ACKCWLBvlxyDSlCyMy4wKjkSQKcFPK9O9PSPkDJKkc46UAErfut6KcrwRUAbyyWHPsattsgj2qOD0FRNGpj3bwAePpQAhO+IMCEJ9RSCLodwLj2xTpE2ooV1J9TSgHAyQTmgCMgsepVh6d6lLOVG8ZNIY9rBmOW7Ujt5gyVO72oAY5G9Qc80xwV559eO9P8t/LOAuRwCeuKBucbMYPr3oAaBuHGQfWgA7m6knrTwJBhD07tR5ZbPzkGgBhUjqKQZxzgmn+Z1DLyOPrSbS3IAxQBDNGXxjAxVd42TqOPUVfZSOablCux+C3egDPoqaWLaflyV9ahoAKKKKACiiigApQSOlJRQA9EZh8ozSYII9fapYSvlkOevvWjrWrS61qL318LZZ2VExBEsSAKoUfKoAzgcnv1oAoRx7m3uPoKmpTgng8UlABQKCM98VKGDJt280ALagCdDjnru9BWhcagETybRMFvvyNWU52KCcginH7y5b3oAGd3OZD06DvVqzVshyegqEKszBiv3eM5p8cZlYqOY+47GgDSgmjQ7lJEmcZIp0jzM2EQvz1bpS6fKgcCTbhTjLcAVpXl7E6bVyEX+LH8qAM17JIgZr64Vf8AYQc5+tZt0kczFhHhVHA9K1mRJIxIxZU/hUnr/U1Wb9+wiiUO38AC8fl6UAZDR7YgsbsT+dWYY40bMnORzirVxa+RKBLhpB1wcCq3nwxzERqXPQ+goAvC/liTbbkH2Y4H41BO09x8zyFhnIJAX9KqfPLKHC4TvzipUfEvAJA75oAY0X7w5kBU8VMtthdoY4XkU+CUNI+QHB6KBjFaFlAGZcRkkc4z0oAoWsM0kirs38cb2xmtuK2uLcx+bISM5woDKv1rU0nT/tNwJJIl2r/E3b8K2tVs5bG286WbyYj93cACfpQBnDWfskifZXImIwZJSMkf7I7Cs671GB7xJrySRxnk8fyrD1NhJKWUgueQxXJH1NQJslQ5bOOvFAHa/wDCQ2cEQWxiG88buhI/pW1pXiu4g8pIZPLz0J5xXmsM6YMa7iR2U4yPetLSnE1wGuVzEBgbRigD2G18XXe9Y7eCCU9XluQWH88VuP8AFVNLURzX2HUZKwxJt+g9BXg+r3bgmOzDHHJA+YkfWsdHmcEy4EfQ5GDmgD2nxB8WtK1GRPOtrsq3JYtnpXPaj45t7py2nzXMEAH+pIHzCvM4w6SbAQ2fxxRcpcJcx4Xr1xQB3sHiBGZpUtYyRySw3kVr6fq8hnikjjVmbs0eEA/CuAshOBs3rGAN5I6mtu3muX8mWC9Cx9GULgj60AetXMUOsaYbdRbI7dfKhZufwryjxXoAtZXV5WMozhjEy/zrtPDfiCW3ZrVSDz/CCC/5Va8aaVNf2QmHyJjkySMCfbGaAPChvVuPmC9TnNSS6nGsZVrdXP3egP41o39msTyRq5Mg6x46VltHjlUGAKAI/OiePKx4P901Ys1CFnLNFx3GBVACMEtKMgepxWjZo/lbREzo3Zh1+metADpoYJIWdN59yODVVIwQQsi5/wBrtVu+lDqqxny8DGNuOaoPLtfBG4jrt7UARonlyMrsC/qOBig7gATtbnPWp5ASRvX5SOneoWAjQFBx6elACiNGQkfKM96jJUkZHyg9qdMzRop3cZ7ipFeN4lKsMg9V9aAGsvmEeWc57Yp3lLGV3LyRTlcNJkyPv6ZAwDR5ZG4uV3L0AoAgXDDavB9DSSxcbW/HNSAq4J2jcDnrSSu24knIPTAoAiiUGEqSBg0+KNmXaPlPYmpI7dApZGBLckE9KZLuXg8AdxQBDcK4Bjkkwe7djUsXlgZLKQeA4PJ9qaMO5bBK+9QxyHc48nIJ4GcYoAfKjRsSCT9etNWTKFiDn071LhXzuU5HSlCbxlSDQBGQZAGHQdqej7cbQG9fanKvlghl5Pam7VDKyxkgnGQelAEYlSRshMKTjPY1PLZuoWSIhoWGOOaLqAxgbTlDyMDoKtaVO8bMgBki6vGv3gP7woAzpC0bqZVAU8A+9XksVvID5BHmrzhu9dNJ4UafShqNrILjT34Z0H+qb/aHY/pXO3cNxpdysiICoPUDhh/hQBlCMgmNhsdeCmP1qCW34LDjFdPNFBfbZ4MBiOUHQf7p9Kyrq1aOQ5GF77uh9v8A69AGOyOwLHsdp9c0xgVOCMGtnUNVlv7WxhuPIVLGE28RjhVSy7i2XI+8ck8msiUhnJUYXtQAyiiigApRjvSUUAFFFFAE0B/eYBwD2qyOelUKsWzKoO5se1AE9OQEk8kUhI2fL949zSk7UXHzFjjigAAIfuw/lT3VQwywOfSkEbqc9PY0sEZ847gMN0oAkhZS4XBK9OlXxEspEcfCjoF4zQluRGufkHY9zV9bR4YD5aZY8Z7fh60AVE2QToGImPTYKv2tt9ouVaaPfg52EYRB6n1qvHbSpKcNGm05kbrgeme9Tm4aSTMc37he46H/ABoA2bqGB48Y3E4G1eCfqapTQyQKY7aNImY5by+Wb6mrFhbnC3MzNsPIZxyx9h6UuoSxooWISTTsMlj91B6n0oAwb22UqSVG8H5iTwKqLA3lbVjXb13DvW/JarLapLsYIOrY5kb2FQz2bxW4DRNEv3iM/Mf8KAMWS3aKHOwtnnjtVZZoS2xMhwOQRXsPhr4b2GteDdB1PUvE0lhJrLXK2tha6DcX8h8iRkY5ick8AHlR19q27P4CaNL4evtch+IMI06xVzdSSaJIj25QZZXjaYOrAfwkZ5HHIoA8RaLYqlAM+oFX7QJGrO8oJx02161d/A21k+HeoeLtH8bR6lYW1jcXkY/sl4vN8pWJX5pcqcoV5Xj0rx+QIgAilAKctkdaAOgspbmPY6svbDE8fgB1qz4gvLe5tzbmR5Lhl+cyms37az2sJhB83gEjgAfjUl357AMkiNIwGVHOPqaAKdrbeZbPEHVQowFRQP1NVpLQ2YAIjcv8vynJq/cM0eU3KUPLODnBpsTShldZVY9sj+vWgCt/ZxhjVog6nryOMVtaVDDHD+9t5WLDK5OM/nSWN0wl89zJPt6Blx+FWL7UDqLJM5MPlDlDigDmbrzft7PFEYlJwcyHgetVSZYC6qC4bnJbqKt3cxubgneiRg4J3Fi1SIRLhkkVo0GMYoAqrKY4UVlDs3YVWaQxTrsTcCfmAzxU9mmxmGQu5shielV5mZJJNqu3OC2elAFiHUJIHZonO09zzgelW11a5fHkYZMHqoyfzrERth8sHzFbnirSBRmJ1ZWznIoA1dN8RyW8wM1uq+W3zOq8j3//AFV6X4d8RaNqNmbbUYrmZ1BZfLmbew/HivI5EUIRcAsf4SOoosLmSxfMZUnO7DjP5UAdx4muNC+1f6Hp1zCCfm8x1J/EgVzV1YwkSSwygoRyocZFMv8AWUu7YrKpVmGCMYwfasWOCOVtvmeSR0Iyc/WgCVLfEoXAkLdAe1dNYmSNU8yNZwv8Kmuf06CW1uVO8yDPBXrXrvgubT/KeWe1Fy5XBVkAx+fNAHl3iiaNpgY7V4SByDkVhyvCACRmTHHWu/8AHU0Go3jJZWiwMDgqCTmvPrgS21wRPGU28HdQAxpZndFOCOhxTn8yNWDBSBS9Tu3Dd2qHDM5D8k9aAFQtIdpwR1qVN6fKoI7j5eKdbREMfl3JjrmrBQMQINwx1BOaAInkyAzkbu/HSkkDsC2wH056ihZHRmDoqnoR60vmDbsjGSPWgBkEq5ZJIyjHgDGc0jq6khUOT0OelSxJGWDklJB3Jz+lDyFzxhvXHFACAMyhWPTqe5pvl9Act361KyEIrADae+eajZHVkKFduOcmgBwHGVHHpVeRwsvzDaPzqxHbtguzjB9DQ0O/CblznpQBBLHJIAEII9RToY5I+SBtbpjtU4tHjYorgZ6E9j9Knhs5yAoQlgOD2oAzZxvYFnOKVwUTdGSR3Fao0q5kjBePaAcH2NVVhaJnBTOOD60AQ2c3A+0ZEJ/iP8JrXk0K5t7db+1BMIORInOG/wA9qy7KZBMFb7mfmBHFd/4M1FdCnYuEu9ImO2eBuduf88GgB3grxCYLrzLRoYr8rtntJB+5u075HY1teJ/DNvqmmSaz4VTdbqT9s02U5ktm/wBk91qp438CIsS634YkaWwY7tg+/C3oa5nRPFGoaPq6XUcxikUFZiwyrL6MO4oA52WwVFkntXMRjBMiE4Cj1A9M1jX19JdxKJNqxg9B1atfxprsGtapNcWdqtta55VD/rG9SfT0HauYYlsZ+lACNjJx096SiigAooooAKKKKACiiigAqSLmQcAnsKjpwJRvQ0AbOnx2Elhfvd3NxFeoE+yRrEGSQlvmDtn5fl5HXJpk+Eb5cDHTFZe93BBOc+tWLWYFQj8knvQBODKyh2UgnrUls21g5Qk9BTpg3I3bVAp6pmIEP8o9KANrTgm4XN+yhF/1cOevufb2pL++a8nXyW+UHaNvGPYVlKpnZRtJAPU1tabbRxRNKGDOo+UHoPc+tAF23treOEfaX5HPljqT6VPNBFEFHlqhYZCdePes62MscwmfLyO3Bbt9BU7tLLOTPLgHjYByT70AWryWRrZVST5mxjnke/sKtRtbx2sUS4kZjn/Zz6k96yJrRWfy4/nl7gc1s2fh820AvNTujBn7qJyxX2Hr70AWGjuMM8aEYXHnOMD8B2qlqVqsNkst1cGa5I3CFOw9TW7cXwe0hRLcxQvwiOfnYerHtWayQ3M5EcQlAOQMYUn1P/16APW/hguoXGh/CH+x7m0tLtm1xlkurZp4wPObIKLIh6f7Qx711fizw3d2tza+GLKWDWdc8Taj/a+sNcObWCS2twmUwokMaFhEg4YnJBJ7eI6b428e+FtIj0/Q9cksdMhaSRUa0t2RC7s7AFoyx+ZmPU0QfGn4gskjS+LpEAGFH2G0OT/35oA9gvpb/QNG+K3hrWbW1sjqOj3uvWMVtctcRgPE6TqHaOM8SANjbx5n4n5RijjaYu7loxztzzmu41f4w+PNV0q90zUfEslxaXcL288a2dsoaN1KsNwiyMgkcYNcraxRSQrMsiRyDjaEzv8AYZ6UAVoI1ldlaXcg5G4Z2+1Xo45ZxtJlZVPJUYzU0cSRwoiW5clgXK8c/hWgLBnnXz7mQZGTHH1x744oAz2lhtNpuQXfPCOKuaV9nvDI4UqW5IPygfjWudChltJJDBdSIpy0vAwPQE9aw762urUokUEn2ZuPmPJHoaAIWvVzNFZTRw9sKNzN9CaksfMFqyxI0j/32OMfhWR5gW52kfOOoxWjaS/u5SjZZRkv0B/KgCY2zOp8/PyjOxUxn8TVIhhiJWVDnLDv9KtrqNzI8MYTywR02biffNMuE8ueQ5jkc8g4wc0AVpIwEkcYIA43DissT2+xla4AkzzlgBWhLDPNtDv8wGdq/d/GvqH4Gavf2Xhn4X6Xbz7LLUDrJuYtinzDHO5TkjIwSehHvQB8krJC7blngTHqwFXzLZSRBpZ7fKDAAcZNffHxO1u90XwuRozKutahcRafYEqG2zSsFDYPB2rufnj5eeK5CbW77WPgT45g1yYTa3pVjqenXz7FTfJHE+H2gAAMhRuAB81AHxrItussa+U4IGRJ6n0qpcTl3IwN4P8ACa2pPs6W3AZEK/LnnP0rBWBlkbcwAxk8YNAD7uYTRgKzjbwcjvUNswSYMq8jo3c01cNuW4yU/hIPNNijOQitsTPBzmgDrPCVv9pvsB8MvOExWvrWpJpjPH5e+U8Yfof503wdZxrbGaZjux8rAYH5is3V4mnvid0mxiTgnjigChNeTJLGyOVPUhTnFQ3l/NcJtn5B6OetCmGOUlwyuDgHFST6XLd2stwzTIq8hgAQfqBQBkS794wN/YHIprROrKWIDH1p/ltGq/KGY+n86Ck42ysoOD060ATC33hQZXQn+70/Gm4aNj/Cy9Gx1q1aShT+9Vif75Hy/lRfZ845OzaONvIOaAKDZZw7Mjt65qSSJ1j81gMnnimvbKZC0jBdwwcf54p9tFPvaLgxH7ozn8aAFlkWRI/Ni2kdHXrSTFkcHGfwp77SRG5dGHGF5IpokkjkVVG7/eHNAEe5DLtz8x7YxUxiJxlcIB9c0qo9xLtUBmzhlIrWs9EMxJUyRbeqnkfnQBlyxKIFKIdo5wK1tP0T+0Ig29lYcg47f1xXSad4b85Bh2kkQZaLjdt9R6iup0i1tbaPNpsJxkwnr9UP9DQBj6X4JaSCMXaFo3GYriM7gfbPr7Gtqw8LRWU6LdIJbKQ4juouqN6MOxqqPFL6HO01gAbZj+/tW5Un1A7GrLeO9OvUeS3UxSOP3sD/AHZB6j3FABrnhe4tJCY0VkZfkkQfLIvp7GvN9UtE+3sGBgnjH3j0Hsw/rXpOl+O4IX+x3xL27fcLjkf41S8UxWGsRfaLRkW5UcEdHHoaAPN0soZZpIbweS5HJHb0IPcVXP2vR5fKlYvG4/dzL91h7+9Wrqfyi0EgDBT8ueoqxYzxTWssGosPsxBYTZxsI70AdF8PvGkGm3EsWqXTLpDRNuZU3sj4+VWX+6fXtXB+NNZg1nVJbmytvIsgx2L/ABOf7x9B6CsfULmN7hxb/NFHwjdNwz3qgXZju447UAIzFsnoCe3Sm54xS4O3PbNNoAKKKKACiiigAooooAKKKKACiiigApyZzkHBFNooAuRTlhtlI2+taEJKKSQDnp7ViZOMdq07O4fBifLMcbQoyT+FAF+JHkKoXIY/eq8ZPKhCrjAPY/zqioaIyCYMhHBVhhgfTB6U6FTI42/KT2PUUAaFk88l4oQtLOOg6Kn+0fatAR4mIjdZJi2zcB3PXb/jVSKRhB5Fs6xJ/wAtWIyz/U9h7VcsDIqo8Z8hF4Dlcs3sooA6YQ6ZoNmPNzc6lJglAeF+vc/SqaX5Dme8Ul25AAzt/pUKPZw273EuXkJwATlifrUVrdJcSGSaN9y/dQj+QoA1IpLq5/0iRVjV/liiPLY9TW/oeiQ6e82oXp8xwu7azdfr2UfrWfpiXDlZHjSCMc/M/wAx+p7fStG71Bbfak7K7j5sOMKnvj/GgDmfEGpT3iymUgM3IwvAHYDPSuB8wu03nsUGexyxNdN4iuBctLdmUmM5CIDjPrxXOAAMrsnToqigBdOTdOQAodejFcgD/Gup0fThJMN6hQerSetc3CfLlD7zHzwK7jwxai4t2cRPNg/PNINqoP8AZ96ALE+kxxKEt5nIH3m25BPoDW5DpmnWyWlvFuLt80p3YJP1qE6hFbWzO8kskMfXYoEcYHue3cmrui6p4XttInutS1zTpWySkX2hHlz6YBz/AEoAsapceREraZHJIqcAAEjPrz1rktc864U+ck0aN82H4ya3I/HWirtSO5tEhPBPnKHA9ucCq3iHxVoOrDyvtVnGka4UmZWyO/IPWgDy++YI5+XZzg/N1pbW4mYoBtVf7oNaWswtIu+2T/RmGVZFzuHY57Csy0sVTZJKQBjJA6gUAapkiklZozNvGN+1sD9KUbgTJECwPOWOefxq2wdo43t2iB7jPOPeor9TBskQ8y9TwVA9c0AU7lmyHuACAOU6fjkV7p8Mtb0+08IfD+/tdf8ACcV9oz6qLiw1bWls3xPO4Xojkcc8qMgj1rxPYlvIFdzMrd1PBP8AWop45g7F08u3xwOKAPqPVNc0Hxf4i0a68WeK/B1hpmliaWODSvFRMslwwVUfzFELKFXzOhz83oTjI8R3fhPRNM+Icmg+M9Cu9N1rQJlNtNrv2u6e9WKRFKl3ZmDIVXG4nKgAY6fL32dcFohuC9MEcVPZQ4XBJyw5z3oAsbN0yiJx5LAjauRis6+s3SZF3YGMbd279a0EkjESxSIqSnqQTj8KSCAz3qqFcqRwGINAFO109ZA5cMVj67COvvT7e2Z7mMRLw5HDqAK6XRbNftj+ekMcKcNgZ3fUV1c3hmBbaMPFGZJXBQo5yvp06CgCtpNrHb2EhurYFtuQ0bHAH0rA1US2aGeHcd3QNH1H9a9HuLA6fZ29uLxGuGOAAfM/76Ujj61y3i60dW8mcJK/BV84x7AdqAOJWGMtzsDP8xUtgqadYXl1p9xItnKGjYfMCf8APFaMyxyWZzbI235dyDn86yL4xwQKTEqu3A2nPFAGffPLdytKFjj3HkJxn6VPZWqPbu0ze237w/HHOajsrKWSUeVnIXO5edo9K0be2jFwomiYlepzigCmsccEhEQZhjkE5qC7kWcj7MI128EoefoRW5qMcJj3whvk67Vww/xrEFrDLKREdjYyTkc/WgCtHIglWOb73dRzkVJNMscii3cInbI61JJZC2O6QgsOT7j29adpVj/aN6IoEJIORG3GfpnvQBTDzz3GFjYsPauht9GF35KXRdWk+63Taa6TQtKtrS4E7yrLs+VtvDx/VTWvcT2qzDCLIvUqB+o/woA5eLSL63nEF4qAxn93Kwxu9if8a3ra5+yyhosR3C8PGwBB9iKXVb57rbbW2XDL8pPb6VhxW1yGaRiCy8Mp56fqKANTVtaslYAxyQSqcqIyQUb1U+ntWReajLLG9zuPmD70igjd/tcd6l1G4Wa0Ed/a7x/BKp5/PvWd5jwwsYuRj7p7/X0oApLqz3cvJO+QYIYdSPWqSO8N5goGGc5B6D0onhLEm2BEmd2zuKsxWguUE0EjLcL1Q+tAGhO8c9kDncBzgcY/HtWauoSWrBw7tF3wev8A9emPdSNvVVEci8OB3qBQyxeY8BWJvvBwQvHXB6Ej0oAv6r5VxB9p3KSoyz4wcVyl/fyTRGFMrbk5Gepov73zlZLdmSAHv1b61mk5xzwKAFdixyenYelNoooAKKKKACiiigAooooAKKU4ycdKKAEopaSgAooooAKKKKACrNpdPa3EU0Luk0TB45F4KMDkEfQ1XzxikoA2hqZ1C/ubnVZpJ7u4kMrzyHLOxPJPuasOGTiI4yeT1yKwA3zAsOgxxWpp9+zbYpmzxtUn+tAGnbhlQDPB52+p+tbdpeCUCPdsAHzyEYK+w9PrWG7EoDgADjip7KZY5Y2nBYfwp6mgDdvHErxCIeXEPuuwwX/3RV/TdHuXuURN7N94oOSPr7+1ULeVJb9HVGuLokBc8gH/AOt610Lag1lbCCzmyxP71ozy7em72oAvx6bcxXm2F0fUMZbHItx/LNUp7H93JNJKJZMn95N0J9QOrGmQX9zNaNDaSiCNm23Dxclj/d3VdttLuLu6SGwhLMwy0z5IUf40AcBq8biRHdzLMDgggZx9B0qukUryAyNt9AvX8RXc6jpf9mvJaOql24eTqxJqnZ+HX1S7jtraI+SmBuXjcfTNAHJRWM7XBkdgFBAVm4yfY9673w/b6lHHGj3MX2dh0IOD9a3dX0XRvDunH+0mivdQ25ijPMUR/wDZj79BUOkFruBmkkit0C5IR8/L6UAYHjMzJpN8BKj2/kMMhsKDtPAHc19RfFbW/Ev9o2eheBLlINYS0n1W4YwrKTDGpWOLDAj97IQuRyNpxXyr4w1A3Vheww+UkKQSemW+U9K+ld3wuv8AxJrWs+JvEvgnXbi+eNYFvJrWRbSGNMCNN7t1JZiRjJbpxQBr6v42utZ0zwTF4VljtLrxUxZLmVBL9kiSEyy/KcBnGNoB4ySccYqe+vtZ8IeKfDtvfa1c63pGtXLWDfbIIUnt5vLZ0ZWiSNSh2EEFSRwQe1cfbW3gOz0tbPT/AIkeHrNrHVJdT0aSG8tx/Zwkzug2mQh4zuk4+Xhsdga1rfW/DF94i07WPFXxJ8Jai+mb2srWznhtoEkZdplYNPIzOFJAO4AZPGeaAPmTwm8ElhYSXI+0oluiGNTyMKBjFZ/iq0nW9J+zPbxMNyRHhiKv+Hr2PT9JsGt5GjUwRtKVA3bto6E1H4hvZNfaI+XuCn5mY5Y/7xoAytKl8tBDb+VGQcsAu4n8TVu4a5kttzCKUBupP3R6Y7VFAktpcee7bIuEI4G4+me1W51Mga4aNjC54IPp6GgCtawOwG5vLc8oSP6VFqXlCIPK8pPQYPB98VPKUkdphJIJEwCS21gPY96qXbefNKokiEWMcnccf40AZtpcIN2+22xty0hxjPv71YSRfNVPKO05wAf60yJMPsif5ui8cGrcMNy7SbdzyLwSB936YoAereZbMHRcnIC7QSPfNVrWOVTH5ZMZjGdyn+tX2iPkKQzmTGct0z6YqrYvMs3ybVG7mPbjI9DQB1PgW0Mt+z7mLXAKg8DP1Jr1Hw74OYSkuiKI2DKwkPQ9+4NcTp6wxWaZeOFgQ6uq5Vf+BV6V8NfFEenai6XUvmRPxtRsgmgDd1Pw3NFLbpDcC4QruWUKud3oGrzHxpBNPdNaTGOJ1ORM64P4nFfS9vLa3doJA6TQPlwvkg7fYgd68y8ReHPt2rTXUSRSQ7cC3kYg49s0AeD3+mxWYAf5Qy9OGDe4xWDqMBa3jjMcWwtwOVP616X4m0d0cxQQbdjfMufmQ/1FcuunS6pdvCrGTyfmMjL9z1oA52GwntZY2JwMc4Xp9auwwyyXDGZA0RGVKjGT6VY1K7uLS8VZJWaADaCoAEnsRTJbjT5dPkK2s0BY7gy4wT9CaAKF2bNpDHExSQjBQrz+BrIhto4nWVpHwSVUlMj6MKvQ2k94UkSN2K8fKuGI9x2rftdEmlgcCN1mXjy5vlLj/ZPegDmxaxyFR5CNuPDocitbR9GeW6LlghiGVGfm/Ktu30OCSyZmtl85DkbMqxx2ZfX3FMexnAF1bIpjDYbD5x/gfrQA6/1E6hCIpI1N1HgC4VQJCPRvX61lSG4J/cugkXggjg/X0/lVy1ncySwXkO+P7yP/ABJ+IqWEiS62TABlGUkPBH4/xCgDPsIpp2dVCGZOXhz933HtUMksvnrNNK6MrbS/Ur7N6j0q1emJdSQyx+XIhyk8PDIfp3U+lS3cttcS+VdIYbmQcSKMCSgCG9uGtk+RFMcn3k6o/qR6Guduo1cl9PbCgcoDyPw71bu55Yd9uw8yIfdLDBB/z3qHSrRbm6V4XaGcfwf3x/snvQBQG+WIeV/r16xMMFh7Go1kmljZoxieLIOOG2+/rWxrCCB9sqAjPHZhWY4VZxNHOY+MmQj+dAFHzGeTcSFXGd57is3VNbu7ywi017qU6ZayvJDBn5Q7Y3MPc4FRapfpcyyCFPKgP8IP3j6j0rLLEgDsO1AA7bjwMAcAU2iigAooooAKKKKACiiigAooooA2/Cf/ACEZf+uR/wDQlqz4x/5dP+B/+y1L8PADrU+cY+zt/wChLV34k4A07AH/AC0/9loA4miiigAooooAKKKKACiiigApykA8gEGm0UAadheOSscpJXsx/lWqkjFgSVVO3HWuciJ2sAcD1rs7u+8MHwbpFtYWN7F4pWVze3k0oMTp2A/DGOOMHOc0AQwXTKjpExRn+Ut0OPSuh0uzD2GRLsX7ufX2H+NcnbRcFm4B4XI/PmtFbpw8URdjtOMg/KPwoA6/z7W1htbSzUPHBzI4+VEz2Hv6nk126eJLXTtMRvPCOw2jy05/D1Nef28drHAs00rOsZ3MSO/91B0/E1jalqoluvOcFFB2xqOcf40AdTf6xbTXQ3BEiU5cyN931J7k+9aF58SrOy0prTw3bBMjDTunzP7+w9q8ykvAzOZF2g8bnFEbGbenmFxjgDgUAabXt1qFw8mpTtM7Hcd/zE+wA6VrzxvaaViOOaONjgljln/2VFY1i7LIyWduxlYYOTwf8a6C0eV2VWlXcARhjls0AZlpaSJdi4ESpgZCsRtQ+h9TU9xGLkfbLpjJIjYK7vlPtWibC5WJmlI8jBw5AUZ9V9aoxzxMzWnmqQBk7V4yfU+tAGnFKsapKhUbxtWKJf8AJrPu7m8knSJpZApfBQEYx/SpYLa4gcyRo0MKjJklGc/h6VKuopNE8s4BmIwoCgEj1oAguYIvvBMtFxiR9wB9veuj8B2li1xam4gH38yAsCc+9ZFnbQTKJmnzPj/Vqm7P+H1rb8IabdHUVlt7SUqJN5llyIxQBqfEfRIDdoypHFCvzNI42qxPQcdq4KWCdLxoFuS9uOqg/Lj0Br1PxFbHUZ3F95gSVgGZH3LgdiKxLvSEkZRcSrCFI8v5xkL+WKAOAkitjGzMwEpyFjIGR+NZ08PkruIDMR91MAk+tdjrvh2II3kTRzREkqC+c/U4rmdW02dhGjFpEUYLp91PpQBhzxSRyII5m4O5gDxWnprKpZG3AkZ4OAfenLpbSsPLZ5ii/wB2rkWkz2kfmS2rKGGFbBJoA09B0YtaS3M0isVOfLbsPerK29pbRveXSRLdElhCy8MB3FUbe9umsVILlE4VnIDk+9UNX1GW9ZUmuGaNBghl5B9fpQA/U/E1xdWUsaosdueDHDjBFVvD2tPY3UMlvIVRSTkPzmsq+jSOPy4nwucgs+Dj6VXsE3MYxsVM5LYwaAPovwH8R5vt6x3sogi7OnAb/exxmvbYPsGqrHcpJOqumPu9T7EV8a6TO0HmxmQ9P3W1hxXqXw2+JeoaNKtlqUsYtF4UAA5PqTigDuvFfhTVbOOfUbA7gSVfzQGyO2MdfrXN6Hok2maNPduP3lwTviMOCx9j3r1LS/EOi65pImsY94LF2RJsFWHfB6/Sq0viXTpYJLW7SBZIz8okU/LQB4ZD8P5dd1cPNbvawq2QSucD6CtG/wDh3ctfhL2QSWyHaojUfOn94Hufau1f4l2VjdzxCZY2T5AqDdn8647xL8SbOewmaKaN8Hc5L7NmTgHPYZ/WgDTXwtpmizQtDerk8I7HkD0Oev41j6rK873EF5DZ3cUT8Mj7GUetcOvjGCdCBrMKuGyBPOrYHsa0dO8T6VeXSrPq+l28vllTK8iBH9m57+tAF65s5GtBGkdyOfl3OGx6HJ5x+tV9PnmWfzEbbOBsl3rw+OPnH9als9W0uG7ymuaMhK5EbX8ZjI9M7uPxpsPivS57w2EU1obiRiFMMqShj/wEnn3H40AULuzhF+80CvZXP8aZ4U9iOxU1HqWlalCkMji3Cy8g4Oxz6gitC5e+iSaJ0iuJIcmLAwwHdSKqw+I5hpxtxCptZDh4JBkK349D7igDCcw2sqmTdjPzxsclD7eoqXxA0VzpqRw4kjIyEPDofY0mq2AujiKVZCV3KOhx6EetVLe2k2fZpjtkxmMtysn0Pb6UAS6FGLhDYa1z5oxFP0bPb8fbvVO9tjo85SVdwU8lfu4/vDvn2qhqFxeCYW8kTA9pB2xVnSdTtG1G1h8VvK9kkqmV4zsZlHYnsf8A9VAEGs3Vtf2rJPL8y8pITjH1PpXFale/aCFVibePocfeNa3jO/0i88RXreGoJrXQvMJt4bg5OPX6Z6DPFcuzFicn3oAHcuST9KZRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHYfDCJJdfuFkBI+zMeD/tpWh8V4I4f7L8sEZ83OTn+5Vb4RxGXxJcqCB/ojHn/fStP4yQmEaPlgc+d0/wCAUAea0UUUAFFFFABRRRQAUUUUAFKuCRk4FJRQAv40oIwQxPHSm0UAa1tqEoCRybHIGVNaVmxnnwnJzzjoD71zIOMY4PrWrZ3jsn2VpAozww4z9aAOwkuUeJbSLAjX77r1dvQVmalJHvXphOAgHSobRjEpWMq5xgFug9TRdXFlHGkUzMz5yNo7/SgBFgSZ8v8AOD0GenvVux8qJXaQKSMkBulZzN5Z2qVGemDzVlJEWB1ADSMOjdqANLTZbhXkaVXEJ5Ow4z/XFbfhm5tZbx5JIdqocImCPzHauVt7ho1YCd3kPRVHI+prU0i6lZtirvMjDcS2MmgD1We1trmyN3e3EUgjGI0I+VfYAVmw+G7i/wBTibT43lR+clNqj6+grUs7VbnTrS0ilUljuZUQkD3Pf863PFb2OjeHY9NguvLu5QCxTlvxI4WgDnNes1s9McySeeLdljnMf+qi3ZwPqcH8qp+LfD9po+leG0LtHrV/A15cxs2IooCf3S46hiOfwNdJ8KbjTLmXUfDfiGXyrDVUErSyOF2vCd4O4/dBXI//AF034ix+H9c1zUrzTdUl1XW7uRBHMEMdlZwLxtU/xnAxnpkk0r6gc1p8dnpk0VzEiOxbc7yJx9FU9T9a7698XxHSVkuI5JDsHlwIAmD0GT0/CszSbXT9NntoLi2u7/U3jaUQ2djNdnYu0F2CKx2guvp1Fc74i07WJ751sfDnieaEZId9EulXJ/ur5eRimAy58STTRiGMsgGTL3AB7YqNNWgu5i1xvkiiX5DH1U46c1Sbw9rcDsbfw34kZMblVdHu1w3ufL5rOS0udHuo4dV0zUdNnud0sUl1ZS2/mbcbsB1G4jcucdMigDo1vrWSOLE8dqxODFszg+rAdauQ3a/ZJdPNzp16X53PGq49gT0rh7yN5WkLsVVuHfdgfXHUmsO+DWAZo5vlJzsHJz/SgD1+xurDT7e3ki0K1BGXkmeXJOPpV7/hIDd26pGmnxRS9EkCkfQd6q6J4C0e80zQbUyeO9U1XUtCttZuItOnsFijWQAEDzgp+9nAGTjHJrrvDnwx8H6h4YfX7PxN4kisoEk843KWgltzESJEcG3JUqVOR7d6APJdZs9DsRcC71J5LuQFkht4sKjf3ST2+lefSb7+9VwGdlPzqOAVHavpPwn8NvCfxL8P/wBoQ6x4rjjhmMLRXcVjFPGwAYZ2QHqrKRz0Irxvw54HvtU06xktLiITXVrHM/mybB8yhvz5oA4+68x5GEIUbVywZc4Hsak0W0In8ra0hPIU8DFdjb/D8Pqa2d9eRRFzgbG3En04r0TT/AGl6JPEt5cxzOBzwScY6kdvrQB5GViSVN4CCM8AdR/jXS+ErS1vobm6nu7eB1yB5imTcPp/hXUX3g3SJ70tbxzW8IDbVmblj1yMdvrXI6vBb6dqkltZTSGzcbdrDoaANoWWnvbOtmJYoQwMsglby2I7r3H0rrLPyLbTC9xaW93JIow5c7wB03c9Kw9Ei0+K2g8vzpfPISTKbmT0yPSul/s20CyxW8G+VSD50jFmUeoXrigDDXR4L64kg1PToZnkG6B4pSNv4jgiqFt4WsNO8T+Hbm3uHiuINY08PA+DvJu4hwR6Zz+Fdgu+yEcay2dwwH7sodhI7jHUH61iahepFd6RqF3ewx2EOs6e8jXJA8lVu4ixLnoBjkk4xmgD02OXxVqHjL4iaTpvie9V9OtIH0yJ7e1KRyzxyMAx8rLKpRQMnpnO481JqPjq+1L4V+Hb/Q5Ps3iHX5rfT4CY1PkXBbbO21gR8gSU8j+Gs3wz4q0ew+JPijWr7xV4GXTNXW3SMw+IUeaMQK6qShRV+YPkjd8uMZbrWX4ZfwvpXxJu9Vm8eeEG8NwT3N7plpHqsXmRXFyqCUsM7QoxJtwf+WhoA7ax1LWPF3inxBYafq9xo2laHOlkZrWGF7i6nMYdyTKjoqLuUABck5OQMCuS+M9rqtn4R8OQeIbmHWZY9eOyWOEQtLF9kuSN6j5Q455XA4BwOlWz4l0Pw/4p1fVvCnjDwRd2usyJPd2N/raW/lzKmwyRyIJPvALlSvVcg84rmfil4osdb8N+H7e78SaBrWptrfnPbaJdJJ9nh+yXC8YYswBIJYgZLYwOBQBw2rXkQlhaB/M2EALKNsi/7LEdfY1j+IWt72J18uSN5AMnADA+/Y10Go6daxQxSQsZ42GBKpySPQisKWyEz7klM0SDbLGD8wU+ooAy7SMOscaXO6VDmN2+8h/un1FV725unkEMyosgYlXznnvj1FbFlaSwwv5g89oj+7YnLMvYZ9aTxDJaXGnfbI1XMY3SqeMY/i+tAHNTTSJdiWdhFFt/e7zwo9Qe4rjvEmq/b7k7PkgA2EkYL4PVv6U/xJrx1PYkSiK2jP3e8h9T/hXPO2cYGMUABOTjJ2jpmmUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAd78GVZvFF0FBJ+xt0/30rV+N6Mo0XepX/X9f8AtnVH4Hf8jZd/9eL/APoyOtf499NC/wC2/wD7ToA8kooooAKKKKACiiigAooooAKKKKACiiigBeMe9HpjOaStXQ0019TiXWZbmGy5Mj2yBnHHAAPFAF7QIbzUru302wtpLy9uDtgiiGXdvTHfgGhyPMbI24+VuOh54HvXZ/EjTPCmh+GPC9z4US+S91APcm6mlPmmIfKMgcKd2enpXC6bcAxC1kCiRvuSE9c9jQA8hVAMSgD9asROiOC2cnjOOaiuIngmEZHC/eOeDTpm2MHDZI6KKALNkrvIy5bZnOyMfO4+vpWokwWdUS18tew35Cj1J9axYwXcMjBD1LE4/CpZDvi3JIBjIwoxmgDv/DWvRW+2K8unCMflERwP8WNdPc+KNCmnMaaZJO+NsbzNgZ/vY/pXktqgEcbkojEfMuc59z71uaRqVjZ3CSXVsZYlONu7DMfpQBpGG6vb64mKq7EbTznjPAArodM028bat9OiW4wA0Q8yT6YFc5P4iaYPJbxLZW5PyLGMkA9s+/rV628RalplqJbR4UKnEaj5sn1OepoA9k+Fehm1+I8KSyTNbXehXyK/2hhNjzrQHLKQVPIxtII9a6GPw7AfjJPoZ1PxJ/Za6BHeiD/hIL//AFxuHQtu87d90AYzj2ryn4PeLo9H+Ijav4nmu0tZtNuIUMdvLcESNLbtjbGrFchCegHFepJ468Gjx9ceLBrGpGMaWumPB/YN7hNsrSby/l/7WNuO2c0AaPh7Xn8Ial480rXr26uLbSl/tqyku52lc2ciElA7kkhJEdRknqK8m+KdrqcOhfD651+ae41ae01G/uDLIzmJ5ZLZ/LGfuqoYIAOBiuj+IXin4d+NdY0q/XxVe2SW4+z30cei3b/brbzY5TAx8sbRujHOD1PFUfi78QtA1zXfD97owk1G3s7S8ScXFnPAql3tiuPMRdxIjfgZ6UAeMXyKsu2W5+aVt2xRudR9RVURxRXkkbIGaXks3p6k+tehaVaaR4nv3mcW+mxbtxijOwOPTJrL8U+H9LkvhbaPJJNMCRwwKY+tAHq/gyLXpdV8Kf8ACL3em21+Ph/ZEfb7Z5kf5uB8siFecfN830NRyX0Vz8NbbwLokLx+KtW1JrPVbG+l2Sq7Fp7qR2VT+7ZQ211Uja4wMjFedaf4w+JWj6ba6ZpPiGRLCwijto0+z2h8qNFCqMtFk4AHqauL8Q/id5cjf8JNePtOAy6faBfxJhoA9m8Ltqnh74u3NvrGn6fp1r4msxLbxWN21xH9ptVCty0Ue0mJl4Ckfu+tfLGlR6jbaTphju54hNDEY8HK/dGK9DsviF8S5b+KGfxRcJE2CzCztCw9cDya0/DHhO0lk0qGRpDHaRiJTMckgAAHsBwKANDSY4rPwr9qkkZr+cbVLgEof9njitnTktvsAKX01vc7MkuufNI7EnOPrU/iGxtbYGK2mEscHOC/zDPp61i2d8J3FvG0Y3k5UttDj3zwPpQBatoY5C8k10u9Vy6OPLMgPoR2HpXO+L/B1hcajA0G9JpI8q0b7o8Hvmt6+ie8fDYMtt9xYlVFAIwc+tVbE29tGY5ka5A4lRTkg+oPYUAV9F0e40fSmsr47XK/I5IMZX2b1qzC0jJah7aScDKtzhlHYjvioZ5QftEUpnWFVDQqWLKjemehpscct1bQR3U4tGIGyZjhS2ev0oAdBbwXc9wrTbJThRvOSMeh6g/pT5JVlRYkngLIfmhkThsf40XNg1rv/tS1dm6b4X4X0bPvTGi3zR2slnKz43AOdrD3DdGBoASSCxlnBije2mThomkJUA9xnkY/Ks+/lnsNNuLm4n+0QqRzbgMAM9x/WrWZUleEXRmuEG17OaMJuX1Ru/0qhCY0mNvHE9kxDKyn5o2PXkdRQBmaxZLr9hJPbwxyEYyS+x/r/nrXKadDLZ2Ur2cUkstu+ZYiSGT/AGgPSu5mKwWwEvyoONyDdj/FapW9xJ54uLaJBJbHDydcqex74+tAGD/aKytv3ywxEBpIjyR6kev86nuNTjs7+HcFR3GEnU/LKD0IPr6g1c1jS7XUL9fOi+zNJ88VxAcKw9CKg13ShZaOwv5IvKjBJl6LjtuHY+4oAtXc7DSbrUGhYWcJCTSkYVGIyBn1OM4rxvxHrz6lJIsTuLIPkJ03H1P9KZrWvXN7B9jWVzp6HPl7iN5HAZh/KsB3Z+vSgAdtxzgA0ylzwBSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHpfwCAPjG8yAf9Afr/ANdI62v2iFAHh/Cgf8fHT/tlWV+z1GJPGl6Gzj+z3PH/AF0jrb/aRiWIeHdpJz9p6/8AbKgDxSiiigAooooAKKKKACiiigAooooAKKKKAFxxntT9zKd3HNR0UAWJrq4uFiWWaSRYl2xqzEhF64HoOTxUQyck9vwplFAGvFesbV4mAaQn5Zm7n0rf+HttFd/ELwtaX8UVzDNqtnFNFIgZJEadAVIPBBHBFcWpzhScLXa/Cm5Z/iN4NiZc41myw3t9oSgD6Yj0q2vNM8caxZ+E/h4ln4b1C8tls5fDwMlxHAivkzCTCsQcf6sjI9+N3wfp/hLWfFY06/8AAXha1tb/AEe11nTP+JVD5hRxiaOQlcFlYr0A4b8ajh+FN9qmn+Nfts13p1/e+IJ7+xV7xpbO4i/dtH51sHMbKzKQdy78AegFaPi+x8Zanofh3xJpHh5bPxnpEksJsPtUPlSRSxlHKvu2lNwjcBsH5cYzQBwfxK0zQLv4X+O9W0rwt4b0+307VILHTbq00+OOZvLuIUmcuB0Ll1G3HAOc5r59Mf2h1P8ArGI6qeQa+rPjBoS+Fv2Y7rR0be9nFZJI4/5aS/aoS7/VnLH8a+SLQySRN5crIRyxA5agDQhPkwmN5PJjHAD5LZ9TXXeFPDcuuJuW+ggtkOf9sn1A7/SuQjIK+Y5Kwn7xbhmrUh1iKGNxapLHERzsJyaAPUrC38N6DdC81i7XbGARCh3TPjuR0WsvxD43XxHfNbWFmltpsQ+SKNThj6sR1Nedi5V3LTbiDycH7x92NTSX7WiMqS7WcglT93HpmgDeEQjLgfZYmI4jyc/UVZu9ONtDGssUYef5o5CwAwOwXvXLw6l5dwJoi1ue5K5B9wasfaZ3kZY5VdHbc7sMsAegHpQAi/LdyxI0auVBZuRtra0gmeRsRF7pvuuq4G31Hqa5vUN8aQSCGbG/adh4b61qaP8A6NLJdzSNbqybVViQfwxQB0FuJ7i8ktVY27ocsRGoyff1rp54buKxt47m+jkjmJVxuO1fTAzXnUF4I9UhltbmfbuGXI5yeMjvWrNZXOrakY7KVggbazMSMse/NAG3oAn/ALUnitxHMIyT5qEZU9mJ9K77TvEdvptk1nZ232idl+a4kGMk9cCuO0nSX015rO3YNOfkcnGJTjnaa2rRMW8S3YiS7iIAgPy7z2Bz0oAdbzyQzysdiR3P8bEMRj2x8tPghttSCNI0f2+cbEkkClHYdBnsarG2mF1dpJAtuRzLHHIXVye+fTHFQptAnItlcHEaIFx+RHU0AV9R0qS0hMFxHNDfLKMOcBA3YNzyKnuPISzjg1CNUmWQKJI3G0E9s9SKrXF9Na3WQrSxMgWQXCH93g/y96vySR3Vt5tzYtDdM/yttzGwHIIx1NACWkLiNGtwFkyW8oHzA+P9k9iK07a5s763SPUkWxkmbY6OmY2PbDfwmlsGU20F1pswODiVG+X5e/B6GqrQwQ318tpFM8MuDJFKeQf7wB6f1oAkezhBexku53uohiE7w+9f7pH9ajj1DUDYvIA8cduMCEoGDY+8Pb1qjdRWnkhIU+z6hCdySMCGI/vKev4VFpxvjbvMl06ws+J2Kg/8CA9D6igCG4tV1Py5mneG6jXeuRlSD6+mKL+F7CyBlJnTgrIPmxnuGHb1olurS3Iga4kWRn+SVSMo3bOex9Kk0/7TYqZrmEtBK22TY2V3eox0oAha9jey+a08zyV34jOJIz6js6H9K56+1GNYVuIQ65zkgDO09QccEVr39zZyq13YiWK8tWJR0GFkHdWXofcVzOpwWlyZb2K5Wwt5l3yo5+SFx/EPQUARXMz2eluyyO1j/rGDn/Ve6nsfavPfFPiq/wBbtYbaeYfZbcnau3a0h7M/qR6dqPE/iWXVYoLSMiKwiOFXPLsP4m749BXKyFjIdx+lACMzOST064pueMdqOuSTSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6r+zihk8b3wGM/2c5/8ixVu/tNRtGPDe7HP2np/wBsqxv2av8Aker7/sGyf+jYq3v2oenhn/t6/wDaNAHhFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVNG48soxGOoyOhqGigDdub2zvBYW8OnWto0FuIZJULE3DbifMbPRsEDjjirthZ6fFEy3BSSU9MqK5dfvDnHvWtps7PMkcr89I2bvQBoS2iRsR5cSNjIIjGR9PemJNMtyiEHaRjJ/rVtrWRjI0zKCOXAOOP8Kpyh3nVVZTuwV7hfx70ATq4eTbGpYscDHIB9PrXR6LpFzO0aoCpc5AmGBx15PaptHns7OBsWyvdnkyBM7B7A96k1K8e68p7iSRYzlQu7JUfh0oAqXkccV4ywTxTuvJKD5B9AeD9arrIbqcC4MbADai/e3H8KV0ljhVwY/IRtwEg6/T1qrHM37xoY0QuN20jHHt6CgDasLX7ZCUmdY5IztI2449OegqxJBGVYQPF5o4AWQYP+fSsSS7Wa2WJNokznMZ+6fcmnwRzxXBaVdsKAFmDDHv160ASs7Mm1nLOcoVBxn3ro9O0XWbpI5ZrO6lsY1AC4G365rEsLG7ubieWys52iZM5YEtj19MVuwS6hBpv2aQXbThsoA5wo9T2xQBmSWDyaqLN5i0KEMm1ud2eASK9E0HTJLBJHkTcxIE24MdrY42nt9a5fwnbGG6zLAZpZDh2VwR/vZrtbq3EcJWW4eIxnYywv5gIPTjr9fSgDTtV06/kgnSRLZ2JQBpBtYgdc+tLDb3N0Jo42t3lXKlpScyY7/XFZgK2kAg+0W4MJ3KrpkOe2SB1qC6ka1COkkxmaMtFsbCg55OOtAGuYdR0t01OytZUnZhERGCUdfbPBpmoX87XUzalpbQ3CqDvgBBGO4HTNVrfXbue3hWS9hmjfa0c0KGJgewcfd/Gpr+5ltGcLevcSzbexZF4/WgCtczu0kRWd7mMoWTcAznPQH3HpRGbqzbasW+GQAxhpCrIc/wk8deay2aRWiMyvMxZm8hRtAPdiev51dg1Ka7nVri2R7ZFIwXztf0oA24dQgsbnd4jgMi3HytLb4Rl/2gOhx6VVvLWKSSKa21ZtT0xRsEyrtlXJ+6Qe4rO1ll1CIQ2peMooG8krz7KeM+461TlsL6GNXtjFcbSC8KnYwb1xwc0AatzLJBDPayO98g+ZZJE5VfQdwf51NYRWVvaNG1x9psLj5lycmJ+vPcj1FYvm3NuZLp3ZUH7pt4OFPo3sfWs28eaC2jWAyQhj80e4MpHoD6UAX9Uaya7AVFkZ8D5vmCHsQw7fWtS5tZ/Jjls9guGABWM/JMPTB4z3Brk/Ngi8ryoPIulHD5wVPofUH3re0rVI7ayuxqn7nSZQZFkbg2sg6/h7flQBkw6vHptxdm9KpgEyMV2qyjvz0I9O9eWfEDxYmv6lL9ktUstMGAkMef3jAY8xs9z6ds1D418WTa5OY1bFjG+UBHzTEcbm/wrkJGDkYBGB3OaAFkbcwJJx+eKbxnknFIcZ6cUHrQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAev/ALMH/I/X/wD2DJP/AEbFXQ/tWdPC3/b1/wC0aw/2WUD/ABB1AN0/suT/ANGw10X7WkaoPCm3v9r/APaNAHzzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUiMOj8jGAfT6VHSjrQBvaXdxyqsF8xRsfLKT1H9016foVhpmlaEdS1SOM3VwMWdljkD++/oK8WjY4ZTj5vX1rrPCE99qclxaRywmWOBpjPczhMRxjJUFjycdAOTQB0s7JZxmVI99xI2QGGc/lUd8Da6W93JvR5DjJ65Pt6VWivmXakMgYJ8zu3RSegrH1u9F65eWdpBGcADgL9KAGzXQ5LFjsAIUnO2iKQzPvlyJCOAeGAqjDLGSFRV3OCd7dwKt2Ql8+P7LlnA5FAF2e5QoSqbkI5MY/Dj3rqNFiVLZniRJFGBunIPJ424qzoHguddNnu9WdbC3UeZsXBmcHngdvrVnT47CxMVwlk7LK37oTtye2SaAO08P6peanZHSY3eNcBdlsgVVXuC3XFc/rmnvaXUlhb3InY5yqvwfUsat3WpyReb/AGeuyEKBMsGACO6j+taHh22itbV5FMSahcAsNrBxGnoxPt2oAptBHZ2wSzdIRhQQB88h75z1rTtIZpPM3CQTI4wQ20fiT2/nTQiy3I2By2dyrsG9SP7o9DzzU0S2rQuzQzNMQE2h22g5+6AOhFADbi5aOC2lQ7MvtZ8bh/unOMCpEnSyeSWeTynJBVlUM+OxH8sUrzpcaGxSONJ92CGBwxz1YHjpUcd3BC8T2jmNjlTuUvg+gz1H8qAII7qeS5EttHDaSlWbayho2Ppj1PtTre5lkkSSS2iEZy0pQj5T/sjsDTpbm1ubUN5UcUsQAkBPyrtPT071TmEv20zym0aN9p87cPKZewXH60ARXTyzI7xJ5RDEopBy46H5j2+lS6bst5Job6G3jMiAIhXIY+pYVVmvVtpme2jV9hLMkr5Rl/uhe49cc1RvvEFhdws9jay2cnV4Mlo8/wCzmgDQlMc7hbSOSK7ibOHbfx7D09qgtY3mu282WdHZsMsuQF9lI6Ee9VI2+3wieCYfaM5A3mNiAccZ649KuX1zf6lpjNLexSyw8F2TDr6Zx1HvQBrRx3NhfN5l5HJLPHtSMnMcqj6/xY6g1kXcYtZnDxP/AGfMMPEh/wBS3qoPT1x+VYH2x7u0hEknkX8L4SQtkH2bsc9jVjTdUura31IXUdvLaWSCe6guJBG6qTgGInljnsM0AN1q4s4Wi+2yOkaDKXCv8jr2JPY+xrzXxN4hlv8AzLeCWdNNVgyxlj+8cfxEdvp2qPxbrEOpX832BJI9PVtyJIeW6df8K5sux3dcHqKAFaTcoBAyO4/rTD9KMkjHagknGe3FABSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAe0fspIZPiJqIBA/4lUh/8jQ10f7XkRjHhPJBz9r6f9sawP2SwW+I2ogAn/iUyf+joa6X9sNSq+EdwI/4/P/aFAHzdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVIjArsbheufeo6KANfT790jEMkgVMkgkdakN4WZiqL8/A461iVesWbeAXVM4IZv5fWgDotL0B3tTe321bdTtRB99yeu0enrmuu0ZYtIEM1jbiO5DdWXk/8A1/pWTYa0lrGPNCRylcQ7xkD1Na1prNs5EkrkfIAzgbmJ9AOw+lAGnrWrX09uDEWa5Y524wE+vqfrVa0uJr+COO72mUjYzPyFYdsVjzajPcs8MMMiJu2lCfnwO/v9au+HoHjuf9Wkk5bmFsnee+fSgDrdMsrO/VbYy/uov3jPGx+cgdMd61pZha7JEiTbKwPlbcPx3b+79KhiaDSBHauVSVwXlVVzsHZR6GmT6nCsccsNvNLJIS0jAZbbn5eSOPoKAJb6bbHl1YRrkCVCAdxGdmRyBTbdN1pdebcG2QIGPlsAcnphu59apzC2uXllkCSzqB+5BKZ9/TOOxqnDKpYyGDy7faSQW3DbjqAPX07YoA3lup/sYkmvnleFsoW5AAHIJ6N6d6fbX9y6XkjwxSCCQO+5x8uR0Hfp6VlLINsSiGFrVYlPzcM454x0P0rQjk+1FVtrWKIp0cP8mR1TnoKACaX7SVaOK3zI+ZI1cKX44b6eoqjBMbaaaafypcANFDsyDg4Ix2H0qvdSWuTDxDJ2mJzlu5A/xqK7v3WMwBori3BDRy7dpLd8emenNAFyS7dmURRWJjMmQo5Zj3Ab296oXskNj++s0VsHLK7Zy2eeD2+lVrRrcC4gdGaOSQ4RWAVWx1UHrWHf3zG7g8xCkbuU80DkGgDqpbqDUrp5GiRYAgcBT8yN32+v86wLm+t4xcQi6naUvhSFxj0NUZL4Q30gdlMiDMUg/i+o9aoR6ttmc3TpIki58wrtKDvn1oAv6g1vDCUkmKXCfNISfu+vHpXFeI9cbV5IF27beBdqAnG4+vtUGu6tJqMxBb9wp2iQj5mHvWMzb25OB/KgALMzFulN5wTnikooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD3D9kT/kpOpf9gmX/ANHQ1037ZfTwf/2+f+0K579jsA/EzU8gH/iUS9f+u0NdR+2oAF8G4AH/AB+/+0KAPmKiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKejADDcjsM8D3plFAG3pd5GLjZdlX7CRucD0FaMuoRpte1UCMHZgjOSPpXLKQxAc4UV1keuRarqfnaraW5ldI4oxbIsKYVQo+UcZ4yT3NAHZ+GNOvfEckaRW/lTrwXkOFC+pPofSuzvRpmjPFpWl3b3GqS/NINo2IV/iB9a8vuvE14JV07TVFrGpCkrnJA/2q6fwZt00Svc28d1MwOZpW3qp6jjqT9aALkN5LFeztdQRxiNsLKxLNuP3jn1rRtbqGeEpBNPBCFKlN3Ej/3vyrlr+7Cyu6P9pjbOXjHCsTnkdKg0999oiz4RoGBG1vk+uB1+lAG1dzmFhBcxhZCwwgYsJEPT8aYk093M8dmWhCoSrEcKo9ce9V7/AFJJrTb50ZZSGAK/OpHAJ9PpVlp9iZWSSORFwGX/AJa8dKAJIlea3CLObhEXO4LyzDrkdcc54q8q2trNHAytKhIDsjndnuCD0z6VjW1zciwj8tiGZtsTAgMOe47EVYutRlgMs6gSXu3ynkcggepOP5UAaOonQZnkzPdWrR/LtnQcZPcj8qyNS025Vk+wNbT27IWadJe3r9a52/upJLiNLndcA5LbBlc46kfrUFk7XbbYLkCQMRIQcAAdMCgC/PqTQ3Wb0k7F2sdmGjUdPr9ar6hrttLDA5jRnU7cZwSOxqr9vi+3SwzB5nPJlZs7/wDZBrCuXOJPlRYixO3jctAFrUL2G4kZgEiZOGZTnFYl/em4AAP7pPlGf4xU2r6w2pRWMMkVtFHZW4tozBCIzIoJOXI+83P3j6CskknjsOg9KABjk98dqSkooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA95/Y1QP8T9UBz/AMgeU8f9doK6n9ttAg8F4JOftv8A7Qrmf2MFL/FHVAuM/wBjS/8Ao+Cuq/bhQoPBWcf8vv8A7b0AfLNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFSrISNrnI7e1RUUAa1neiKRI7gnjG2RDgj61v2V8A48yb92mSgB4Y+p9a41MklRjJ71YtpEKiOUE5OAfSgDtE1a1lEu1AWVup+XJ9x3FO+3abLa7GaXzlYnzNuFPtWDY2trJGPNuNzkkAZ5P8AjU0D2kpYLvBAw5HfHAzmgDfgntFZxJKNg/dt/wBNOByT361asFSWe0to7jcFkKoobByAcHP04rm7K3tbkMk05hkCkg44xjtUenRQRHctxzDknI65PynPpQB6NPoN4dOS9lntpbdAXSPOGDHjjHaucLuJImJU9kXA529c+1V9QuUjktvLvS0THJTPyg4/xzXOXF3htsc4LDK5B6c0AXpLxMzyyqUcg7R2GfSsi1uTHvZ8jPzDA5/OmPcSkNCrLgc7jVQEod7vnPHHSgCZbrZFICcFjkeo9xVV52ZwSd2Bj0zSTOJHyBx6+tQ0AKaSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA9w/ZF1vStB+JOpXWuanY6bbPpMsay3lwkKFzNCQoLEDOATj2NdL+2V4j0PxB/wiH9g6zpup+R9s837FdJP5e7yNu7aTjODjPXBr5rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA7Dwt4btNX8MeINTutdsdPudLiWWG0mHz3XPRf5cZ5IzxzXLu5++qlDk5wevtRC+1QSckH5QO3qaZNhmO04QfdBoAtx3UgcMsuWC4Xd0UelPW6VgQDtwck/3hVDyzgEFST0APNR0AadxcKZgTIGx09BVW4lWRsn5uahCZbAZfrnFBQjPIwO/r9KAOt8B+HLLxPqF1aX+t2WiRW9pJcJLdjIlKjO0fzPfA4BrlZmbhTjaOhHf3pUl2xY4PPQ8/jTJXLvnJP1oAb0bg8U2iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKdkY6UANooooAK1fDen2uqa1aWV/qMWmWsz7ZLyZSyRDBOSBz7fjWVTlbBFAHs8HwD1WfTopV1W2S9KMXtpIyMOT+7QHrl1G4ZAqy3wBlKEw+I7V2ZVEf7kgO6n9/36R/mfQV5KfEutG7+1HVb43HmJN5hnYtvQYVs56gcD2qIa5qgChdQulCiQLtlYYEn+sx/vd/WtOaPY5PZYj+f8D1yP4HW5tLWdvFNoU3CW6kWPCRW75EMgyQTvIAA461Jd/AUiUQ2niK3ecI1uyMgBa+A3C3Hzd15yeleNPql86Mj3lwyMiREGQkFEOUX6AgYHapP7b1Mz+d/aF353mm43+a2fNIwXz/exxnrS5o9g9lX/wCfn4I9cb4EZtzcQ+KLJ7cosyS+VhWhXH2iTO7GI+frjtTbT4EzG+uv7Q1+2tdPVttvKYyZJQzBYXK5wquTxya8iGq34gSBb25EKRvCkfmHaqOcsoHYE8kd6fJreqSpsk1G8dcRrtaZiMR/cHX+Ht6U+aPYfsq/8/4HrQ+CFvc6jdafp3iqymv7cGA2pTEpulALR7d33QMncM9OlRah8Cb8yr/YusWd7FLJH5RZSpaFshpjjOEVgy++K8lg1K9g1E38N3cR3xZn+0LIRJubOTu65OT+dT2uvaraAi11K7iHkG1wsrD90Tkp7Lkk496OaPYPZV1tP8D1Cb4B6+rWccN/YySyCT7QDuC25HMYJxyXGNvFF78CNTtozjWdPeaTatvGQy+bIATKmexjAJJPXHavNH8Ta48skjate75HjdyJmG5oxhD9VA4psviPWZlRZNUvCEeWRf3pGGl/1h/4F39aLw7C9niP519x68nwNsbLSnvNa8SJGtsr3Ny0EYKfZgMLIhbk5YjtUdh8GtAvZDZW/jGCXVRGqeUioVeeQbowh3ZZccHuDXk2o+JNX1G2tbe81CeWC2tls4oy2FWFTkJgdRnnn0FZsM8kEqSwO0UqMGV0O1lI6EHtRzR6IFRrdan4I9quPgQ01znSfENrNakKUaRfmcK22cgKTxGfzzRffAlYLWWZfEtqkUZM7TTREKLUj93KQCT8zcYGR715BZ6zqNkwa1vrmJgjxgrIRhX++Po3f1pG1jUWRka/uyjRJCVMzYMaHKL1+6D0Hajmj2D2Vf8A5+fgey/8KCc2ce/xBBHqJHkfZ/KyGu8bhCDkH7uDnH4U0/AKRh+58TWkgfa0TeQcMinE7/e4EZ49/avIBr2rfaBP/ad75wm+0CTz23ebjG/OfvY4z1psOtanDHsi1C6VBG8IAlbARzl1Hsx5PrRzQ7B7LEf8/PwR6lbfAPXpZJzPqNhBAkskaSNuy4HEbYxwHPAq9ZfAC8Eoj1HW7SIyRqsXlqSTcdWiOSPuqCc15S/ivXn+/q963yxLgyk5ERzH/wB8npUN34h1e7nea41O7eR5nuSTKR+9f7zgdifUUc0OwezxD+2vuPWtT+DehQXNtHB4wtoku2NxbvchQrWa4DvkHBcMTgd8U3UPgQ9raPKfENqjxbhKskLYUscW44JOZMj6e9eLPPI6Ikjs6oMIGOQo64Hp1NX21/V2Z2bU70u7xyMxmbJaMYjJOeq9vSlzR7D9lWW1T8EewL8AJjEY/wC37drxkCpGIjjz15lj6/wLznr7VXh+BNw2pyyvrVt/wj0bg/bSpDvDtBMqryNoJx1ryddd1VXV11K8Dq8kqkTNkPIMO3Xqw6nvSPruqvaLatqN2bZYfs4i85tvlbt2zGcbc84p80OwvZV/5/wPVh8Cbkag1rLr9mhVdjAod6zvkwREEjJdecjpU9z8BXSF3g8SWjNsBjVo9od0P+kDOeBGMnPU46CvIxr2rC6W5/tK7adZkuA7Ssx81RhX5/iA4B7CmnWtTKqp1C6IXzNo808eZ/rMf73f170c0eweyr/z/gey3XwDjZI107xNbSSf693kiwi27j91JwSfmIx+NVT+z/qbWa+TrFo1+sZE1uYzhLjqIQc8nb82cD6V5ENY1IRsgv7oI0aQsvnNgohyi9ei44Hapv8AhIdY80yjVL4Smf7SX89txlxjfnP3scZo5odg9liOlT8D11PgHcp5u/xHaK25XgdYjteEf66Q85GzOMc59qSP4GgX7peeKrWO3VDKrCA7trttgYgnGJDnHP514+Na1MRqn9o3mxY3hVfObARzl169GPUd6WTXNTlJMl/dNlYlwZTgiP8A1Yx/s9vSjmj2D2VfrU/A9lb4DO1oiDxHAupPmBbYw533Sjc0YOcjC85xVVvgFqEQeV9fsBbxvvaURtgWwXLT/QHjH615Idd1U3HnnUrzz/Oa48zzm3CRhhnBz94jgmnSa/q0lukDaldmFIDaqnmkDyi24p/uknOKOaHYPZYj/n5+B7DpfwKR7WKS/wDE1vFI+EKxxZAeT/j3GWI++OenFeL6rZT6fqV3ZXihbm1leCUDkBlJB/UU+TW9Tl3eZqF25Z0di0rElkGEJ91HA9O1U5JnlleSVi8jkszMckk9SamTT2RrShUi25yv8j07wh8GdZ8Q6ba6i9/ZWNhOqyebKGJWMrnfjHIBIXr1NTRfAvxQ8tvGZLNHmWU4Yt8mw4UNxwX6rXnx8SaybFbI6pdm1WD7MsRlO0Rbt2wDsM81Yj8Y+Io5HkTWr8O8kcrN5zHLx/cP4dqd4diJQr3dpL7j0GX4IXoLLba7YXMpmFvDFHG26aRceeo/65dT647VNqfwI1CCRRZa3YzxGbLSSKUWK2K7kuHIJwpwRivLF17VleNk1O8VojIyFZmBQyffIweN2efWnReIdWhguIYtRuliuIFtpV804eJTlUPsPSi8ewvZ1/519x6ZZfALxHPZrLPd2VtPIhMVu+7c0meEPHBK/MParen/AAU0+4e73eLrORLYGSVYUBdEjz55ZScjaeB65ry9fFuvrLHINYvi8cwuVZpmJEgXaG57gcVmR3txHLNLHPKksyskjK5BdW+8D6g96OaPYPZ13vP7ketD4W+FEtjLN45t8rCLpgkSkGGQ4ix82d2cbhjIHapl+E3hgSNDJ42tjN5iWQ2BCouiu4k/N/qsdG9eteMb/YflRuGMbRRzLsP2NX/n4/uR7hqPwP0+O2kurLxRE9uFF2rOi8WS8STEhucNkYHWlt/gfpd3aRT2njO0lU4QukQZTJJ/qEHzcFunPQ14wNTvQiJ9rn2JEYFXecCMnJTH90nnHSmQ311BE0cFxLFG0iylUYqC652tgdxk49KOaPYXsa1v4n4I9gsvglb3kFzbQeKLOXXIiYTYxqCVnTmVG5zhRzuAPQ1DF8BNbku5w2qafHp8cmFvG3bZItoPmqMfdyQvXrXk8Go3lveteQXU8V2xYmdJCHJYEN83XkE5+tXD4k1prVbZtUvDbrB9lEZlO0RZ3bMemeaFKPVA6VdbT/A9HufgR4gha2QX1gXdW87cWCwSZGyMnHJfIx9a0f8Ahn+/BmRtds/MKqbYCI/viozMOvAj59c+1eWS+K9flknkk1i+LzyxzSnzj87p9xj7jAwfaoF8Qaurxsup3gMfmbCJm+XzP9Zj/e7+tO8OwvZ4j+dfcd14z+FLeHfCcmuWutwapEsiMEghIzbvwsxyeAWyuMfjXmB61bi1K8it57eK6nSCdBHLGJDtdQdwUjuAecVUNQ2nsb04zirTdxKKKKRoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRSmkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal parasagittal image illustrating the position of the ventricular septal defect in this echocardiographic window (arrow). The defect is immediately below the aortic valve and adjacent to the septal leaflet of the tricuspid valve.",
"    <div class=\"footnotes\">",
"     PA: pulmonary artery; AO: aorta; LA: left atrium; RV: right ventricle; TV: tricuspid valve; RA: right atrium; IVC: inferior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42210=[""].join("\n");
var outline_f41_14_42210=null;
var title_f41_14_42211="Gallbladder polyp vs stone US";
var content_f41_14_42211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Gallbladder polyp versus gallstone on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound images of a gallbladder adenomatous polyp (left panel arrowhead) compared with a gallstone (right panel arrowhead). Note the shadow cast by the stone (red arrow) compared with the absence of a shadow behind the polyp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42211=[""].join("\n");
var outline_f41_14_42211=null;
var title_f41_14_42212="Severe hidradenitis suppurativa";
var content_f41_14_42212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42212=[""].join("\n");
var outline_f41_14_42212=null;
var title_f41_14_42213="Anterior anatomy of tibia and fibula";
var content_f41_14_42213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anterior anatomy of tibia and fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 632px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42213=[""].join("\n");
var outline_f41_14_42213=null;
var title_f41_14_42214="Transfusion reactions caused by chemical and physical agents";
var content_f41_14_42214=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transfusion reactions caused by chemical and physical agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42214/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/14/42214/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to the transfusion of blood products are unfortunately not rare, and may be fatal. Chemical and physical causes of untoward reactions to transfusion of blood products will be reviewed here. Other reactions to blood products are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSFUSIONAL VOLUME OVERLOAD (TACO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema secondary to congestive failure can occur with transfusion-associated",
"    <span class=\"nowrap\">",
"     volume/circulatory",
"    </span>",
"    overload (TACO), especially in elderly patients, small children,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with compromised cardiac function and may occur more frequently in association with surgical or intensive care settings, where large fluid volumes and some blood are administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms include dyspnea, orthopnea, tachycardia and a wide pulse pressure, often with hypertension and hypoxemia, and may begin near the end of the transfusion, or within six hours. Headache is common and seizures have been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2010, TACO was the second most common cause of transfusion-related mortality as reported to the United States FDA; these episodes are likely to be underreported. This was shown in a combined",
"    <span class=\"nowrap\">",
"     retrospective/prospective",
"    </span>",
"    analysis of TACO events caused by plasma at a tertiary care hospital. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the retrospective seven-year analysis period, using the blood bank&rsquo;s records, the prevalence rate of TACO was 1 in 1566 transfused plasma units.",
"     </li>",
"     <li>",
"      In the one-month prospective analysis period, using active surveillance of plasma recipients, there were four TACO reactions, for a prevalence rate of 1 in 68 transfused plasma units. None of these reactions were reported to the blood bank.",
"     </li>",
"     <li>",
"      Over both study intervals, the majority of patients who experienced TACO were in the intensive care unit at the time this occurred. On average they had received 4.0 &plusmn; 2.3 units of plasma at an average rate of 647 &plusmn; 315",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      in the 24 hours before the TACO reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of these issues was illustrated in a two-year prospective cohort study of consecutive patients receiving blood product transfusion in the medical intensive care unit of a tertiary care institution. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-one of 901 transfused patients developed TACO (6 percent). This is even higher than the 1 to 4 percent rate previously reported in studies of orthopedic (hip and knee) surgery patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with matched controls, TACO cases had a significantly greater positive fluid balance (1.4 versus 0.8 liters), larger amounts of plasma transfused (0.4 versus 0.07 L), and a faster rate of blood component transfusion (225 versus 168",
"      <span class=\"nowrap\">",
"       mL/hour).",
"       <br/>",
"       <br/>",
"       In",
"      </span>",
"      a secondary analysis, left ventricular dysfunction before transfusion (OR 8.23; 95% CI 3.36-22.0) and the use of plasma for anticoagulant reversal (OR 4.31; 95% CI 1.45-14.3) were significantly related to the development of TACO.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to avoid TACO for routine transfusions of blood components, a transfusion rate of approximately 2.0 to 2.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour is acceptable. For an average sized adult, we use the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One unit of packed red cells with a volume of 350 mL should be transfused over a 1.5 to 2-hour period.",
"     </li>",
"     <li>",
"      Six units of pooled platelets or one apheresis unit of platelets with a volume of 200 to 300 mL should be transfused over a 30- to 60-minute period. There are no definitive data, though some argue that, after a slow initial rate to monitor for an immediate reaction, the 30-minute timeframe is preferable if the patient can tolerate it.",
"     </li>",
"     <li>",
"      One unit of fresh frozen plasma with a volume of 200 to 250 mL should be transfused over a 30- to 60-minute period depending upon the clinical situation and the patient&rsquo;s ability to handle the volume load.",
"     </li>",
"     <li>",
"      Patients deemed to be at risk of TACO (eg, small stature or low body weight, elderly, known or suspected poor cardiac function) can generally be safely transfused at a rate of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. Such patients should also be monitored more closely during the transfusion for signs and symptoms of TACO.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other actions that may be taken to minimize the risk of TACO include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limiting transfusion of red cells to two units per day in patients who are not actively bleeding.",
"     </li>",
"     <li>",
"      If, because of the patient's prior response to transfusion, the estimated time for transfusion of a full unit of blood will exceed four hours, the blood bank may be able to provide smaller \"split\" units.",
"     </li>",
"     <li>",
"      Evaluating the patient's symptoms and physical signs (eg, estimated or measured venous pressure, examination of the lung bases for detection of rales) prior to infusion of each additional unit to be transfused within the same 24-hour period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link&amp;anchor=H14#H14\">",
"       \"Examination of the jugular venous pulse\", section on 'Jugular venous (right atrial) pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of the patient with suspected heart failure\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of small doses of a diuretic between transfusions.",
"     </li>",
"     <li>",
"      Isovolemic exchange can be performed, in which one unit of the patient's blood (with a low hematocrit) is removed at the same time as a unit of packed cells (with a hematocrit of 60 to 80 percent) is infused [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While TACO should not be mistaken for transfusion related lung injury (TRALI), it may be difficult to distinguish one from the other. Although hypoxemia may be present in both conditions, the CVP is normal in TRALI and elevated in TACO. In TACO, as opposed to TRALI, N terminal Pro-BNP (NT Pro-BNP) is elevated, pulmonary wedge pressure is elevated, and the ratio of protein in the edema fluid to plasma is low, reflecting a transudate rather than an exudate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of fluid mobilization (diuretics) and supplementary oxygen, and is similar to other causes of cardiogenic pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive positive pressure ventilation may be helpful in the acute management of patients with severe respiratory compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phlebotomy in 250 mL increments, with or without reinfusion of the removed red cells, may be necessary if symptoms persist or diuresis cannot be promoted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADDITION OF DRUGS AND DILUENTS TO BLOOD PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No drugs should ever be added to a blood component or given through an intravenous line through which blood is flowing, as osmotic hemolysis can result. Only 0.9 percent saline is acceptable as an additive or diluent for a blood transfusion. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If blood is mixed with 5 percent dextrose and water, the sugar is rapidly taken up by the red cells, water follows across the red cell membrane, and lysis occurs.",
"     </li>",
"     <li>",
"      If lactated Ringers solution is used, the added calcium can cause plasma, if present, to clot in the intravenous line or filter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THERMAL HEMOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transported, as well as stored, blood products must be carefully maintained (and monitored) at temperatures appropriate to the products: 4&deg;C for packed red cells, 22&deg;C for platelets, -30&deg;C for frozen plasma, while frozen red cells in glycerol are maintained at -80&deg;C or lower.",
"   </p>",
"   <p>",
"    If red cells are frozen without cryoprotectant or are too rapidly thawed after appropriate freezing, they will hemolyze. Only carefully monitored equipment for storage of blood components should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood warmers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood warmers, used on the recovery wards or in intensive care units and operating rooms, must also be carefully calibrated and continuously monitored to avoid heating of the blood cells above 40&ordm;C, with resultant hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H21#H21\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Heat denaturation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heating of blood via microwave devices or by running the blood under uncontrolled hot water is not recommended, since uneven heating and lack of blood mixing may lead to excessive hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COAGULATION DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, coagulation defects due to massive transfusion (&ge;1 blood volume in &le;24 hours) are much less common than expected (ie, based on a simple \"wash-out\" calculation), due to the presence of significant reserves of all the coagulation factors, including platelets. However, the larger molecules, which exist primarily within the intravascular space (eg, fibrinogen, Factor V, and Factor VIII), may need to be monitored for this potential effect (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H3#H3\">",
"     \"Massive blood transfusion\", section on 'Alterations in the coagulation system'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CITRATE TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most whole blood is collected in the United States using a balanced citrate solution to chelate calcium and prevent the blood from clotting. Red cell concentrates are then prepared by removing the plasma and supernatant platelets and resuspending the red cells in a preservative solution containing one or more of the following: citrate, saline, phosphate, adenine, glucose, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . In units so collected and treated, citrate is present in the plasma and platelets, but may have been removed from the red cells. In case the presence of citrate is a potential issue, labels on all blood products clearly indicate the anticoagulant and preservative used in the collection, preparation, and storage of the blood components.",
"   </p>",
"   <p>",
"    Citrate toxicity is rare. In the past, it was believed that it required transfusion of more than one unit of citrated whole blood (or frozen plasma) every five minutes to cause significant chelation of calcium to produce hypocalcemia, the manifestations of which might include a sense of heightened anxiety, carpopedal spasm, tetanic contractions, and arrhythmias. This \"old saw\", which is repeated in numerous texts and handbooks, is said to have been based on older animal studies, but there is no ready reference. With the exception of patients receiving large-volume plasma or whole blood replacement, such as occurs in liver transplantation and exchange transfusion, the switch to additive red cell solutions not containing citrate has markedly reduced the risk of citrate toxicity.",
"   </p>",
"   <p>",
"    Mild citrate toxicity, manifest as chilliness, anxiousness, circumoral paresthesias and tightness of jaw",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other muscles is occasionally seen in association with cytapheresis or plasma exchange, and responds to slowing the infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to ingestion of milk or calcium-containing antacids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=see_link&amp;anchor=H18#H18\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Citrate toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newborns (or others) undergoing exchange transfusion with a citrated blood product should be monitored by EKG for signs of hypocalcemia (eg, prolonged Q-T interval), and treated appropriately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H9#H9\">",
"     \"Massive blood transfusion\", section on 'Complications of citrate infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine intravenous administration of calcium salts should be rigorously avoided, since intravenous calcium itself can cause severe arrhythmias. It is better to monitor the EKG of patients (newborns, adults with severe liver disease) receiving massive doses of citrated blood products and to give slow infusions of calcium only if evidence of severe hypocalcemia is noted.",
"   </p>",
"   <p>",
"    Calcium should never be added to the blood product, as this might cause immediate clotting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPERKALEMIA, HYPOKALEMIA, AND METABOLIC ALKALOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperkalemia and potassium leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leakage of potassium from red cell products (eg, prolonged storage, irradiation) may be a problem in some settings (eg, infants and patients with renal impairment). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of red blood cells for transfusion\", section on 'Potassium leakage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following transfusion, citrate, if present, is rapidly metabolized to bicarbonate, which drives potassium into the cells. Accordingly, hypokalemia and alkalosis are common after massive transfusion. Thus, when large volumes of citrate-containing blood are rapidly transfused (ie, more than one blood volume [7 percent of the body weight] within 24 hours), it may be necessary to give potassium salts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes of metabolic alkalosis\", section on 'Alkali administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is occasionally seen in recipients of large volumes of refrigerated (1 to 6&ordm;C) blood products. Slowing the infusion, warming the patient, or warming the blood with properly functioning blood warmers (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Blood warmers'",
"    </a>",
"    above) are helpful interventions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link&amp;anchor=H14#H14\">",
"     \"Use of blood products in the critically ill\", section on 'Hypothermia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=see_link&amp;anchor=H12#H12\">",
"     \"Accidental hypothermia in adults\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IRON OVERLOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusional iron overload (hemosiderosis) may occur in chronically transfused patients, such as those with sickle cell disease, thalassemia major, aplastic anemia, myelodysplastic syndrome or other illnesses requiring many red cell transfusions over long periods of time. Each unit of red cells contains approximately 250 mg of iron. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .) Under normal circumstances, total body iron burdens are two to four grams, most of which is circulating as hemoglobin (",
"    <a class=\"graphic graphic_table graphicRef76998 \" href=\"mobipreview.htm?15/22/15723\">",
"     table 1",
"    </a>",
"    ). Thus, if there is no attendant blood (iron) loss, the transfusion of 10 to 12 units of red cells effectively doubles an adult's total body iron burden.",
"   </p>",
"   <p>",
"    Free iron is toxic to tissues, which is why iron is closely bound to enzymes, hemoglobin, or stored in a complex molecule such as ferritin or hemosiderin. When reticuloendothelial storage sites are saturated, iron begins to be deposited in organs such as the liver, heart, endocrine organs, and pancreas, leading to hepatic fibrosis, cardiomyopathy, arrhythmias, endocrine dysfunction (including hypogonadism), and pancreatic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemic patients with iron overload obviously cannot undergo therapeutic phlebotomy, the preferred treatment for removing excess storage iron in patients with idiopathic hemochromatosis. Iron deposition under such circumstances can be retarded or reduced by administration of iron chelating agents. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     AIR EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of plastic equipment and closed blood delivery systems, entry of large volumes of air into the venous system is no longer a problem with routine transfusions. However, significant amounts of air may be inadvertently transfused following the use of more complex transfusion systems, such as apheresis and blood salvage equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42214/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GENERAL RULES CONCERNING ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the use of any therapeutic drug or procedure, careful deliberation concerning the advantages of the therapy outlined versus the risks is important. Meticulous attention to the clinical status of the patient is imperative. When an adverse reaction presents, it is not always immediately clear what is happening. For that reason, when a patient exhibits fever, shortness of breath, or any other signs of an adverse reaction to a blood component, one should take the following immediate steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stop the transfusion",
"     </li>",
"     <li>",
"      Keep the intravenous line open with saline",
"     </li>",
"     <li>",
"      Identify and treat the cause of the reaction",
"     </li>",
"     <li>",
"      Re-institute the transfusion only if it is deemed to be clinically essential",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior attention to this last item might obviate the need for giving a blood component in the first place, thus avoiding these risks entirely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699541\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to the transfusion of blood products are not rare and may be fatal. The major reactions covered in this review include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion-associated volume overload (TACO) can be avoided using a transfusion rate of approximately 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour in most patients. Patients deemed to be at risk of TACO (eg, small stature or low body weight, elderly, known or suspected poor cardiac function) can generally be safely transfused at a rate of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. Such patients should also be monitored more closely during the transfusion for signs and symptoms of TACO. Treatment is similar to other causes of cardiogenic pulmonary edema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transfusional volume overload (TACO)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: Components of therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood warmers, used on the recovery wards or in intensive care units and operating rooms, must be calibrated and continuously monitored to avoid heating of the blood cells above 40&deg;C, with resultant hemolysis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Blood warmers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypothermia is occasionally seen in recipients of large volumes of refrigerated (1 to 6&deg;C) blood products. Slowing the infusion, warming the patient, or warming the blood with properly functioning blood warmers (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Blood warmers'",
"      </a>",
"      above) are helpful interventions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypothermia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link&amp;anchor=H14#H14\">",
"       \"Use of blood products in the critically ill\", section on 'Hypothermia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=see_link&amp;anchor=H12#H12\">",
"       \"Accidental hypothermia in adults\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transfusional iron overload (hemosiderosis) may occur in chronically transfused patients, as each unit of red cells contains approximately 250 mg of iron. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Stack G, Judge JV, Snyder EL. Febrile and non-immune transfusion reactions. In: Principles of Transfusion Medicine, Rossi EC, Simon TL, Moss GS, Gould SA (Eds), Williams and Wilkins, Philadelphia 1996. p.778.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/2\">",
"      Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/3\">",
"      Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/4\">",
"      Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology 1996; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/5\">",
"      Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/6\">",
"      McLeod BC, Reed S, Viernes A, Valentino L. Rapid red cell transfusion by apheresis. J Clin Apher 1994; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/7\">",
"      Kruskall MS, Pacini DG, Malynn ER, Button LN. Evaluation of a blood warmer that utilizes a 40 degrees C heat exchanger. Transfusion 1990; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/8\">",
"      Linko K, Hynynen K. Erythrocyte damage caused by the Haemotherm microwave blood warmer. Acta Anaesthesiol Scand 1979; 23:320.",
"     </a>",
"    </li>",
"    <li>",
"     Huestis DW, Bove JR, Busch S. Practical Blood Transfusion, 3rd ed, Little Brown, Boston 1981. p.352.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/10\">",
"      Linden JV, Kaplan HS, Murphy MT. Fatal air embolism due to perioperative blood recovery. Anesth Analg 1997; 84:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/11\">",
"      Engelhardt W, Blumenberg D. [Risks and side effects of intraoperative autotransfusion]. Beitr Infusionsther 1991; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42214/abstract/12\">",
"      Delva E, Sadoul N, Chandon M, et al. Air embolism during liver resection: an unusual mechanism of entry from a peristaltic pump. Can Anaesth Soc J 1986; 33:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7919 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42214=[""].join("\n");
var outline_f41_14_42214=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10699541\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSFUSIONAL VOLUME OVERLOAD (TACO)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADDITION OF DRUGS AND DILUENTS TO BLOOD PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THERMAL HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood warmers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COAGULATION DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CITRATE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPERKALEMIA, HYPOKALEMIA, AND METABOLIC ALKALOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperkalemia and potassium leakage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      AIR EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GENERAL RULES CONCERNING ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10699541\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/22/15723\" title=\"table 1\">",
"      Storage iron pool",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_14_42215="Long-term supplemental oxygen therapy";
var content_f41_14_42215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Long-term supplemental oxygen therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Brian L Tiep, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Rick Carter, PhD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42215/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/14/42215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term oxygen therapy (LTOT) increases survival and improves the quality of life of hypoxemic patients with chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1-14\">",
"     1-14",
"    </a>",
"    ]. Each year, approximately one million patients receive LTOT through Medicare, at a cost exceeding two billion dollars per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/13\">",
"     13",
"    </a>",
"    ]. This cost is increasing at an annual rate of nearly 13 percent.",
"   </p>",
"   <p>",
"    Because LTOT is a costly therapy, Medicare reimbursement for its prescription is tightly regulated. In this topic review, we describe the benefits of LTOT and indications for its use. In addition, we address practical issues including reimbursement, documenting the patient's need for LTOT, and the process of prescribing LTOT that is necessary for the patients to receive their oxygen. The diagnosis and general management of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four randomized, controlled trials have evaluated the effect of long-term oxygen therapy (LTOT) on mortality in patients with COPD. Two of the trials, the Nocturnal Oxygen Therapy Trial (NOTT) and the Medical Research Council (MRC) trial, demonstrated improved survival among patients that received LTOT (",
"    <a class=\"graphic graphic_figure graphicRef82598 \" href=\"mobipreview.htm?38/49/39709\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67353 \" href=\"mobipreview.htm?18/33/18973\">",
"     figure 2",
"    </a>",
"    ), including correlation between survival and the average daily duration of oxygen use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In contrast, two trials found no effect of LTOT on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important difference between these trials was the inclusion criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/13\">",
"     13",
"    </a>",
"    ]. The trials that demonstrated a survival benefit included patients with more severe resting hypoxemia (arterial oxygen tension [PaO",
"    <sub>",
"     2",
"    </sub>",
"    ] &le;60 mmHg [7.98 kPa]) than the trials that showed no benefit (PaO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;69 mmHg [9.18 kPa]), indicating that individuals with less severe hypoxemia may not derive survival benefit from LTOT.",
"   </p>",
"   <p>",
"    LTOT may improve outcome measures other than mortality, including quality of life, cardiovascular morbidity, depression, cognitive function, exercise capacity, and frequency of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/3,5-12,16,17\">",
"     3,5-12,16,17",
"    </a>",
"    ]. Improved quality of life was demonstrated in a prospective study that measured health related quality of life (using the St. Georges Respiratory Questionnaire [SGRQ]) before and after six months of LTOT delivered via a concentrator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/16\">",
"     16",
"    </a>",
"    ]. Prior to therapy, health related quality of life was worse among the patients with COPD who had hypoxemia (and had already been receiving LTOT for at least six months via a cylinder), compared to patients with COPD who were not hypoxemic. After six months of LTOT, health-related quality of life had improved and was similar in both groups. This suggests that LTOT improves quality of life and the improvement is related, at least in part, to the time spent using supplemental oxygen, which also relates to the delivery system(s) used. The effect of combining concentrators and portable devices to improve mobility and further enhance quality of life has yet to be determined. Prescribing oxygen during exertion with highly portable lightweight devices without the support of a pulmonary rehabilitation program may or may not lead to a more active lifestyle.",
"   </p>",
"   <p>",
"    All of the studies described above evaluated the impact of LTOT used during rest and exertion. Controlled trials have also evaluated the impact of supplemental oxygen when used during exertion only. Among patients who have COPD with a resting PaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;60 mmHg (ie, are unlikely to derive a mortality benefit from LTOT), supplemental oxygen improved dyspnea and the distance walked during a five-minute walk test compared to supplemental air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, recovery time following exertion was shorter among the patients who received oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that LTOT has adverse effects in patients with COPD when administered correctly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/13\">",
"     13",
"    </a>",
"    ]. Although there exist theoretical concerns about potential toxicities in patients administered oxygen in high concentrations (above 50 percent) for extended time periods (eg, absorptive atelectasis, increased oxidative stress, and inflammation), clinical experience has provided little support for these concerns in the setting of LTOT. More explicit study is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for continuous long-term oxygen therapy (LTOT) for patients with chronic lung disease include (",
"    <a class=\"graphic graphic_table graphicRef76543 \" href=\"mobipreview.htm?35/62/36843\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial PO",
"      <sub>",
"       2",
"      </sub>",
"      (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) less than or equal to 55 mmHg (7.32 kPa), or an arterial oxygen saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ) less than or equal to 88 percent",
"     </li>",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      less than or equal to 59 mmHg (7.85 kPa), or an SaO",
"      <sub>",
"       2",
"      </sub>",
"      less than or equal to 89 percent, if there is evidence of cor pulmonale, right heart failure, or erythrocytosis (hematocrit &gt;55 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oxygen may be prescribed during sleep if the PaO",
"    <sub>",
"     2",
"    </sub>",
"    is 55 mmHg or less, the SaO",
"    <sub>",
"     2",
"    </sub>",
"    is 88 percent or less, there is a fall of PaO",
"    <sub>",
"     2",
"    </sub>",
"    greater than 10 mmHg (1.33 kPa),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is a fall of SaO",
"    <sub>",
"     2",
"    </sub>",
"    greater than 5 percent during sleep with signs or symptoms of nocturnal hypoxemia (eg, impaired cognitive process, restlessness, or insomnia).",
"   </p>",
"   <p>",
"    Oxygen may be prescribed during exercise if there is a reduction of PaO",
"    <sub>",
"     2",
"    </sub>",
"    to 55 mmHg or less, or of SaO",
"    <sub>",
"     2",
"    </sub>",
"    to 88 percent or less during exercise. Additionally, oxygen may be warranted during exercise even in those patients who do not significantly desaturate during exercise, if they have dyspnea and ventilatory abnormalities during exercise that suggest supplemental oxygen may permit greater exertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/20\">",
"     20",
"    </a>",
"    ]. This is supported by the observation that hyperoxia increases exercise endurance in dose-dependent manner, up to an inspired oxygen fraction of 50 percent, or a flow of 6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of 100 percent oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of supplemental oxygen in the palliative treatment of dyspnea is not well supported by the literature. A randomized trial and systematic reviews have found that supplemental oxygen provides no symptomatic benefit beyond room air for patients with dyspnea, but not hypoxemia, due to advanced heart failure or end stage cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H935678#H935678\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRESCRIBING OXYGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responsibilities of the clinician prescribing long-term oxygen therapy (LTOT) include (",
"    <a class=\"graphic graphic_table graphicRef77321 \" href=\"mobipreview.htm?23/44/24267\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proper determination of need",
"     </li>",
"     <li>",
"      Determining the oxygen flow rate for each condition (ie, the required flow rate may be different during sleep, exercise and sedentary wakefulness)",
"     </li>",
"     <li>",
"      Assuring the selection of a qualified durable medical equipment supplier",
"     </li>",
"     <li>",
"      Completion of the Certification of Medical Necessity (CMN)",
"     </li>",
"     <li>",
"      Providing a prescription for ambulatory oxygen if required",
"     </li>",
"     <li>",
"      Testing patients using the portable oxygen device provided during typical exercise to assure adequate oxygenation",
"     </li>",
"     <li>",
"      Reassessment for prescription renewal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      modification",
"     </li>",
"     <li>",
"      Patient education and training [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Determining need",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term oxygen therapy (LTOT) should be prescribed only when there is evidence of persistent hypoxemia in a clinically stable patient who is receiving otherwise optimal medical management. Patients who are clinically unstable or whose medical management is not optimized should be prescribed oxygen therapy and reassessed later for their long-term oxygen needs.",
"   </p>",
"   <p>",
"    There are specific requirements for determining a patient's need for LTOT that must be met for LTOT to be reimbursed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas analysis or measurement of arterial saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      by pulse oximetry) must be performed by a physician or by a Medicare qualified laboratory. The intent of this requirement is to prevent the oxygen provider from also being involved in certifying the medical necessity, since this could represent a conflict of interest.",
"     </li>",
"     <li>",
"      The arterial blood gas or SaO",
"      <sub>",
"       2",
"      </sub>",
"      measurement must be obtained within two days of discharge if the oxygen is prescribed at the time of hospital discharge.",
"     </li>",
"     <li>",
"      The blood gas measurement must be repeated in 60 to 90 days in order for oxygen to be continued beyond the initial three months of therapy if the arterial oxygen (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) is 56 to 59 mmHg (7.45 to 7.85 kPa) or the SaO",
"      <sub>",
"       2",
"      </sub>",
"      is 89 percent. This requirement is due to a Congressional misunderstanding of a recommendation made by the oxygen consensus conference, which stated that arterial blood gases should be repeated in one to three months whenever therapy is begun for a clinically unstable patient in whom the medical management may not be optimal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oxygen flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not required by payers, we believe that arterial blood gas measurements should be the standard to document the need for long-term oxygen therapy (LTOT) rather than the measurement of arterial oxygen saturation via pulse oximetry alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This reflects our opinion that no patient should be administered LTOT based on the less precise measurement of arterial saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) by a pulse oximeter and without the benefit of knowing the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    and pH. We suggest that every patient have a baseline arterial blood gas performed. The arterial blood gas will indicate whether the SpO",
"    <sub>",
"     2",
"    </sub>",
"    and arterial oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) correlate and, therefore, whether the SpO",
"    <sub>",
"     2",
"    </sub>",
"    can be used for future assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flow rate&nbsp;during rest &ndash; The flow of oxygen needed to correct hypoxemia should be determined by measurement of PaO",
"      <sub>",
"       2",
"      </sub>",
"      or SaO",
"      <sub>",
"       2",
"      </sub>",
"      when LTOT is initiated (",
"      <a class=\"graphic graphic_table graphicRef73572 \" href=\"mobipreview.htm?2/26/2475\">",
"       table 3",
"      </a>",
"      ). The threshold PaO",
"      <sub>",
"       2",
"      </sub>",
"      or SaO",
"      <sub>",
"       2",
"      </sub>",
"      that optimally improves survival and quality of life is not known. One of the early studies that demonstrated increased survival among patients with chronic obstructive pulmonary disease (COPD) who received LTOT raised the mean PaO",
"      <sub>",
"       2",
"      </sub>",
"      to 71.3 mmHg (9.48 kPa) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/25\">",
"       25",
"      </a>",
"      ]. In the Nocturnal Oxygen Therapy Trial (NOTT), the investigators attempted to maintain the PaO",
"      <sub>",
"       2",
"      </sub>",
"      between 60 and 80 mmHg (7.98 to 10.64 kPa) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1\">",
"       1",
"      </a>",
"      ]. A PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 60 to 65 mmHg (7.98 to 8.65 kPa) or an SaO",
"      <sub>",
"       2",
"      </sub>",
"      of 90 to 92 percent is generally considered to be acceptable. This represents clinically \"adequate\" correction of hypoxemia for most patients and is unlikely to cause significant CO",
"      <sub>",
"       2",
"      </sub>",
"      retention. However, high flow oxygen may cause CO",
"      <sub>",
"       2",
"      </sub>",
"      retention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=see_link\">",
"       \"Use of oxygen in patients with hypercapnia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flow rate during exercise &ndash; It is common for patients with COPD who qualify for LTOT and experience hypoxemia at rest to desaturate further during usual activities of daily living, such as walking. As a result, higher oxygen flows are often necessary during exertion. It is therefore important to determine the exercise oxygen prescription while the patient is walking and to include this information in the oxygen prescription. The difference in oxygen flow necessary to correct hypoxemia at rest and during exercise may be magnified when some of the oxygen conserving devices are being used, especially those that utilize an oxygen pulsing device [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. An additional consideration is the use of hyperoxia to improve ventilation, reduce dyspnea, and enable the patient to exercise longer or at higher intensity during training programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/20,29\">",
"       20,29",
"      </a>",
"      ]. Therefore, not only should patients be evaluated for desaturation (hypoxemia), but other outcomes such as dyspnea and exercise improvement during exercise on various O",
"      <sub>",
"       2",
"      </sub>",
"      liter flows regardless of a desaturation response.",
"     </li>",
"     <li>",
"      Flow rate during sleep &ndash; Among patients prescribed LTOT for daytime hypoxemia, clinicians should determine if higher flows of oxygen are necessary to prevent nocturnal oxygen desaturation. The importance of nocturnal desaturation is uncertain since some persons have oxyhemoglobin desaturation during sleep without daytime sequelae. Nevertheless, most clinicians managing patients who qualify for LTOT because of daytime hypoxemia adjust the flow rate to prevent hypoxemia during sleep. As an example, the oxygen flow was routinely increased by one",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      during sleep in the NOTT trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients who do not qualify for oxygen when awake may require oxygen therapy only at night. As many as 30 percent of patients with COPD who have no daytime hypoxemia experience desaturation during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In those patients with COPD who have cor pulmonale, right heart failure, or erythrocytosis without evidence of hypoxemia while awake, any period of prolonged desaturation during sleep may potentially be detrimental. Thus, nocturnal monitoring of hypoxemic events and titration of supplemental oxygen are advised. Some patients may have obstructive sleep apnea (OSA) in addition to their COPD, as a cause of nocturnal desaturation. Overnight polysomnography can help clarify whether OSA is playing a role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36119?source=see_link\">",
"     \"Cor pulmonale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Equipment selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should also know the durable medical equipment (DME) providers in the area and encourage the use of those providers who are willing and able to provide the best service and to fill the prescription appropriately.",
"   </p>",
"   <p>",
"    Every attempt should be made to provide portable or wearable oxygen systems in support of patients striving for an active lifestyle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. For highly active and mobile patients, the clinician should order ambulatory liquid oxygen, a lightweight aluminum or fiber-wrapped ambulatory cylinder, or a portable oxygen concentrator. Each of these systems may be combined with an oxygen conserving device or transtracheal catheter to substantially increase the functional time and reduce the size and weight of the unit that the patient carries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This requires the clinician to order portable oxygen with or without an oxygen conserving technology, in addition to a stationary LTOT system. The proper prescription depends on the individual needs of the patient. The DME supplier may not provide patients with the best available technology unless the clinician has the knowledge and ability to prescribe it. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=see_link\">",
"     \"Oxygen conserving devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Portable oxygen is reimbursed if the Medicare patient is mobile in the home and regularly goes beyond the limits of a stationary oxygen delivery system with 50 feet of tubing. The Center for Medicare and Medicaid Services (CMS) does not consider travel outside of the home in making this determination and also does not recognize a distinction between portable and ambulatory oxygen. The distinction made by the pulmonary community is that ambulatory oxygen delivery systems should weigh less than 10 lbs (4.5 kg) and be easily carried by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/32\">",
"     32",
"    </a>",
"    ]. This 10 lb limit is high enough to encompass the use of several portable oxygen concentrators; several portable gas and liquid systems weigh less than 5 lbs. These units should be provided for patients who are highly mobile and active.",
"   </p>",
"   <p>",
"    Twenty pound E cylinders on a two-wheeled stroller cannot be carried by the patient and are difficult to maneuver on stairs and on public or private vehicles of transportation. These E cylinders may be prescribed for patients who are less mobile and leave the home only occasionally, or who require the higher storage capability of these cylinders. Additionally, E-cylinders are typically placed in the patient's home as an emergency backup in the event the primary O",
"    <sub>",
"     2",
"    </sub>",
"    delivery system fails.",
"   </p>",
"   <p>",
"    Oxygen is reimbursed on a prospective payment basis by CMS, and there is no Medicare requirement concerning the type of equipment being provided by the home oxygen supplier. CMS considers all oxygen delivery systems to be equal and \"modality neutral.\" For patients who require portable systems, there is a small additional reimbursement for a \"portable add on\" device, which must be ordered by the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Certification of Medical Necessity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician or a member of his or her staff must complete a Certification of Medical Necessity (CMN) and only the clinician can sign the form. The requirement for the clinician to sign the CMN Form DMERC 484.2 (",
"    <a class=\"graphic graphic_figure graphicRef56867 graphicRef63509 \" href=\"mobipreview.htm?43/34/44586\">",
"     figure 3A-B",
"    </a>",
"    ) was recommended by the Office of the Inspector General of the United States after a five&ndash;state survey indicated that the clinician's knowledge of home oxygen therapy and involvement in writing the prescription were often inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/33\">",
"     33",
"    </a>",
"    ]. In many cases, the home oxygen supplier was determining the need for therapy and also supplying the equipment without adequate clinician input. This requirement is intended to assure the clinician's involvement in the prescribing and administration of long-term oxygen therapy (LTOT).",
"   </p>",
"   <p>",
"    The CMN no longer serves as the clinician's prescription. A separate oral or written prescription must now be provided to the home oxygen supplier when oxygen is ordered and prior to completion of form DMERC 484.2 (",
"    <a class=\"graphic graphic_figure graphicRef56045 \" href=\"mobipreview.htm?38/5/39007\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ongoing assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the aid of the durable medical equipment (DME) provider, the clinician should monitor the use of the oxygen by the patient and the environment in which the oxygen is being used. Patients who continue to smoke while using oxygen create a hazard to themselves, their families, and other occupants of buildings where they live.",
"   </p>",
"   <p>",
"    Oxygen should not be continued if the patient is unwilling to use it, and advanced ambulatory equipment should not be supplied if the patient is unwilling or unable to be physically active. All patients receiving LTOT must be recertified every 12 months; retesting of PaO",
"    <sub>",
"     2",
"    </sub>",
"    or SaO",
"    <sub>",
"     2",
"    </sub>",
"    is not required by Medicare but may be required by other third party payers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REIMBURSEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most clinicians and health care professionals consider oxygen to be an important drug for the treatment of hypoxemia, the Center for Medicare and Medicaid Services (CMS; formerly called the Health Care Financing Administration, or HCFA) does not pay for oxygen as medication. Rather, CMS classifies oxygen and oxygen delivery equipment as durable medical equipment (DME); this definition allows oxygen to be reimbursed as a form of \"medical equipment.\" As a result, a specific Certificate of Medical Necessity (CMN) called the DMERC 484.2 (previously the HCFA&ndash;484 form) must be completed by the clinician in order for oxygen therapy to be reimbursed at a level of 80 percent of the Medicare allowable charge. The patient or the supplemental insurance provider is responsible for the remaining 20 percent of the cost.",
"   </p>",
"   <p>",
"    The requirements for medical necessity established by CMS are also utilized by most third party payers. These requirements are based primarily on the parameters for entry into the multicenter Nocturnal Oxygen Therapy Trial (NOTT) sponsored by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1\">",
"     1",
"    </a>",
"    ]. Indications and guidelines for therapy have been further refined by six national consensus conferences on long-term oxygen therapy (LTOT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/22,24,32,34-36\">",
"     22,24,32,34-36",
"    </a>",
"    ]. These guidelines apply not only to hypoxemic patients with COPD, but also to patients whose hypoxemia is due to other disorders, such as chronic interstitial lung disease, chest wall disease, and cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within these guidelines, it is the clinician's responsibility to be involved in selection of appropriate equipment and provision of an individualized prescription that must be transmitted to the DME provider (",
"    <a class=\"graphic graphic_figure graphicRef56045 \" href=\"mobipreview.htm?38/5/39007\">",
"     figure 4",
"    </a>",
"    ). The prescription must contain several required elements including liter oxygen flow and any changes that may be required for sleep, exercise or other condition, duration of need,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the issuance of portable oxygen devices. The clinician is now instructed not to sign the CMN form (DMERC 484.2) unless the provider has correctly restated the prescription in Section C (",
"    <a class=\"graphic graphic_figure graphicRef56867 graphicRef63509 \" href=\"mobipreview.htm?43/34/44586\">",
"     figure 3A-B",
"    </a>",
"    ). Periodically, the clinician will need to recertify the patient for supplemental oxygen and this recertification must be completed within a specified period of time to ensure that oxygen is provided without interruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADDITIONAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transtracheal oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transtracheal oxygen appears to provide advantages over nasal oxygen delivery by assuring oxygenation and perhaps reducing the work of breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/38\">",
"     38",
"    </a>",
"    ]. Although transtracheal oxygen therapy is a more invasive alternative, patient acceptance has been exceptionally good and compliance with therapy is substantially enhanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/39\">",
"     39",
"    </a>",
"    ]. This is a technology that may be underutilized, but it does require patient education as well as organization and commitment by the clinician and his or her staff. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37015?source=see_link\">",
"     \"Transtracheal oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exercise training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemic patients are prescribed oxygen in order to prevent exertional desaturation as described above. However, a double blind study performed on COPD patients, who were not hypoxemic at rest, demonstrated that oxygen during exercise enabled patients to tolerate higher training intensity and increased exercise tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/29\">",
"     29",
"    </a>",
"    ]. The exact role of oxygen as a rehabilitative adjunct remains to be delineated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42215/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89455156\">",
"    <span class=\"h2\">",
"     Nocturnal desaturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with nocturnal desaturation, a clinical evaluation for sleep-disordered breathing and overnight polysomnography are often appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/22/33122?source=see_link\">",
"       \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89455082\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for continuous long-term oxygen therapy (LTOT) for patients with chronic lung disease include (",
"      <a class=\"graphic graphic_table graphicRef76543 \" href=\"mobipreview.htm?35/62/36843\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Resting arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) less than or equal to 55 mmHg (7.32 kPa), or a pulse arterial oxygen saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ) less than or equal to 88 percent",
"     </li>",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      less than or equal to 59 mmHg (7.85 kPa), or an SaO",
"      <sub>",
"       2",
"      </sub>",
"      less than or equal to 89 percent, if there is evidence of cor pulmonale, right heart failure, or erythrocytosis (hematocrit &gt;55 percent)",
"     </li>",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 59 mmHg (7.85 kPa) or lower, or an SaO",
"      <sub>",
"       2",
"      </sub>",
"      of 88 percent or lower, during exercise or sleep may benefit from administration of supplemental oxygen during those times, although the evidence for benefit is less clear",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supplemental oxygen is unlikely to reduce dyspnea in patients with end stage cancer or heart failure who are not hypoxemic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H935678#H935678\">",
"       \"Assessment and management of dyspnea in palliative care\", section on 'Oxygen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When determining the flow rate of supplemental oxygen, a goal PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 60 to 65 mmHg (7.98 to 8.65 kPa) or an SaO",
"      <sub>",
"       2",
"      </sub>",
"      of 90 to 92 percent is generally considered to be acceptable. The oxygen flow rate often needs to be increased during exertion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oxygen flow rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every attempt is made to provide portable or wearable oxygen systems for patients striving for an active lifestyle. Ambulatory liquid oxygen and portable oxygen concentrators weigh less than 10 pounds (4.5 kg) and are preferred for more active patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Equipment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of oxygen conserving devices, such as reservoir cannulas, oxygen pulsing devices, or transtracheal oxygen delivery may provide improved efficiency and a longer oxygen supply when away from home. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Equipment selection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=see_link\">",
"       \"Oxygen conserving devices\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients on portable oxygen systems should be tested using the device provided while performing a typical level of exercise to assure adequate oxygenation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oxygen flow rate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nocturnal oxygen desaturation, clinical evaluation for sleep-disordered breathing and polysomnography are often appropriate. (See",
"      <a class=\"local\" href=\"#H89455156\">",
"       'Nocturnal desaturation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/1\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/2\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/3\">",
"      Eaton T, Lewis C, Young P, et al. Long-term oxygen therapy improves health-related quality of life. Respir Med 2004; 98:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/4\">",
"      Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/5\">",
"      Stewart BN, Hood CI, Block AJ. Long-term results of continuous oxygen therapy at sea level. Chest 1975; 68:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/6\">",
"      Heaton RK, Grant I, McSweeny AJ, et al. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1983; 143:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/7\">",
"      Weitzenblum E, Oswald M, Apprill M, et al. Evolution of physiological variables in patients with chronic obstructive pulmonary disease before and during long-term oxygen therapy. Respiration 1991; 58:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/8\">",
"      Borak J, Sliwiski P, Tobiasz M, et al. Psychological status of COPD patients before and after one year of long-term oxygen therapy. Monaldi Arch Chest Dis 1996; 51:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/9\">",
"      Clini E, Vitacca M, Foglio K, et al. Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia. Eur Respir J 1996; 9:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/10\">",
"      Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? Eur Respir J 1996; 9:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/11\">",
"      Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J 2002; 20:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/12\">",
"      Haidl P, Clement C, Wiese C, et al. Long-term oxygen therapy stops the natural decline of endurance in COPD patients with reversible hypercapnia. Respiration 2004; 71:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/13\">",
"      Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med 2006; 174:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/14\">",
"      Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest 2010; 138:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/15\">",
"      G&oacute;recka D, Gorzelak K, Sliwiski P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/16\">",
"      Tanni SE, Vale SA, Lopes PS, et al. Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia. J Bras Pneumol 2007; 33:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/17\">",
"      Yamamoto H, Teramoto S, Yamaguchi Y, et al. Long-term oxygen administration reduces plasma adrenomedullin levels in patients with obstructive sleep apnea syndrome. Sleep Med 2007; 9:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/18\">",
"      Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med 2007; 176:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/19\">",
"      Quantrill SJ, White R, Crawford A, et al. Short burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease. Thorax 2007; 62:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/20\">",
"      Snider GL. Enhancement of exercise performance in COPD patients by hyperoxia: a call for research. Chest 2002; 122:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/21\">",
"      Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/22\">",
"      Doherty DE, Petty TL, Bailey W, et al. Recommendations of the 6th long-term oxygen therapy consensus conference. Respir Care 2006; 51:519.",
"     </a>",
"    </li>",
"    <li>",
"     American Thoracic Society / European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. Version 1.2. New York: American Thoracic Society; 2004 [updated 2005 September 8]. Available from: file://www-test.thoracic.org/copd/ (Accessed July 9, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/24\">",
"      New problems in supply, reimbursement and certification of medical necessity for long&ndash;term oxygen therapy. Am Rev Respir Dis 1990; 142:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/25\">",
"      Neff TA, Petty TL. Long-term continuous oxygen therapy in chronic airway obstruction. Mortality in relationship to cor pulmonale, hypoxia, and hypercapnia. Ann Intern Med 1970; 72:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/26\">",
"      Austin MA, Wills KE, Blizzard L, et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010; 341:c5462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/27\">",
"      Tiep BL, Barnett J, Schiffman G, et al. Maintaining oxygenation via demand oxygen delivery during rest and exercise. Respir Care 2002; 47:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/28\">",
"      Palwai A, Skowronski M, Coreno A, et al. Critical comparisons of the clinical performance of oxygen-conserving devices. Am J Respir Crit Care Med 2010; 181:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/29\">",
"      Emtner M, Porszasz J, Burns M, et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003; 168:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/30\">",
"      Fletcher EC, Miller J, Divine GW, et al. Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mm Hg. Chest 1987; 92:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/31\">",
"      Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992; 145:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/32\">",
"      Petty TL, O'Donohue WJ Jr. Further recommendations for prescribing, reimbursement, technology development, and research in long-term oxygen therapy. Summary of the Fourth Oxygen Consensus Conference, Washington, D.C., October 15-16, 1993. Am J Respir Crit Care Med 1994; 150:875.",
"     </a>",
"    </li>",
"    <li>",
"     Office of the Inspector General, Office of Audit Services. Results of national review of the medical necessity for oxygen concentrators. Audit Control No. A&ndash;04&ndash;88&ndash;02058, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/34\">",
"      Problems in prescribing and supplying oxygen for Medicare patients. Am Rev Respir Dis 1986; 134:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/35\">",
"      Further recommendations for prescribing and supplying long&ndash;term oxygen therapy. Am Rev Respir Dis 1988; 138:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/36\">",
"      Petty TL, Casaburi R. Recommendations of the Fifth Oxygen Consensus Conference. Writing and Organizing Committees. Respir Care 2000; 45:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/37\">",
"      Zieliski J. Long-term oxygen therapy in conditions other than chronic obstructive pulmonary disease. Respir Care 2000; 45:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/38\">",
"      O'Donohue WJ Jr. Transtracheal oxygen: a step beyond the nasal cannula for long-term oxygen therapy. Nebr Med J 1992; 77:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42215/abstract/39\">",
"      Christopher KL, Spofford BT, Petrun MD, et al. A program for transtracheal oxygen delivery. Assessment of safety and efficacy. Ann Intern Med 1987; 107:802.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1445 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42215=[""].join("\n");
var outline_f41_14_42215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H89455082\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRESCRIBING OXYGEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Determining need",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oxygen flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Equipment selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Certification of Medical Necessity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ongoing assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REIMBURSEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADDITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transtracheal oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exercise training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89455156\">",
"      Nocturnal desaturation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89455082\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1445|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/49/39709\" title=\"figure 1\">",
"      Benefit of LTOT in NOTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/33/18973\" title=\"figure 2\">",
"      Benefit of LTOT in MRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/10/33962\" title=\"figure 3A\">",
"      DMERC 484 LTOT form A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/21/34138\" title=\"figure 3B\">",
"      DMERC 484 LTOT form B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/5/39007\" title=\"figure 4\">",
"      Home O2 prescription form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1445|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/62/36843\" title=\"table 1\">",
"      LTOT indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/44/24267\" title=\"table 2\">",
"      MD responsibilities LTOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/26/2475\" title=\"table 3\">",
"      Initial oxygen flow in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=related_link\">",
"      Oxygen conserving devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22150?source=related_link\">",
"      Sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37015?source=related_link\">",
"      Transtracheal oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_14_42216="Rapid cycling bipolar disorder in adults: Treatment of major depression";
var content_f41_14_42216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid cycling bipolar disorder in adults: Treatment of major depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     Ralph Kupka, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42216/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/14/42216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H92693288\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is characterized by mood episodes that are nearly always recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients who experience at least four episodes during a 12-month period are classified as &ldquo;rapid cycling&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/1\">",
"     1",
"    </a>",
"    ]. The term was first used in 1974 to describe bipolar patients who were unresponsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it is now clear that pharmacotherapy is often less beneficial for rapid cycling patients than non-rapid cycling patients, and that lithium may be as effective as other drugs for rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the treatment of major depression in rapid cycling patients. The treatment of manic, hypomanic, and mixed episodes in rapid cycling patients, and the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder are discussed separately, as is the diagnosis and general treatment of bipolar disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=see_link\">",
"       \"Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92693295\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/1\">",
"     1",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid cycling specifies a particular course of illness that can occur in bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnostic criteria for rapid cycling are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least four mood episodes in a 12-month period",
"     </li>",
"     <li>",
"      The episodes meet both the symptom and duration criteria for a manic, hypomanic, major depressive, or mixed episode; the episodes that occur as part of a rapid cycling pattern are no different from episodes that occur as part of a non-rapid cycling pattern.",
"     </li>",
"     <li>",
"      The episodes are demarcated by a period of partial or full remission for at least two months, or by a switch to an episode of opposite polarity. Manic, hypomanic, and mixed episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the clinical features and diagnosis of rapid cycling are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link\">",
"     \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92692334\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes.",
"   </p>",
"   <p>",
"    Response to pharmacotherapy appears to be poorer in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. A meta-analysis of nine studies (primarily observational, 1424 bipolar patients) examined improvement of mood episodes and rates of recurrence in rapid cycling and non-rapid cycling patients, and found that an inferior response to medications was more probable in rapid cycling patients (risk ratio 1.4, 95% CI 1.3-1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinicians may find that it is not feasible for rapid cycling patients to fully remit from a mood episode or avoid recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/10\">",
"     10",
"    </a>",
"    ], and that a more realistic goal is to improve functioning and reduce the frequency, intensity, and duration of mood episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/4\">",
"     4",
"    </a>",
"    ]. The difficulties posed by rapid cycling usually necessitate referral to a psychiatrist.",
"   </p>",
"   <p>",
"    Additional information about the general principles of treating rapid cycling bipolar disorder, including the frequency of monitoring patients and the duration of a treatment trial, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=see_link&amp;anchor=H86794887#H86794887\">",
"     \"Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes\", section on 'General principles'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92694034\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling bipolar patients with major depression are typically treated with pharmacotherapy. However, refractory patients may benefit from electroconvulsive therapy (ECT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92692341\">",
"    <span class=\"h2\">",
"     First line medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    as first line treatment for rapid cycling bipolar major depression based upon its efficacy and tolerability in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In addition, other randomized trials have demonstrated that quetiapine is efficacious for the general treatment of bipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    is usually started at 50 mg at bedtime and titrated up by increments of 50 to 200 mg to achieve a target dose of 300 mg per day within four to seven days, provided that side effects do not intervene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/16\">",
"     16",
"    </a>",
"    ]. (Doses of 600 mg per day have been studied for bipolar major depression, but provide no advantage over a dose of 300 mg per day.) The side effects and pharmacology of quetiapine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524693#H76524693\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Quetiapine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    for rapid cycling bipolar patients with major depression includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (300 or 600 mg per day) with placebo for treating bipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/16\">",
"       16",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 108), response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received quetiapine than placebo (66 versus 29 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8,11\">",
"       8,11",
"      </a>",
"      ]. This was consistent with the finding that each dose of quetiapine was superior to placebo in the total sample [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      extended release (300 mg per day) with placebo for treating bipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/12\">",
"       12",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 74), improvement was greater with quetiapine than placebo. This was consistent with the finding that quetiapine was superior in patients without rapid cycling (N = 196). &nbsp;",
"     </li>",
"     <li>",
"      A one-year, open-label, randomized study compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (mean dose 465 mg per day) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      (mean dose 1340 mg per day) in 38 rapid cycling patients who were euthymic or primarily suffering from depressive symptoms at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/19\">",
"       19",
"      </a>",
"      ]. The number of days with moderate to severe depressive symptoms was significantly fewer in patients who received quetiapine than valproate (12 versus 28 percent of days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92692348\">",
"    <span class=\"h2\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many rapid cycling bipolar patients with major depression do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. For these resistant patients, we suggest sequential treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . To switch drugs, quetiapine is tapered and discontinued over one to two weeks at the same time that another medication is started and titrated up. We generally taper quetiapine by 50 to 200 mg per day, every one to two days.",
"   </p>",
"   <p>",
"    The following drugs are listed in order of preference, based upon how often each drug has been studied and how well it worked. For resistant rapid cycling bipolar patients with major depression who do not respond to one second-line drug, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another second-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    200 mg per day is decreased by 50 mg per day, every two to three days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      &ndash; The initial dose of lamotrigine is 25 mg per day for weeks one and two. For weeks three and four, the dose is increased to 50 mg per day, taken in two divided doses (an extended release formulation is available for once a day dosing). The dose can then be titrated up by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of life-threatening skin rash, such as Stevens-Johnson syndrome. The target dose ranges from 50 to 300 mg per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/20\">",
"       20",
"      </a>",
"      ]. The side effects and pharmacology of lamotrigine are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of lamotrigine in treating rapid cycling bipolar patients with major depression includes the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A 26-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (mean dose 288 mg per day) with placebo in 177 rapid cycling bipolar patients who were clinically stable for two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/21\">",
"       21",
"      </a>",
"      ]. Relapse occurred in significantly fewer patients who received lamotrigine than placebo (59 versus 74 percent). In addition, discontinuation of treatment due to adverse side effects was identical for lamotrigine and placebo (two percent of each group). &nbsp;",
"     </li>",
"     <li>",
"      A randomized, crossover trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (mean daily dose 274 mg per day) with placebo in 31 patients with treatment-resistant mood disorders (74 percent had rapid cycling bipolar disorder) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/22\">",
"       22",
"      </a>",
"      ]. In the total sample, response occurred in significantly more patients who received lamotrigine than placebo (52 versus 23 percent).",
"     </li>",
"     <li>",
"      A 16-week, open-label, randomized trial (outcome assessed by blinded raters) compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (median dose 250 mg per day) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      (median serum concentration 0.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in patients with bipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/23\">",
"       23",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 68), significant improvement from baseline occurred with each drug, with no significant difference between the two medications; this was consistent with the finding that improvement with each drug was comparable in the total sample.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      &ndash; The dose, side effects, and pharmacology of lithium, as well as the use of serum levels, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the benefit of lithium in treating depressed, rapid cycling patients includes the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As discussed above, a study found that improvement of rapid cycling bipolar major depression was comparable for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of three observational studies found that in 172 rapid cycling bipolar patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , recurrent mood episodes did not occur in 34 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/24\">",
"       24",
"      </a>",
"      ]. In a separate pooled analysis of three observational studies with 90 rapid cycling patients who received lithium, the frequency, intensity, and duration of mood episodes decreased by 50 percent or more in 59 percent of patients. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      &ndash; For patients who do not respond to sequential trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , we suggest olanzapine plus fluoxetine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8,25\">",
"       8,25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The initial dose of olanzapine is generally 5 mg per day taken once daily, and the usual target dose range is 5 to 20 mg per day. Olanzapine is increased by 5 mg per day, every one to seven days, depending upon the intensity of specific symptoms, intervening side effects, and response to treatment. As an example, persistent insomnia should prompt a dose increase. The side effects and pharmacology of olanzapine are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The initial dose of fluoxetine is usually 20 mg per day taken once daily, and the target dose range is generally 20 to 60 mg per day. For patients who do not respond to 20 mg per day within two to four weeks, the dose is increased by 10 to 20 mg per day, depending on how well the medication is tolerated. Patients who remain unresponsive to treatment should receive additional increases of 10 to 20 mg per day every two to four weeks as tolerated, to an effective dose within the target dose range. We generally taper and discontinue fluoxetine over one to two weeks soon after the depressive syndrome has resolved (eg, within two to three months). Fluoxetine is decreased by 10 mg per day, every one to two days. The side effects and pharmacology of fluoxetine are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of olanzapine plus fluoxetine includes an eight-week randomized trial that compared olanzapine (mean dose 7 mg per day) plus fluoxetine (mean dose 40 mg per day) with placebo in patients with bipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/25\">",
"       25",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 164), response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received the combination than placebo (78 versus 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8,25\">",
"       8,25",
"      </a>",
"      ]. This was consistent with results in the total sample that found the combination was superior to placebo. In addition, discontinuation of treatment due to adverse side effects in the rapid cycling subgroup was comparable for patients who received the combination or placebo (5 and 3 percent), as was switching from major depression to mania or hypomania (10 versus 4 percent of patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some authorities avoid antidepressants in rapid cycling bipolar patients with major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/26,27\">",
"       26,27",
"      </a>",
"      ], because observational studies suggest that antidepressants may exacerbate rapid cycling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/10\">",
"       10",
"      </a>",
"      ]. However, other observational studies have failed to find this association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/24,28,29\">",
"       24,28,29",
"      </a>",
"      ]. The possible role of antidepressants in the pathogenesis of rapid cycling is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H190200740#H190200740\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92692355\">",
"    <span class=\"h2\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon several studies, rapid cycling bipolar patients with major depression frequently do not respond to pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/9,21,23,30-32\">",
"     9,21,23,30-32",
"    </a>",
"    ]. For refractory patients whose depression does not respond to trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , we suggest electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Electroconvulsive therapy (ECT)",
"      </strong>",
"      &ndash; ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/35\">",
"       35",
"      </a>",
"      ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"       \"Medical consultation for electroconvulsive therapy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Electrode placement and other aspects of ECT technique for treating rapid cycling bipolar patients with major depression have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"       \"Overview of electroconvulsive therapy (ECT) for adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"       \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of ECT in treating rapid cycling bipolar patients with major depression includes the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A prospective observational study followed 43 patients with rapid cycling bipolar disorder who received ECT; 26 percent recovered (the mood episode resolved and there were no recurrences for at least one year), and the remaining patients improved temporarily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective observational study, 14 rapid cycling bipolar patients with major depression received ECT (mean number of treatments 23, mean duration of treatment 21 months). Rapid cycling resolved in every patient and the mean number of mood episodes per year decreased from six to one [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/36\">",
"       36",
"      </a>",
"      ]. Other reports also suggest that ECT may be beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of ECT in 50 bipolar patients with major depression (not selected for rapid cycling) found that remission occurred in 64 percent (which was similar to the remission rate of 61 percent in the 170 patients with unipolar major depression) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Second-generation antipsychotic",
"      </strong>",
"      &ndash; For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, a reasonable alternative is an adjunctive second generation antipsychotic. A prospective observational study of 10 patients who were treated with adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (2 to 6 mg per day) for at least six months found that mean depression rating scale scores decreased significantly from baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/39\">",
"       39",
"      </a>",
"      ]. However, second-generation antipsychotic monotherapy does not appear to be useful. An eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      monotherapy with placebo in bipolar patients with major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/25\">",
"       25",
"      </a>",
"      ]; in the subgroup with rapid cycling (N = 261), response (improvement from baseline on the depression rating scale &ge;50 percent) was comparable for olanzapine and placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"       Levothyroxine",
"      </a>",
"      <strong>",
"       (T4)",
"      </strong>",
"      &ndash; For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, and do not respond to treatment with a second generation antipsychotic, a reasonable alternative is adjunctive levothyroxine (T4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/40\">",
"       40",
"      </a>",
"      ]. Use of T4 for rapid cycling patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=see_link&amp;anchor=H86796271#H86796271\">",
"       \"Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes\", section on 'Refractory patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vagal nerve stimulation",
"      </strong>",
"      &ndash; Vagal nerve stimulation added to pharmacotherapy may possibly help rapid cycling bipolar patients with refractory major depression. A prospective observational study of nine rapid cycling patients with primarily depressive symptoms at baseline, who were treated with vagal nerve stimulation in conjunction with various medication combinations for one year, reported that symptoms and functioning generally improved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/41\">",
"       41",
"      </a>",
"      ]. The most common adverse effects were hoarseness, postoperative pain and burning at the device site, voice change with stimulation, and shortness of breath.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92692362\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmenting pharmacotherapy with psychotherapy may possibly be useful for rapid cycling bipolar patients with major depression. We suggest psychoeducation (which teaches patients about the clinical features, treatment, and prognosis of rapid cycling bipolar disorder), based upon the demonstrated efficacy of adjunctive psychoeducation in a meta-analysis of six randomized trials for the general treatment of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/42\">",
"     42",
"    </a>",
"    ]. However, reasonable alternatives include cognitive behavioral therapy (CBT), family therapy, and interpersonal social rhythm therapy. Adjunctive psychotherapy for treating bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H20#H20\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Adjunctive psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective observational study, 10 depressed or euthymic bipolar patients with rapid cycling were treated with 20 sessions of CBT that included psychoeducation, cognitive restructuring of depressive and manic thoughts (eg, &ldquo;No one loves me&rdquo; or &ldquo;I can afford to buy everything&rdquo;), and skills for managing mood shifts and comorbid psychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42216/abstract/43\">",
"     43",
"    </a>",
"    ]. Symptomatic improvement occurred in the six patients who completed the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92693814\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"local\" href=\"#H92693295\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during a 12-month period. The episodes that occur during rapid cycling are no different from episodes that occur as part of a non-rapid cycling pattern. Separate episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See",
"      <a class=\"local\" href=\"#H92693295\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H16495348#H16495348\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes. (See",
"      <a class=\"local\" href=\"#H92692334\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For rapid cycling bipolar patients with major depression, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H92692341\">",
"       'First line medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For resistant rapid cycling bipolar patients with major depression that does not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , we suggest sequential treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H92692348\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For refractory rapid cycling bipolar patients with major depression that does not respond to trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , we suggest electroconvulsive therapy (ECT) rather than additional pharmacotherapy trials (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H92692355\">",
"       'Refractory patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For depressed rapid cycling bipolar patients, we suggest augmenting pharmacotherapy with psychotherapy rather than using pharmacotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use psychoeducation; however, cognitive behavioral therapy (CBT), family therapy, and interpersonal social rhythm therapy are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H92692362\">",
"       'Adjunctive psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/3\">",
"      Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/4\">",
"      Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/5\">",
"      Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     Kupka RW, Frye MA. Diagnosis and treatment of rapid cycling bipolar disorder. In: Yatham L, Kusumakar V (Ed.) Bipolar Disorder. A clinician&rsquo;s guide to biological treatments, 2nd Ed. New York, Brunner-Routledge, 2009.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care.",
"National Clinical Practice Guideline Number 38, 2006. file://www.nice.org.uk/ (Accessed on April 26, 2011).",
"    </li>",
"    <li>",
"     Ketter TA, Wang PW. Management of rapid-cycling bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA.  (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/9\">",
"      Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 Suppl 11:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/10\">",
"      Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/11\">",
"      Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/12\">",
"      Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010; 121:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/13\">",
"      Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/14\">",
"      Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/15\">",
"      McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/16\">",
"      Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/17\">",
"      Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/18\">",
"      Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/19\">",
"      Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008; 28:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/20\">",
"      Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/21\">",
"      Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/22\">",
"      Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/23\">",
"      Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/24\">",
"      Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/25\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/26\">",
"      Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord 2003; 73:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/27\">",
"      Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/28\">",
"      Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/29\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/30\">",
"      Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/31\">",
"      Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/32\">",
"      Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62 Suppl 14:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/33\">",
"      Bailine S, Fink M, Knapp R, et al. Electroconvulsive therapy is equally effective in unipolar and bipolar depression. Acta Psychiatr Scand 2010; 121:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/34\">",
"      Dubovsky SL. Treatment of bipolar depression. Psychiatr Clin North Am 2005; 28:349.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/36\">",
"      Minnai GP, Salis PG, Oppo R, et al. Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. J ECT 2011; 27:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/37\">",
"      Vanelle JM, Loo H, Galinowski A, et al. Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/38\">",
"      Kho KH. Treatment of rapid cycling bipolar disorder in the acute and maintenance phase with ECT. J ECT 2002; 18:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/39\">",
"      Vieta E, Gasto C, Colom F, et al. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998; 18:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/40\">",
"      Bauer M, Adli M, Bschor T, et al.. Clinical applications of levothyroxine in refractory mood disorders. Clinical Approaches in Bipolar Disorders 2003; 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/41\">",
"      Marangell LB, Suppes T, Zboyan HA, et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. J Clin Psychiatry 2008; 69:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/42\">",
"      Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; :CD004854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42216/abstract/43\">",
"      Reilly-Harrington NA, Deckersbach T, Knauz R, et al. Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study. J Psychiatr Pract 2007; 13:291.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16890 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42216=[""].join("\n");
var outline_f41_14_42216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H92693814\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92693288\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92693295\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92692334\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92694034\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92692341\">",
"      First line medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92692348\">",
"      Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92692355\">",
"      Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92692362\">",
"      ADJUNCTIVE PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92693814\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=related_link\">",
"      Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=related_link\">",
"      Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_14_42217="Lipid lowering with drugs other than statins and fibrates";
var content_f41_14_42217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid lowering with drugs other than statins and fibrates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/14/42217/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/14/42217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid altering agents encompass several classes of drugs that include HMG CoA reductase inhibitors (statins), fibric acid derivatives, bile acid sequestrants, and nicotinic acid. These drugs differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular drug are influenced by the underlying lipid abnormality.",
"   </p>",
"   <p>",
"    Conventional dosing regimens and common adverse reactions are described in this table (",
"    <a class=\"graphic graphic_table graphicRef77498 \" href=\"mobipreview.htm?28/1/28701\">",
"     table 1",
"    </a>",
"    ), and the range of expected changes in the lipid profile are listed in this table (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lipid lowering is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of benefit seen with lipid-lowering are incompletely understood. Regression of atherosclerosis occurs in only a minority of patients; furthermore, the benefit of lipid lowering is seen in as little as six months, before significant regression could occur. Thus, other factors must contribute; these include plaque stabilization, reversal of endothelial dysfunction, and decreased thrombogenicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics and efficacy of the lipid-lowering drugs other than the statins and fibric acid derivatives will be reviewed here. The efficacy of statins, fibrates, and diet and dietary supplements is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BILE ACID SEQUESTRANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available bile acid sequestrants include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/1\">",
"     1",
"    </a>",
"    ]. These agents bind bile acids in the intestine, resulting in interruption of the reabsorption of bile acids which is usually 90 percent efficient. The ensuing reduction in the cholesterol pool lowers intrahepatic cholesterol, which promotes the synthesis of apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptors. The apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptors bind LDL from the plasma, causing a further reduction in blood cholesterol. The bile acid sequestrants also induce a minimal elevation in High Density Lipoprotein cholesterol (HDL-C) via intestinal formation of nascent HDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile acid sequestrants are effective in patients with mild to moderate elevations of Low Density Lipoprotein cholesterol (LDL-C). Low doses (8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    or 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    ) can reduce LDL-C by 10 to 15 percent. A more pronounced reduction (about 24 percent) can be achieved at maximal recommended doses (24 and 30",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    respectively). A similar reduction in LDL-C can be achieved with 1.5 to 4.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Colesevelam can lower A1c by 0.5 percent in patients with type 2 diabetes and hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Colesevelam'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bile acid sequestrants are also effective when used in combination with statins or nicotinic acid in patients with markedly elevated plasma levels of LDL-C. As an example, bile acid sequestrants and statins have synergistic actions to lower LDL-C (about 50 percent) and raise HDL&ndash;C (11 to 18 percent) (",
"    <a class=\"graphic graphic_figure graphicRef63912 \" href=\"mobipreview.htm?40/17/41246\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Maximal doses of bile acid sequestrants with nicotinic acid (4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    can reduce LDL-C by 32 percent and elevate HDL-C by 43 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     Colestipol",
"    </a>",
"    (2.5 g) has also been given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    mucilloid (2.5 g), three times daily with meals; this regimen produces equivalent LDL-C lowering and a more favorable change in the ratio of total cholesterol to HDL-C than full dose colestipol (5 g TID with meals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/7\">",
"     7",
"    </a>",
"    ]. Combination therapy has two other advantages over full-dose colestipol: it is less expensive (approximately $412 versus $984) and fewer colestipol-induced side effects such as belching and constipation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"     Colesevelam",
"    </a>",
"    (625 mg tablets) may be administered as six tablets with dinner or three tablets twice daily with meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a bile acid sequestrant is often limited by side effects. The major adverse reactions are gastrointestinal, including nausea, bloating, cramping, and an increase in liver enzymes;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    , is better tolerated and less likely to cause gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/1\">",
"     1",
"    </a>",
"    ]. Bile acid sequestrants can also bind to and impair the absorption of other drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and fat soluble vitamins (",
"    <a class=\"graphic graphic_table graphicRef77498 \" href=\"mobipreview.htm?28/1/28701\">",
"     table 1",
"    </a>",
"    ). This effect can be minimized by administering the other drugs one hour before or four hours after the bile acid sequestrants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NICOTINIC ACID (NIACIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid is available in several formulations that include immediate-release (crystalline) and sustained release formulations such as Niacor&reg; and Niaspan&reg;. Nicotinic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    are the two common forms of the vitamin most often referred to as niacin, however nicotinamide does not have the lipid lowering properties of nicotinic acid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of water-soluble vitamins\", section on 'Vitamin B3 (niacin)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nicotinic acid has a variety of effects on lipid metabolism (",
"    <a class=\"graphic graphic_figure graphicRef62384 \" href=\"mobipreview.htm?43/2/44079\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It inhibits the hepatic production of VLDL and consequently its metabolite LDL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It raises HDL-C levels by as much as 30 to 35 percent, both by reducing lipid transfer of cholesterol from HDL to VLDL and by delaying HDL clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another favorable property of nicotinic acid is a reduction in plasma fibrinogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are clinical endpoint studies that suggest niacin may have mortality benefits when used in secondary prevention of coronary heart disease (CHD), and may have greater benefits than other non-statin medications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow-up from a clinical trial of niacin suggested some mortality benefits in secondary prevention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The randomized ARBITER 6-HALTS trial found that in patients with CHD or a CHD risk equivalent who were being treated with a statin, extended release niacin decreased a composite cardiovascular endpoint compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H45#H45\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ARBITER 6-HALTS trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to ARBITER 6-HALTS, the AIM-HIGH trial, which examined a similar population of patients (established cardiovascular disease, low HDL-C, elevated triglycerides, all patients treated with a statin), found no additional benefit to treatment with extended-release niacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/13\">",
"     13",
"    </a>",
"    ]. The study was stopped early for futility and because of a concern about increased numbers of ischemic strokes in patients treated with niacin, which were not significantly different from placebo after final adjudication. However, HDL-C levels in the &ldquo;placebo&rdquo; arm (which received 100 to 200 mg of niacin daily) increased more than expected, which may have reduced the ability of the trial to detect a real benefit with niacin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H708622578#H708622578\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'AIM-HIGH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed below, preliminary results from the HPS-2 THRIVE trial also showed no benefit when a",
"    <span class=\"nowrap\">",
"     niacin/laropiprant",
"    </span>",
"    combination was added to a statin, however, further interpretation awaits publication of the trial in a peer-reviewed journal. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given these results, it is uncertain whether adding niacin therapy improves outcomes in patients who have achieved a low LDL-C level on statin therapy alone, even when such patients have a low HDL-C level or moderately elevated triglycerides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The content of over-the-counter (OTC) preparations of niacin are not federally regulated in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/14\">",
"     14",
"    </a>",
"    ]. OTC preparations that are marketed as causing \"no flush\" may have no free nicotinic acid and are ineffective in treating dyslipidemia, while some formulations of sustained-release OTC niacin have been associated with an increased risk of hepatotoxicity (see below); Slo-Niacin and perhaps Enduracin appear to be relatively safe. The sustained-release prescription brand Niaspan appears to be safe and effective although it is more expensive. OTC immediate-release niacin preparations are inexpensive, contain a full amount of free nicotinic acid, and are safer than most sustained-release preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid is effective in patients with hypercholesterolemia and in combined hyperlipidemia associated with normal and low levels of HDL-C (hypoalphalipoproteinemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/8,9,15\">",
"     8,9,15",
"    </a>",
"    ]. The HDL-C raising properties of nicotinic acid occur with dosages as low as 1 to 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, the VLDL cholesterol and LDL-C lowering effects are typically seen with higher doses (3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one study, for example, nicotinic acid in a dose of 500 mg TID raised HDL-C by 20 percent but reduced LDL-C by only 5 percent. In comparison, a higher dose of 1.5 g TID produced more prominent changes of 33 percent (HDL-C elevation) and 23 percent (LDL-C reduction). At higher doses, nicotinic acid can also lower lipoprotein (a) levels by as much as 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional LDLC lowering can be attained by the addition of a bile acid sequestrant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HMG CoA reductase inhibitor (statin). In one study of 269 patients, the reduction of total and LDL-C with sustained release niacin was 11 and 18 percent, respectively, compared with 23 and 32 percent, respectively, in those taking a combination of niacin and a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy with crystalline nicotinic acid is initiated at 100 mg three times daily and gradually increased to the targeted dosage as tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Niaspan&reg; is a controlled release formulation of nicotinic acid that is administered once daily. Niaspan&reg; is initiated at a dose of 500 mg nightly for one month and the dosage is titrated to 1000 mg. The standard dosage of Niaspan&reg; is 1 to 2 grams nightly. It is advised that the medication be given with a night-time snack, but our experience suggests improved tolerability with dosing after the evening meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nicotinic acid is often limited by poor tolerability. At standard doses (1.5 to 4.5",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    flushing occurs in 80 percent of patients taking the crystalline preparation, and pruritus, paresthesias, and nausea each occur in about 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/9\">",
"     9",
"    </a>",
"    ]. Symptoms after a dose of nicotinic acid can last from ten or twenty minutes up to several hours.",
"   </p>",
"   <p>",
"    With the crystalline preparation, pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325 to 650 mg) 30 minutes prior to dosing or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (200 mg) 60 minutes prior to dosing can minimize flushing and other prostaglandin-mediated side effects associated with niacin. This adverse reaction often diminishes in seven to ten days, gradually improving over time. Symptoms may recur episodically on a stable dose or with dose titration. Nicotinic acid is better tolerated when ingested with food, which minimizes gastrointestinal side effects.",
"   </p>",
"   <p>",
"    Flushing appears to be less common with controlled release Niaspan&reg;. In one study of 269 patients receiving a median dose of 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 48 weeks, 4.8 percent discontinued the drug because of flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/16\">",
"     16",
"    </a>",
"    ]. In another report in which both formulations were given in a dose of 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four months, Niaspan&reg; was accompanied by fewer flushing episodes per month (1.9 versus 8.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/17\">",
"     17",
"    </a>",
"    ]. A newer formulation of Niaspan&reg; (coated caplets), appears to further reduce flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that can decrease niacin-induced flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A large randomized trial found that laropiprant plus extended-release niacin, compared with extended-release niacin alone, decreased episodes of flushing and reduced rates of discontinuation of niacin, despite more rapid titration of the niacin dose in patients receiving laropiprant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/19\">",
"     19",
"    </a>",
"    ]. However, more patients treated with laropiprant experienced worsening of their diabetes. Laropiprant is available in some countries, but was not approved in the United States.",
"   </p>",
"   <p>",
"    Preliminary results from the HPS2-THRIVE trial apparently showed no benefit from adding a combination of laropiprant and extended-release niacin to statin therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg daily; addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    10 mg daily if inadequate LDL-C lowering) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/21\">",
"     21",
"    </a>",
"    ] and also showed an increase in non-fatal serious adverse effects in the",
"    <span class=\"nowrap\">",
"     laropiprant/niacin",
"    </span>",
"    arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/22\">",
"     22",
"    </a>",
"    ]. Because of this, the European Medicines Agency recommended suspending the marketing and supply of the combination in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/23\">",
"     23",
"    </a>",
"    ]. A 2013 report on the decision to stop the trial only discussed the increased side effects and suggested that analysis for CV benefits may be ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients in the",
"    <span class=\"nowrap\">",
"     laropiprant/niacin",
"    </span>",
"    arm had higher rates of definite myopathy (risk ratio [RR] 4.4, 95% CI 2.6-7.5) and appeared to also have higher rates of abnormal aminotransferase levels. HPS2-THRIVE included a run-in period, so all patients had previously appeared to be able to tolerate simvastatin (or simvastatin plus ezetimibe) plus laropiprant and extended-release niacin for approximately one month. Despite this, more patients in the",
"    <span class=\"nowrap\">",
"     laropiprant/niacin",
"    </span>",
"    arm stopped treatment (25 versus 17 percent), and most of this was due to stopping for side effects (16 versus 8 percent). Patients in China appeared to be at significantly higher risk for myopathy with combination therapy (RR 5.2) than patients in Europe (RR 1.5).",
"   </p>",
"   <p>",
"    While awaiting publication of the CV results of HPS2-THRIVE in a peer-reviewed journal, which should provide further information on the implications of the trial for niacin therapy as well as for the use of laropiprant to treat niacin flushing, we suggest not using laropiprant and would continue to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as the primary agent for managing prostaglandin-mediated symptoms of nicotinic acid therapy.",
"   </p>",
"   <p>",
"    Additionally, although the absolute increase in risk appears to be small, these results suggest that niacin may increase the risk of myopathy in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and perhaps other statins (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H107312713#H107312713\">",
"     \"Statin myopathy\", section on 'Concurrent drug therapy'",
"    </a>",
"    ). This increased risk may be a particular concern in patients from China, and we suggest avoiding the combination of simvastatin and niacin in Chinese patients and only using niacin with caution in patients receiving other statins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H7754121#H7754121\">",
"     \"Statin myopathy\", section on 'Niacin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevations in hepatocellular enzymes are also common with nicotinic acid and may lead to severe hepatotoxicity, jaundice, and fulminant hepatitis. The onset of hepatocellular injury is not predictable; therefore regular monitoring of biochemical studies is mandatory. Crystalline niacin is preferred to most sustained-release preparations, since the former is associated with a greater hypolipidemic effect and seemingly less hepatotoxicity (",
"    <a class=\"graphic graphic_figure graphicRef53574 \" href=\"mobipreview.htm?4/4/4175\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. An exception may be extended release Niaspan, which has been found to minimally raise transaminases in clinical trials, but not cause significant hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other important problems with nicotinic acid include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nicotinic acid can increase glucose levels. As a result, hyperglycemia may develop in susceptible patients and the glycemic state may be worsened in those already being treated for overt diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. This effect appears to be greatest with some extended release preparations, and minimized with crystalline niacin and perhaps Niaspan&reg;. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nicotinic acid can induce hyperuricemia and precipitate acute gouty arthritis; it should therefore be avoided in any patient with a history of gout.",
"     </li>",
"     <li>",
"      Nicotinic acid can produce hypotension in subjects treated with vasodilators, and can exacerbate unstable angina pectoris [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nicotinic acid causes a dose-dependent elevation in plasma homocysteine levels that may negate its favorable effects on the lipid profile in certain subsets of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"       \"Overview of homocysteine\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EZETIMIBE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    is the first in a new class of cholesterol absorption inhibitors that impair dietary and biliary cholesterol absorption at the brush border of the intestine without affecting the absorption of triglycerides or fat soluble vitamins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/30\">",
"     30",
"    </a>",
"    ]. Its mechanism of action may involve Niemann-Pick C1 like 1 (NPC1L1) protein or an associated protein involved in cholesterol transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Its effects on cholesterol may be due to interference with NPC1L1 in the liver in addition to in the intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two randomized, double-blind, placebo-controlled trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    at a dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduced LDL-C by approximately 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Ezetimibe is also effective as adjunctive therapy to a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]; in one study, a 10 mg dose of ezetimibe lowered LDL-C by 14 percent above the LDL lowering effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Its clinical benefits are less clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A surrogate endpoint trial, ENHANCE, involved 720 patients with heterozygous familial hypercholesterolemia who were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      80 mg daily with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      10 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/41\">",
"       41",
"      </a>",
"      ]. Decreases in LDL-C were greater in patients treated with combination therapy (56 versus 39 percent) as were increases in HDL-C (10 versus 8 percent). Despite the large additional reduction in LDL-C with ezetimibe, after two years there was no statistically significant difference in the primary outcome of change from baseline in carotid intima-media thickness (0.0111 versus 0.0058 mm, p=0.29). There did not appear to be a difference between the two arms in the small number of cardiovascular events seen in the trial (10 versus 7 events).",
"     </li>",
"     <li>",
"      As discussed above, the randomized ARBITER 6-HALTS trial found that in patients with CHD or a CHD risk equivalent who were being treated with a statin, extended release niacin decreased a composite cardiovascular endpoint compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/12\">",
"       12",
"      </a>",
"      ]. The AIM-HIGH trial showed no additional benefit from adding extended-release niacin in patients receiving a statin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/13\">",
"       13",
"      </a>",
"      ]. This raises a concern that one possible explanation for the results from these two trials could be that adding ezetimibe to a statin might actually worsen outcomes; additional trials are underway that should clarify this issue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H45#H45\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ARBITER 6-HALTS trial'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H708622578#H708622578\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'AIM-HIGH trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials, such as the SHARP trial in patients with chronic kidney disease, found reductions in cardiovascular endpoints with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/42\">",
"     42",
"    </a>",
"    ]. However, trials of this sort cannot be used to demonstrate additional clinical benefit from ezetimibe beyond what would be expected with a statin alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H6#H6\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Cholesterol lowering with a statin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    in patients with aortic stenosis, SEAS, found an increased risk of cancer and cancer death in the active treatment arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/43\">",
"     43",
"    </a>",
"    ]. Statins do not appear to increase the risk of cancer, which raised the possibility that ezetimibe treatment could cause cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H16#H16\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of this concern, an interim analysis of two other trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (IMPROVE-IT and SHARP) was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/44\">",
"     44",
"    </a>",
"    ]. This analysis found no increased risk of incident cancer but a trend toward an increase in cancer deaths. However, an early increase in cancer deaths in a trial without an increase in incident cancer would be somewhat unusual.",
"   </p>",
"   <p>",
"    At this point, it appears most likely that the observed effects on cancer and cancer deaths are due to chance. However it will be important to watch for further evidence of cancer in other trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    , and as the IMPROVE-IT and SHARP trials are reanalyzed with longer term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/45\">",
"     45",
"    </a>",
"    ]. In a preliminary report of the final analysis of the SHARP trial, there continued to be no increase in cancer incidence with ezetimibe but there was a statistically nonsignificant increase in cancer deaths (3.2 versus 2.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    relative to other lipid lowering drugs is unclear. Similar reductions in LDL-C can often be achieved simply by maximizing the dose of statins, which have a number of potential health benefits in addition to lipid lowering. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link\">",
"     \"Statins: Possible noncardiovascular benefits\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, one randomized trial found that the reduction in LDL-C concentration was the same with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    10 mg plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    as with atorvastatin 80 mg alone; however, adding ezetimibe to atorvastatin 80 mg did result in an additional 9 percent reduction in LDL-C concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/46\">",
"     46",
"    </a>",
"    ]. Ezetimibe plus atorvastatin also produced a greater reduction in serum C-reactive protein than atorvastatin alone.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    may be helpful for avoiding high doses of statins (and potentially increased susceptibility to muscle injury) in patients who do not meet cholesterol goals on low dose statin therapy alone. However, the clinical benefits of either ezetimibe monotherapy or combining ezetimibe with statin therapy remain to be proven. Given the results of randomized trials of combination therapy, use of other combination therapies with a statin, particularly niacin, is likely preferable to combination therapy with ezetimibe.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    has been well tolerated in clinical trials to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/34,35,39\">",
"     34,35,39",
"    </a>",
"    ]. When administered alone, the incidence of either myopathy or serum transaminase elevations was similar to that of placebo; when coadministered with a statin, the incidence of serum transaminase elevation has been slightly higher than with statin therapy alone. The manufacturer suggests measurement of liver function tests prior to initiating treatment with ezetimibe plus a statin.",
"   </p>",
"   <p>",
"    Health Canada, the authority that regulates drugs in Canada, issued an advisory in 2005 stating that there have been reports of myalgia, rhabdomyolysis, hepatitis, acute pancreatitis, and thrombocytopenia in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/47\">",
"     47",
"    </a>",
"    ]. Some of the patients who developed rhabdomyolysis were apparently taking ezetimibe without a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     Gemfibrozil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    have been noted to increase",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], although the clinical significance of this is uncertain. Ezetimibe and fenofibrate have been safely used in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], and we use this combination clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROBUCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probucol modestly lowers LDL-C, but more prominently reduces HDL-C (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"     table 2",
"    </a>",
"    ). It also increases the resistance of LDL to oxidative modification to more atherogenic forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H15#H15\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Lipoproteins and atherosclerosis'",
"    </a>",
"    .) Probucol facilitates resorption of cutaneous and tendon xanthomas in patients with homozygous familial hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/55\">",
"     55",
"    </a>",
"    ]. However, a randomized clinical trial, published only in abstract form, showed no clinical benefit with probucol in patients with peripheral vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/56\">",
"     56",
"    </a>",
"    ]. Probucol is no longer available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    (in an oral dose of 2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    reduces LDL&ndash;C and Lp(a) levels by almost 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/57\">",
"     57",
"    </a>",
"    ]. It acts by forming an insoluble complex with bile acids, thereby lowering lipid levels by a mechanism similar to the bile acid sequestrants as described above. Neomycin also inhibits the secretion of apolipoprotein (a) from the hepatocyte surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/58\">",
"     58",
"    </a>",
"    ]. It may therefore be particularly useful as adjunctive therapy in patients with familial hypercholesterolemia and Lp(a) excess. The risk of nephrotoxicity and ototoxicity is quite low at the neomycin doses typically used for hypolipidemic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ESTROGEN REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen replacement therapy (ERT) in postmenopausal women has a favorable effect on the lipid profile. Among the changes that occur are reductions in LDL&ndash;C (15 percent) and Lp(a) (20 percent) and elevations in HDL-C (10 to 15 percent) and triglycerides (24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. Transdermal estrogen does not affect lipid levels, perhaps due to lack of first-pass effect on the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/63\">",
"     63",
"    </a>",
"    ], and concomitant progestin administration can partially negate the beneficial effects of oral estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H27#H27\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Lipids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It had been thought that these lipid changes might contribute to a cardioprotective effect of estrogen replacement therapy. However, such a benefit was not confirmed in the Women's Health Initiative, mostly of primary prevention, and the HERS trials of secondary prevention. Estrogen-progestin replacement had no cardioprotective effect and may have produced harm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-estrogen",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    appears to lower total and LDL-C (12 and 19 percent, respectively, in one report) without changing HDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/64\">",
"     64",
"    </a>",
"    ]. There are conflicting data as to whether tamoxifen does [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/65\">",
"     65",
"    </a>",
"    ] or does not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/64\">",
"     64",
"    </a>",
"    ] raise serum triglycerides. Tamoxifen has not been shown to affect cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=see_link&amp;anchor=H9#H9\">",
"     \"Managing the side effects of tamoxifen\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THYROMIMETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eprotirome is a thyroid hormone analog that has minimal uptake in nonhepatic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/66\">",
"     66",
"    </a>",
"    ]. A trial in 184 patients, nearly all without known cardiovascular disease, who were receiving statin therapy but had an LDL-C &ge; 116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    randomly assigned patients to three different doses of eprotirome or to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/14/42217/abstract/66\">",
"     66",
"    </a>",
"    ]. After twelve weeks, eprotirome reduced LDL-C in a dose-dependent fashion; at a dose of 100 mcg daily, LDL-C was reduced by 32 percent, compared with a 7 percent reduction with placebo. Similar changes were seen in levels of triglycerides, lipoprotein(a), and apolipoprotein B. Clinical endpoints were not assessed, and, over the 12 weeks, eprotirome did not appear to produce clinical hyperthyroidism, hypothyroidism, or have adverse effects on the heart or bone; some patients treated with eprotirome did have elevations in serum aminotransferase levels.",
"   </p>",
"   <p>",
"    Eprotirome appears to be able to reduce serum lipid levels. Long-term studies with clinical endpoints are required to determine whether eprotirome provides clinical benefits in patients with hypercholesterolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24516293\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although statins are the preferred therapy for most patients requiring treatment of dyslipidemia, a number of other agents are available with varying levels of evidence for clinical benefits. The use of statins and fibrates are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"       \"Statins: Actions, side effects, and administration\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"       \"Lipid lowering with fibric acid derivatives\"",
"      </a>",
"      .) Additionally, therapeutic decision making in patients with elevated lipid levels is discussed in detail separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the non-statin agents, nicotinic acid (niacin) has some of the best evidence suggesting mortality benefits in secondary prevention of coronary heart disease (CHD). Nicotinic acid has not been found to provide additional benefit in patients who have achieved LDL goals on statin therapy. Flushing, pruritus, paresthesias, and nausea are common side effects and may limit use; pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (325 to 650 mg 30 minutes prior to dosing) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (200 mg 60 minutes prior to dosing) can improve tolerability. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nicotinic acid (Niacin)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bile acid sequestrants include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"       colesevelam",
"      </a>",
"      . These agents reduce LDL-C but have only limited evidence for improvements in clinical outcomes. The use of these agents is often limited by gastrointestinal side effects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bile acid sequestrants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       Ezetimibe",
"      </a>",
"      is a cholesterol absorption inhibitor that impairs dietary and biliary cholesterol absorption at the brush border of the intestine without affecting the absorption of triglycerides or fat soluble vitamins. Although ezetimibe reduces LDL-C, including when used in combination with a statin, there is as yet no convincing evidence that it improves clinical outcomes beyond treatment with a statin alone. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ezetimibe'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/1\">",
"      Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/2\">",
"      Shepherd J, Packard CJ, Morgan HG, et al. The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 1979; 33:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/3\">",
"      Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/4\">",
"      Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/5\">",
"      Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med 1993; 153:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/6\">",
"      Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/7\">",
"      Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med 1995; 123:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/8\">",
"      Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/9\">",
"      Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/10\">",
"      Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/11\">",
"      Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/12\">",
"      Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/13\">",
"      AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/14\">",
"      Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003; 139:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/15\">",
"      Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 1994; 154:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/16\">",
"      Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/17\">",
"      Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/18\">",
"      Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 2006; 44:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/19\">",
"      Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/20\">",
"      Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62:1959.",
"     </a>",
"    </li>",
"    <li>",
"     www.thrivestudy.org/HPS2THRIVE%20RELEASEUSWIREVERSIONfinal.pdf (Accessed on January 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/22\">",
"      HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013.",
"     </a>",
"    </li>",
"    <li>",
"     www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_detail_001687.jsp&amp;mid=WC0b01ac058004d5c1 (Accessed on January 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/24\">",
"      Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc 1991; 66:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/25\">",
"      Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/26\">",
"      Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/27\">",
"      Rosenson RS. Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. Nat Clin Pract Endocrinol Metab 2007; 3:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/28\">",
"      Pasternak RC, Kolman BS. Unstable myocardial ischemia after the initiation of niacin therapy. Am J Cardiol 1991; 67:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/29\">",
"      Garg R, Malinow M, Pettinger M, et al. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J 1999; 138:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/30\">",
"      Sudhop T, L&uuml;tjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/31\">",
"      Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/32\">",
"      Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science 2004; 303:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/33\">",
"      Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007; 117:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/34\">",
"      Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/35\">",
"      Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/36\">",
"      Gagn&eacute; C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/37\">",
"      Gagn&eacute; C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/38\">",
"      Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/39\">",
"      Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/40\">",
"      Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/41\">",
"      Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/42\">",
"      Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/43\">",
"      Rosseb&oslash; AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/44\">",
"      Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/45\">",
"      Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer--an uncertain association. N Engl J Med 2008; 359:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/46\">",
"      Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409.",
"     </a>",
"    </li>",
"    <li>",
"     www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ezetrol_hpc_e.html (Accessed on March 15, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/48\">",
"      In Brief: Rhabdomyolysis with Ezetimibe. Med Lett Drugs Ther 2005; :17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/49\">",
"      Kosoglou T, Statkevich P, Fruchart JC, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004; 20:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/50\">",
"      Gustavson LE, Schweitzer SM, Burt DA, et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin Ther 2006; 28:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/51\">",
"      Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/52\">",
"      McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/53\">",
"      Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992; 12:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/54\">",
"      Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994; 94:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/55\">",
"      Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57:29H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/56\">",
"      Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/57\">",
"      Gurakar A, Hoeg JM, Kostner G, et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/58\">",
"      Lanford RE, Estlack L, White AL. Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface. J Lipid Res 1996; 37:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/59\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/60\">",
"      Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/61\">",
"      Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/62\">",
"      Binder EF, Williams DB, Schechtman KB, et al. Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial. Ann Intern Med 2001; 134:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/63\">",
"      Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/64\">",
"      Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/65\">",
"      Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/14/42217/abstract/66\">",
"      Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4562 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42217=[""].join("\n");
var outline_f41_14_42217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24516293\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BILE ACID SEQUESTRANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NICOTINIC ACID (NIACIN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EZETIMIBE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROBUCOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ESTROGEN REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THYROMIMETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24516293\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4562|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41246\" title=\"figure 1\">",
"      Effects combined statin resin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/2/44079\" title=\"figure 2\">",
"      Mechanism nictonic acid action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/4/4175\" title=\"figure 3\">",
"      Plain versus time released",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/1/28701\" title=\"table 1\">",
"      Types of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/47/22268\" title=\"table 2\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_14_42218="Advanced case 11";
var content_f41_14_42218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1274px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Advanced case 11",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42218=[""].join("\n");
var outline_f41_14_42218=null;
var title_f41_14_42219="Causes of tertiary adrenal insufficiency";
var content_f41_14_42219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of tertiary adrenal insufficiency in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Isolated ACTH deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CRH gene defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CRH receptor defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital malformations of the brain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septo-optic dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infiltrative diseases (also cause secondary adrenal insufficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langerhans cell histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Brain injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Temporary isolated ACTH deficiency due to suppression of hypothalamic CRH secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cessation of pharmacologic glucocorticoid therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Megestrol acetate (Megace) therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resection of a unilateral cortisol-secreting tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resection of an ACTH-secreting tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants born to steroid treated mothers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACTH: adrenocorticotropic hormone; CRH: corticotropin releasing hormone.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42219=[""].join("\n");
var outline_f41_14_42219=null;
var title_f41_14_42220="WHO MEC for patients with systemic lupus erythematosus";
var content_f41_14_42220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: systemic lupus erythematosiu",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positive (or unknown) antiphospholipid antibodies",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe thrombocytopenia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 3",
"        </p>",
"        <p>",
"         Continuation: 2",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 3",
"        </p>",
"        <p>",
"         Continuation: 2",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunosuppressive treatment",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 2",
"        </p>",
"        <p>",
"         Continuation: 1",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        None of the above",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1: A condition for which there is no restriction for the use of the contraceptive method.",
"    <br>",
"     2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"     <br>",
"      3: A condition where the theoretical or proven risks outweigh the advantages of using the method.",
"      <br>",
"       4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"       <div class=\"footnotes\">",
"        COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"       </div>",
"       <div class=\"reference\">",
"        Adapted with permission from: Medical Eligibility Criteria for Contraceptive Use, 2010 update. World Health Organization. Available at: file://whqlibdoc.who.int/hq/2008/WHO_RHR_08.19_eng.pdf.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42220=[""].join("\n");
var outline_f41_14_42220=null;
var title_f41_14_42221="Pressure support ventilation";
var content_f41_14_42221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Pressure support ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 137px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in airway pressure, flow, and volume as measured in the distal endotracheal tube during unsupported and pressure-supported spontaneous breaths in intubated patients. The unsupported patient (blue lines) must first generate an initial negative pressure \"spike\" to open the ventilator demand valves and then must maintain a small amount of negative pressure during inspiration to produce flow through the ventilator circuitry. The addition of increasing levels of pressure support (green lines) provides plateaus of positive pressure that augment the spontaneous tidal volume in accordance with the patient's spontaneous respiratory flow demand and inspiratory time pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Respir Care 1987; 32:447.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42221=[""].join("\n");
var outline_f41_14_42221=null;
var title_f41_14_42222="Estimated average ionizing radiation by source";
var content_f41_14_42222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Estimated average ionizing radiation by source at the US population level in 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the National Council on Radiation Protection and Measurements,",
"     <a href=\"file://NCRPonline.org\" target=\"_blank\">",
"      file://NCRPonline.org",
"     </a>",
"     . Ionizing radiation exposure of the population of the United States. Bethesda, MD: National Council on Radiation Protection and Measurements; 2009: Report No 160. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42222=[""].join("\n");
var outline_f41_14_42222=null;
var title_f41_14_42223="Thumb movements";
var content_f41_14_42223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Thumb movements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 212px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADUAg4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArifG/8AyFYv+uA/9Cau2rifG/8AyFYv+uA/9CaonsaU/iOdx70Y96WjNZnQJj3pce9GaM0AJj3ox70uaWmA3HvS/n+dRXchit2ZfvDgfWsTQZLltUuPNunliKklGOcHIAI/Ws3UtJR7m8MPKdN1eiN/FGPelpTVmA3FLj3ozRmgLiY96XHvRmlzQK4gHPWqtvqFpc3UlvBcI88YyyA8j/GpL47bSYk4G3rXJ+HJYDr5IUhjlASMHOM4+nFZVKnLJROyjhfaUp1G9js8UYoorY47iY/zmjH+c0tFIYmKUD3opRQAuPelA+tArC8QeIf7Kl8mC3WeVV3vufaAPT60OXKrsqnSnVlywV2acmo2UVytvLeQJcMcCNpACT6Vb2n3rxG8uRrOlXz7Rv3NuHfJOev413/g3xVHP4RtZ9SlZ7uBjbTbVLMxXo34qVJPqTWMKyk3c7sTl8qSi4a3/M64g+pppHvVfSdTtNWtPtNhKJYslT2KsOxHY81ZNbJ3V0ec04uz3G496MUppKBiY/zmjHv+tLRQAmPf9aMe9LRQA3HvS496WimK4c+9KQcd8VmavrVjpPli9lZC5ABVC4XJxk46CudujcWertc/aZTPnkFjgj0I6Y7VjUrxgdmHwU66bWn6naY4pNvvSQSLPAkqH5XAIp+K1Rxu6dmNx70Y96U0lA7hj3/WjHv+tLRQAmPelx70UUxXDB9aUKSeM1U1W5e0025uIwC8aFlDdM1xNlNrF1oN/LcalLmQEE8fKO4XA4rGrXVN2Z2YbBTxEXKLskeg9RkHPuKMe9cT4Mt/sO1oZGKSPtZC2Q2e/wBa662vrO5lkitrqCaSMkMsbgkH3xRSqqor7E4rCyw8+W913sTbfejb7040lbHLcTHvRj3oxRSGGPejHvQKCQqlmOAOppi3Db70oX3rNn1WA3S2Ks6XL9MjHHXg1zv9tX1h4xt7WeVm0+4PklZOdjkfKQfrgfjWTrRTsdkcFVlBz2t0O12+9Jj3pBNEZfKEiGTGdm4ZpxrS5x6rcTHvSY9/1paKBnbeCP8AkFS/9dj/AOgrXQVz/gn/AJBUv/Xc/wDoK10FbR2OWfxMK4nxv/yFof8ArgP/AEJq7auJ8b/8hWH/AK4j/wBCapnsVS+I540lLRiszcSilxRigAFFFA60wMzXmzabOdpyT+FZPhaMw6hLHnKrDnPuSK29Wj3W0jDqF4496yfDu5NUnVgAHQYH0rim/wB+kexTVsC7HSGjtRR2rtPHEooopALRRiloBlbUQWtiB3Iri7EImr2zPkZuOo9a7x4/MwuMnOa47UbPyruU8jy5N4NcWKvGSke1l7UqM4ep2XSg1FaSme1hlddrOoJGc1LXcnfU8VqzsFFFFIApRSUooBj1rg/GloJNXuOQA0Ct9RyDXZ6lepYWbTurOchQoOMk1xGpatFqutRpJbmG4SBgUZtysM9R+tY12rWPRy2E1U9pbQ4jRQPtOqW4YhWRZAo/75/wpul77PVGjWRkW4UqQT8uR3/KrNjGLDxXETjyp1kiP1xuH8jVPxDI0ax3QBAhmDZAx35A/AmuM91T3On8B3cuneKTDwLW9Gx/TeMlW/p+NerMK8YngmtruOWC4cMpV1YexzXsdvMt1awzp0kQN+Yrqw0rpxPFzWklUVRdRTTac1NNdJ5aCiiikAUUUUAFFA61HdTpbQNLLnavYDJP0p3S1YJOTsjD8X2kc0Ozy8vNGU+ueKyo5Xu9P0q5CszSW6Byf7w4b9Qa3U1KDW7aKW1V4pLSYwzRygBh3B4zwQeDVbw8gXR7iylIMtneSx8f3WO9f0avMmk5O3U+loVHCnFSWqOdsGmudNIuJHY295LEUJx5fzZA/I5rsNAvGubYxSnMkXGe7L2rlfEEI0zVhcoM2OplUkx/BOowD/wID8xWrowlt54ZSrCP7pPbBopVHGauLFUI1qDaWvQ6g0UppK9M+aQUUUUhhQKKUU0DMzxMCdDuQOrAD681zV8ht/BV9MDhfKIwOvJArpfFIH9jsjdXkUdcVg+IvLPhdNPiOLm52hVHcBgTn8sV5+I1m/Q+gy3Sil3ZT05t3hO7O4iQW7nd/dO01n+A12WETxAK0Sqy4/Wuq02xWLQryCYDzBA4K+nymub+Hiebp8fDFlX0rn1Vj0uaMlI9HBDorDowzSVFZ8WsYznAxn6VKa9eLukz46ceSTj2CiiigQCmTgNGFOPmYCnkhVyelUYdQguNVjsDvSf/AFgX+8B15qKkklZm+GpylJSS0RyerlofG2mKpDu9xtOT6qRSeOrFzdRXLsuFlRzkYwAw4FN16BbfxjpF0itgXqDk8cnH9a0PHshlsbrC8gFOB09DmuGS0Z9Ep+9F+RlfEHzUEF1asYriJhIjrxgg13GkXyanpVrfRjCzxh8eh7j881xmqW76n4asLt5fnlgV+OgyOla3w4kY+HPs0m3dbTPGMeh5H862oStO3c8/MacXRU1umdPiilNJXYeMjtvBP/IKl/67n/0Fa6Cuf8E/8gqX/ruf/QVroK1jsc0/iYVxPjf/AJC0X/XAf+hNXbVxPjf/AJC0X/XAf+hNUz2KpfEc/RSUtZm4UUUUAIaUUhpRTEwkjElrKG6EVz8GLfXrUDpIrL/X+ldHcKW018EgE9q5aGT/AIn9ijckbiP++TXBVf75HsUl/srXkdNRR2orvZ46CiiikMKSlpBTBjhwwNZGrKgvZEJGWGceorXBwciqGuxqLsMFGMAZFcuLXu3PRy56tMj8Oys+mBG+9E7RkegByP0xWkaw/DDFZtRhJyqyhx+I5/lW4a1oy5qaZyYiPLVkgooNFaGICnLTacKAZR15FbTSzlQqSKxJ9M4/rXmHiecaZ4ktLpY5NqSKhYjqrcH+der6iu/TrkYz+7J/LmvKvH+x7N/LI37d45ztPX+dc1danr5bU9xxM/WbK4ttUtryeEiCG6Vju7LnGf1rpvFNrFPplwscUatIBgqOOlVPGNzHc+ERMOlxbhs+pKg1U0i7udS8H2Nw0YMhUIxYn5u2RWHR2O5Su7lbT/PvvDtlfxyxk4CuB1BHBz+Vei+A717jR3t5l2y2r7OuQykZBH615l4Vb7DDdaaZMjzPOAI5G4ZIx7HP5V3Hge7QX8kO7/WKVx6kcj+tXTkozVjDGwdTDtvdHammmnsKYa7jwEJRRRSGFFFFAAKpa0jHT2dWwFbk1dFPmQPp0zMAdpFZ1v4bsdGEdq0WzglR9I1+B43/AHd7CQ6g9WQ5B/ImrhuFbxRdrbFdk9pFM4yR84Zlz+VWfFVussmiTd0mdeD6p/8AWqpewJpmq6RfudiXAeykJ9/mTJ+oP515q3sfQSkppSW5a12wkvvDV4FYrJEDOmB/EnzD+RFM8P6it3aRI5P7xMjjjHsa6BWjk0+4ReSUbOe/BriPBsfnaPp9yQDlOnoOlD0dwhK8Wmd3aSiWAHOSpKn6ipTVezQR+Yq9ODirBr1KUuaCZ85iI8lRpbBRSUtUZBThTRUiCmJmP4qRpotNtE+9cSsQfQDqfwArzfUrm41jxlb6Xp8rRqm7dKDyqICWI969H8eX8WneH/tCHZdmMxRyDqAeTj8q8r+FsxuvGl/JIwaU2ExQ+52//XrgqJSqNH0ODvGhzdjvfD+kQ2ml3F95szTtuUkyE7hzxVD4aqI9PjLnGV4/wroLSY3GmyW8B8uNvvso6nuAfSsbwxZLp9y9p0WOYkZGeDznNc7a5kkdUZOSmmdrjGcetIaMEM4JJ5zRXq0/hR8zXVqsgopBRVGQ+JBJKivnafQVxJnaH4j2ELIV8xJVU565Un+ld1buE8wt/d/GuEIK/E3RZJVcZ80dOMmNsc1yV/iPYwErU2vJkPiS2uRrGlGRWETXkW4jt84FdX4vWH+yZ1ZQVbqGPFcl8WdaawswYTtKSI2c8gg5/pWt4wllk0Ca5VD5TQebndyAaxb3sdivLkKPhC2k1HwPYGCIKqM8QDd1DsOKXwLus9e1XT5AVJVZACPQ4z+tN+ElyzfD+OORwCJpSvPON5I/XNT6ZKT4zicHiSF1b3NVG0ZRMMQ+enNM7E000y6uYbZd0zhR16E08EMoZSCpGQR3ruutjw+VpXaO28E/8gqX/ruf/QVroK5/wT/yCpf+u5/9BWugraOxzT+JhXE+N/8AkKxf9cB/6E1dtXE+NudVi/64j/0JqU9iqfxHPUtLg+lB468VmjYSilIpCKB3ENKKMVJEucscbVpN2QRjzOyJrnaNOGDnjj3ri7LLeK4fRUc/piutvHCW6xbs7R3rj9Nl2+I0ZjgNlPzrzZNOqmeyo2oyiux1xpKKK9M8VBRRRSGFJRSimDIL5vLgT96YldwpYdR9Ky5Ll2v3s3kM4jbKyP8Aex7+tWfEsc/2G3mt5GjKMSWXHP8An1rmbGaVb9ZZJ3lMmFZpGzyOgrzcTU95o9vCU7UlJG1o58vX7yLON8QPPcg//XroK5LUpjp2sxXOcqCCfcHqK6xWDqrKchhkGujCTThy9jgx0GpqfcDSUtJXUcYU4U2lFADmXzIXTONylc49RXnV/ZQw6K5dS8ighnb7xPT8s16QtcjqGnm4kvknGbfe4CZxuFc9daHdl8rSaOO0O3/tHwjavegMiSyKgbvFuIH8yK3b9obGK0tIFSK3ddqKgwF4yOBWdrkq2ltaLbIsUduu1Y14AUdqqa1eb7DTpQQxHygj8sVy3PbUdrm80UC2gu1RPMK8uF5OKwLi8e01S3voWC+W4cYHHuKv3F0INHhSZ/mC4IHc1zVzdF4yVUugPJNEna1gULxaZ7nFIk8CSxkFHUMp9jTSKyPBjSnw7apPE8ToCFDHPyk5H6H9K2cV6EHzJM+YqQ5JuPYYRRilNIaokSkpaSgAFJfF/wCyLtV4XCkmnUXBzp11GANzgAZ7dazq/AzXD/xYnnFzr9rGbKC8cBlu48MTyFzhj9ADWt4r0gSWs0Lid41lWdPKPVl5H+fevOvGugXMEEksYLFnLSN1O3sPp/k1pfD/AOI0Zhh0PxI3leQuyC9Y54HAV/w4B/OvPhHmTfU+iq+7a2zO0sdXuzEF+zTRuw+Yldy49aoaNY3WnGSOK4SS2L741ZcBc9QMdq66wnimhSSLZLE/3JEPysB3Bpl1arDKJY8eQzfN/sn+9WfK+pmp2dmiXT5S20Ou0kYHOc1fOO1ZKzRtIDA28IQS2P5VrGvQwzvFo8nHwtNS7hRSUV0HEOWp413MNxwgGWPoO9RIOKwfFurT2lq1jZGFbiYYZnYkqPQAVFSoqcbs0oUXWmoo87+J+sXWqak8e5VtoiVTHTAqv8OLX7LqFhOssS3ErSGVWyS0RG0Aenc/lVLxFpN4E8+eZSG67FK4/OsrwpqQtfEVnuYlY2I/A15ilKWp9ZyRUFBHsGko8N48DMUbfx6GtC5tv7P1KGaQho5TtJHY9s1Ta6trsPd2civLAwSdQeVJ5Un8K6hFj1DS1YhWI5KkVLjZnDKo4u7Gkg8joefrTabEAqBVztH3QfSnV6lF3gjw8SrVZBQKBSitDAmtVXc0jAfIuAT2zXA6obnVfGtm9mwhttPmWa4mI+XjI2j1J6fnXoFtEZARnIPG2sfxMFt7BxEMHk5A61x1U27nsYG0YpdWMvNHsL15ZtRtIZ/K/eKrrkA9c471ZttuoxQq4DQyAhlI6jGOlZEepFPDEs8jAMUCEsenrWl4dLrYLcS/Iuz5ARzj1qI2vY6JXsV7bSbHSJJYbGCOGJhnywTjOSePTqa5e4u47PxJp92SY4hJscE8AHjNdBf3kbzuYSzyHOQOfxNcJrUr3UU6QIzyIwGFGcN2GaU2lqjalT9pdS66HYeIL3dpM8kLhmb5sDkEdhWz4ZvIr/w/Y3EL7wYgrezDhgfcEVx/iKLUINExc2qRSkAgrIpx7H/61O+FMdzb/wBoRMwNo+JFH91+hx9R/KroztP1OXHUU6N10PdfBP8AyCpf+ux/9BWugrn/AAV/yCpf+ux/9BWugr0o7Hzc/iYVxPjY7dUjJBIEAOB1PzNXbVxXjX/kKRf9cB/6E1TPYql8R4Z4i1mNr2dpC77CSYi5VwP6GtPQtXnUK1ndTPCCMw3J3Aj0BPSul8TeG7PXrfEqBLpfuTAc/RvUVwBs7rR75re4idCpG1jyHHqK8qqqlJ3Wx9RQr0cVDkaV+x6lY30N4uYyVcD5kfhh/wDW96s4rk9ImSVVLE8fccHkVuzX8ltBudBKeANvBaumliYyXvHmYjBOMv3exfxST3MdtbgSHl26e1c7cavfPIUWFLdB3JyapTTTzJhnLMpyW9amriFa0TTD4OUJc0zWub5JNzMcbuFHpXK3ty0N9D5QyxcAfXIx+tW5lkI4yAP1rPt1Da3ZBm3F7hAB+Irgu3JHo2jGLZ6Sw5PrTSKkammvaPmxtFFFIYUCjFKBTEylrm99LdcnYDXJxxMYQHxkHjHrmu015hFowU8O38q5e1TETtIRtUZrysTbnPewjtSSY7xI6SRbZMDKZBPfiui0gEaRZBjlhCmT+ArnPFcH7iA9FyFP0xW94fkaXQrF3OSYgPy4rTBP35HJjnenH1LxpKU0hr0TzQpRSU4UgZInNcfLe5nvAWziRh+vSuwTrXAXARdZvgFBbzm684yayrbI7suSc5X7GJrUyTyYRSWb5cDniudlufs0kKTkEo37tAeBz1ro9YUld4OMDqBXLvb+brELOQRkcGuG+p7bldaGtcwT3Qt45SQH+byxwxz6+ldPZ6FDbQpHMqtccEjsvoPemaFaLdXvmnlohkZrXuoWiwWO6RzkkZrW2lzLmu+U2NLmkR/ncNHtCnjGPStO6nitojJcSLGg7k1ySGSJHJJPGB7+tYeq35aREDs7YwozkiqVdwVrHPVy9V6ilex01/4mIJTT7cyHtJJwPy61R/4Su6tVD31rFLH38klSPz61U0vw7quqkSYFtCf43OK39O8MWNvt+2tJeMDnBbamfp1pRnVm7xKq0cFh48s/+Ca9tcR3VtFcQHMUqh1JGODUlACqAqKFUcADoBRXar21PCla+mwCpLnEemtKwO1mx+VR1duIw2ixFupLEfnUVvgZthbe1VzlbmG3vIJhtBdlIHGa8W8aeFpLJ3uLeFkjIyzH+le6ghCTgYri/iVcE6UYiyhpCECjkn/CvMTcXdH0EXf3XsXfgpqTX3hJNPvFw9o5jtnbgyJ1IHqVJP4EV3Dxlcg4KNwR6+tcto3h+O18LaVp1yjRyxxmTcjFWjkPzZDDoRnGa39LF2YlS7kMzpwJ8YL+m4Dv7jrWsm5HK0r3RGW8tZLaRQGCExk9x6fUVdjIaNCOhANVfEUghSAhRuLA5P61JYP5lpEw6YwK1ws/ecTixqvCMifvSik70tdp5w9XVAXk4RRuY+wriZbo32qzzxWck5JyNuAPofeu0m2jT71m6LEf1ritMu5zI0cJEKfxNjn8+wrixbd0j1suSUXKxznjWe/lsWiewmiI6YxgfrzXil/dyWt7vQtG2eueQfWvePF05+xTpbksuPnnfnJ9q8l8GaAPEXjFVkO62tf30pPO7B4H4n+VRhbXdzrxdSXs0oaO53/wyiurDSbmWUPL9oUGWHPzRgjKMB375716p4TnL268h0Y4yPX/AB9q5SDTUOo7YvlcfJkHgj0PtXdaFDGiMwBEuME/3gOx9x61lO8pEzkuWzHSDZMyj7vUe1JT7gj7UwHpTDXfh3emjx8T/EYUc0lOHUVsYFrTz8sxXAxn5jXMazGbi5bzrgCMdsV0VrJ8sg3AZzXL66hWViCRg8nNcc2e1QMUSWsd99nmZrjnKI33A3qRXYzxm60/fLM1paEdejso649BXIaJpa3fiBJ5V37R/H90e+O9egXsUV8YoXP7lcMw9VHb86mGqZpVkrpGTb2MCWpcReRY43LHuwz/AO3I3X8K5dNe06TXrDS9NkhEclwN0cCZDY5JJxnt1rutSEs8TrHtjhxjJXcT9BXKvp39nzm4t+Zk5DMQXPtxwo9e9TOL6GtKUVq9yDxpH9t3RgEovIwe1S/DRf8AiSzttx++IBPfFQ6/qtta6eiKA880ZUZ6g960/AkBt/DkKsMMzMx/GrppOqjlxd1Q+Z6r4K/5Bcv/AF2P/oK1v1z/AIK/5BUv/XY/+grXQV6Udj56W4VxXjb/AJCsX/XAf+hNXa1xPjb/AJCsX/XAf+hNSnsVS+IwBUF/ZQX9uYblAy9Qe6n1FTZpRWVk1Zm6bi7o5BbGXSrgx8Op5B7EVdhu0m+V2xjtW9e24uISoxvHKn3rzy5vo7bUHgulkilQ8mvNr0/ZO62Pbwtb28fe3R0Go7QQxO7B4PfFV4ZolG58DtxUbSCeBWVww6ZrIuhNG/Q4x2rnlLqbcnQ1bu5VoyUxyOg71m6SvneLNNX+7IW/JSaZbLI6kPnjkGpvC4LeMLZsDhHOP+A0qcuapFCqrlpS9D0c0005qYa91nzyEoooqRiirFrD5rEkfIoyx9qgFSG6+yWVw5IBxilOVlc0pR5ppGF4ovUkulQMMKAAvtWO0yvazpF8zlcAe54rG1e+knvPMz1OTntWc15LFfFlJUEAHHevDrVHzaH0NOlaKR1XiW8V7BUBy2RXR6BF5Wh2CekKn8+f615pe3TTMqZJJbJr1LS+dKsyOnkpj/vkV14B80pM83MVyxS8yc00040016bPMQU4dKbThSAetebeISYvEF8oOMyZ9OozXpIrzn4j2zWutQ3gIEdzHt/4EvH8sVjX+G525dJKrZ9StF/pEDKxycEgYrmZIyL5VOBg4xXUaDKJOXwMDkelZF5aE6wrocq84RePTrXGz24LWx23h5I7OxeRwPOkPP0HSi4uEDb5G+XNUrmf7Pabc8gkYPesRHlvny0gjTODmtL2M0rNyZZvtTL7FjBY7ucf59cV1/gfwwS0mp6jkRAZG4dPpR4Q8N2U7tI370AfM4+6Aff2rqdQvBKiwQjbAnT/AGj61VOm6ju9jlxeN5I8kNyC5n85vlXZGPup6f8A16rk+1BNNrtSSVkeLdt3YtIaWkoAStSVc6HEe4J/nWXWpbybtHlQ87G/nUVfgZrh3+8Ryt1mNHdjjaK5LR7ZvEvj7TraUbreANdyfRcbR+ZFdPqas8UkYyWfj86d8K9PEOv61fv90Rx26E9upb+n5V5lNc00j3ak+SnKXU6HVUEUoQEAg1LpyqkJOT0796ra9Kr3LEYznHNQ2txugAPHp2rom7M4km4oyPFFxseMHnrgDqfatWxiMFnDE3Dqo3fXvWRNH9r8Q2ynBSIGY+5HA/X+VbpHNPCQ3mznxk9oB3paKBXacJYSITaffL1/d5x68153Y7XuWVmON35/hXpWklTM8T9JUKV5lqxbT9WnQrtIcgD2rhxad0z2Mt96LiR/EtRD4fWOBQrSHAA7jvXFfCFhYahqjsP9ZKEyfbt+tehxwHWLyBLggokZUD3PeuF8NWkmm65qEMybobl8DjhJFPQ+mQa56dSya7nXUp8yS7Hdwtv1BthIJIwPSu/0pQkDO4GSuMetcNpVs0M8EkmXhbhZCeg9G9/euyDSrCq9QP4h3FNTvqYVY7JET4M5Ydhg0Gk53tntiiu/D/w0eTiHeoxRS0gpw6VsYlaCXa7Bto5PHvWFrcoeUIGyec4FWdQnaC9kUHuCPxqpdQNcFQvQ8dP61wz6o92klyqRZ8PRebOjDkZ5xXVsFjZwqgucA1jaFF9nbZtJ2jqBzVu5uI0JZzgGqjoiamrJb65SCPAwXI6e1cL4ivZEiOH8oZyF9a2NX1K2RSckgD864hml17WFtbZSwYjIz90UpyHTVtWS+FNCute1j7TLkWiHLMehr1COJYYxHH9xeBxTrO0j0vTo7KFQMcuQOtBrWhT5fee55+Lr+0fKtkdp4J/5BUv/AF2P/oK10Fc/4J/5BUv/AF2P/oK10Fdsdjy57hXE+N/+QrF/1wH/AKE1dtXE+N/+QrF/1wH/AKE1TPYql8Rz9AooFZo3Y8Vy/jjTY7m3SYp83QsO3pXTikmijuIHimUNG4wRU1Ye0jymlGq6M1M8ktrue1fYpOwHBU9q1/tqSxZGQ3cVLrXhR7NpHhdpI3PyMeqn0Nc1Lpl9AxZyQw7DvXh1oyhLlZ9FSnCtHmTN+0nLRsSpVRz1p3hUj/hLrbI5KSD6fLVawkmNt+/ADAdRVe0uv7P16yu2PyJMA3PRTx/I0qMuWpFsmvC9OSXY9YamGntTDX0J8yhtAooFSUOFZHihmWxO3OD+ta4qtqdkL+zeAuUJGVb0P+FTUi5RaRpRmoTTZ5rhmc4HOKzLs7JwXxVqRb/T9SktruLLgkAgZB9waSeJnJLqR26V4NTR2Z9PBp6oLSMu3m7cjHynHWvTvDU32jQLJ85ITaeO4JGK4OOB004Ek8DIx6dq6T4fXQayubTdlo3Eij2Yf4iurATUalu6POzKHNTv2Z1BphqQ0w167PEQUCiikMkWsLxzpY1Xw5cBFzcW4M8X1A5H4jNbi9akU4pSSasxwk4SUl0PBtH1JFAGeD096623g32JnDL5iPvjHqQcmuO1fSLnT/EF/FAqiJZ32bj1XPGKtafNqG1UYxJGOPmYt/KvO2dj6h1OeCl3OpW1vtZfMMWVJw656Y710Fl4MjaSJS5LydcdAfr+lcppmr3NhMro+4pySoK5/HPI+tegeDPElzqEk7vBDHFjIKnn3PShNX1OWtKpa6N5lh0qwGnWQwAMSP3PtVA052LMzHqxyc0w16UUkrI8CUnJ3YhooooAKQ0tIaAEq7pjBvNhb+NePqKpU6NzHIHHVTmiSurFQlyyTIbq2SOXcwwRnFWPC6JbWt1sIDNKxYeoPSjV3TCEsAhHWqWnTKWZUbr6DNecvdmezL36dyjrtxmZkxuH8qrWtzI6EE5x7Yq9qcJD7hgZ9qp2y4SUkAcHFY1JO5cErD/DkhuLm+nYD5SsSnvwCT/MVu1i+F1KQ3gP/PfPT/ZFbXavRw38JHkYp/vZBSUtJW5gSRsUdWHUGud8d2IeRLxVyJB17g1v1U8RxvPoh5GEPQisMRG8DswFRwq2MHw9AGXzFBDdj9Kqa9p0cOvfbIPlWdP3ydiw6N9av6S2yPdvICjoKZqIEqne0mWGR7V5ulj15z97QsaeCbqYAERtglcfdY9SK6hWWOIcDGOa5/QIgoaXLHdjqa27hh5KqB944pxV9DnnLUiGTknqeaKcR6UlevGPKkjxHLmd+4CnD0pBThTA5/xYTbLBdDO3Oxvr2/qKzYNaijhUscqvQZ6cV1Gr2Yv9MuLYD5nX5D6MOR+teOX19IkZVLefdnBUKf1rjrpxldHtZfJVKTi+h6Xp3iGJtxUgAgAbj0rM1vXYkWQ54PTHr61yXh57udjutXOepdgBUWsrMLl8wkIo6EgisnJtHQ4RUtCWSa41WZbdThnxgg4GPevWPBvhi20TTWvrjm4IwM+uO1eb+B/IudSje4AXkDAPWvXLmczPtXAij+VAOn1q6EVKWpx4yo4RsivIxdix6nmmGnGmGu7Y8nfU7bwT/wAgqX/ruf8A0Fa6Cuf8E/8AIKl/67n/ANBWugrWOxzT+JhXE+N/+QrF/wBcB/6E1dtXE+N/+QrF/wBcB/6E1TPYql8Rz9FFFZnQLTgaZSimhCzIJYHQgHI7+tcfqMZ8x94ULXZKa5/VYAzuBgHnB9K4cdG6Uj0MvnZuJyMSmNmIkGzPPeszVcb9vZucg9atrP5d60dw5654HHFVtT2MUMZUjOc9q8g9ux6P4Q1A6loULuczQ/uZM9SQBz+IrXNcR8L3YDU4Sfl3Iyj8CK7hq+goTc6akz5nEQUKsoojNFKaStDIUU4UwU4UxGV4j09bqBXCZkH8Q6iuVFuGDCRcMO4PWu8uyfszkDOOtcZqqjeWUnPpXlY2CUrns5fUbhysox71R0XmP1Pb2qvouof2R4jtixIhkPkyjtgnj8jg0llcCd5Izhc9d2cn6Vka6rRyqVypByAfrXFTlyzUkd1SHNBxZ7Qw9aYaS2fzbWGTg70Vsj3FK1fRXvqfMbaDaKKKQxy1IMdSeKjWq2sT/ZdJu5u6xkD6nj+tD2uEVzNI4O5C3t3cSmJXWR2IyA3fNVTbbGwsUYGMfdxVm1g2YZTwccVPdqEViS21Rnrn9a83c+hb5Y2KVvZRSPHayOElmbauF+6PU12MOpQWVv8AZrVItpG1WU8kCuFs5XjX7XcEmX5mAJ6ADgU3Sr8tPFKUJwM47g1nOfK9BOHMtT1ZWDxoy/dZQRSGlhwbeIgYGwcenFBr11sfPdRtFFFIYUhpaQ0AJQaKDTQmPmiEljuZFO1iASKbpiYjyRjcelWpVP8AZsYXqxJquHEKx+x6V51T42z1aTfs0irrakybW+Xp1NZ32ZkjYjkAZI9al1yZmumcnA3gYpwmO87fmOPyFck3qzqhdJFTw0zLeahAxJ27Hwe2cj+lb1c34XlMusaxkkFDGCueP4sGulr1MJ/BieTjFatL+uglFFJXQc48CsXxhN5dpbwbypI3EA9c1txrudV9SBXG+NZ/N1l0ydqADHaufEytA68FC9Tm7FXT3wnJJAP61NO4lu9g+9t6A1RtpkXaM8Zyat26F5ZZsgKByfevNieq9zqNLURWcaDlu4q1qQXyojkLh1yc4xzVeCNUFuGPQA1W8RXHl2eWB2eYo4PJGeaaeqMGtzWNIaccHkd6SvZPFQlOFNpaBsev69q4XXNDiuL6dlnEQaRmI25xk/41200gigkkP8IzWNCiyx8lsk/WubEu9kd2BTTczEsdKitYAPMVs9cL/OsDxXZLBGr7ggOT0ru51htreTfjArzHx3e3E2piKWQCMKCqL2Fcz0R3Rbk9A8JXE6XsL7vkB3HPGK9f0hy9irsclmJB9q8K0i6dL2ONcsucHivbfDbOdN2yAAI20Y+gqsK/3hhj/wCGvU0TTae1MNegzyUdt4J/5BUv/Xc/+grXQVz/AIJ/5BUv/Xc/+grXQVrHY55/EwrifG//ACFYv+uA/wDQmrtq4nxv/wAhWL/rgP8A0JqmexVL4jn6KKKzOgKBRQKBDxWXqsW/zDg56gjtxWmO1V7kAhwTjNc2MV6Z04N2qHmN9ujv2LlenXHFVdUyuRHtOcH863NetD9oLxAZXJwOhFc7qA8w7EHKtvY/3a8S1nY+hi7o3/hndhPEV9bMD+9hyv8AwFu/516U1ePeBrg2vjHTzvGJt8T59xx+OQK9icV7WCd6Vjwcwjy1vWxEaSnGm11s40FOFNpRQgFlXfEw9RiuQ1OMiIyc7gcHiuwFYOpoGidSM4Y1wY1bM9DASsmjzhpA+pJu3FcE4HHNGup5MS7QzZ5XnNTalGbe5Z8HIONwHOKZqp8yzDB+FCqpA6jr/WvJTse49UemeC71b/wtp8qnJWPy2z2ZeK12riPhHds2k39jIctbz7x67X/+uDXcNX0VKXNBM+Wrx5KkokZopTSVRA4Vj+MX8vQnHPzSIvH1/wDrVsiuc8eMRpttGCRvmz+QNTUdoM0oK9WKMfTjmPnHHT2pmsHbbIhIw5556inaZlRym855NQ6u3mSbThSBwK4Fse1Lexz2qXRSMhRwQVAqDQpC06gk7lBI5qLVwPlHf60aGT9owi5/hx3rmq9zZLSx7cnEEYzn5R/KkNFmS1lAT1Ma/wAhStXtp3R811GUUUUhhSGlooAbSUtKgy6j3FPYNzRnXaiKTwFFYE8mbvjIVWx0roL/APdoW65HpXMzyKsgA6g8+leXVdnc9ektCHVlMzoNuRvyeaSVhGmRwuOcH07VK7BpEAxjrmotSJWzdoydxXNcctbs6VukZHgSUz6xrcjHklMADAA5rtK4f4cKWvtacjB3RqwPXPJruDXr4T+DE8jG/wAeX9dBtKKQ0orpOYtWAzdIePly3PsK828TSZ1WWTI5+U/nXpVln98R1CHFeY+I0PmyMv3iev41xYvVWPRwHUr2b72B98Cuh8vZAka9GKqD6+tc9pXM42jKjHWuwjQGe1TAyDu5rgWx3vRmqw2NkY4GK5jxPcsbiwt1AJluFXk9s108hznPT2rkL4+d4r0mMrvjEmfxpr+JFeZi/gk/I7cjn2pKXuaSvbPEQgpRQKVaBsp6nJiNI+PnOT9BVa2VlUhVwetM1ORW1AIWOEUfmeaeHEcLvnJx0riqvmmz06EeWkincp9q1CKMYWKH5n46n0rynxlN9q8U3hQ/LH8or05p/sttJI3XBYk149IWnmurlycu5P61jPsdVJWuS6UXW+ieIbmU5wRXuvhV2l0GF36sz/luOK8V8Nx5v1kHSPqvrXuWghxo1oZUEbsm4qD6nNaYT42cuYP3Eiy/WmGpHqM13nmI7bwT/wAgqX/ruf8A0Fa6Cuf8E/8AIKl/67n/ANBWugrWOxzT+JhXE+N/+QrF/wBcB/6E1dtXE+N/+QtF/wBcB/6E1TPYql8Rz9FJS1mjosFAooApiY4VBMMmTPU/4VOBzUDAkufc1zYv4Dpwi99nG6ozGdlYbfxrB8tDJKGIGeRzXRasw+1EjBUcdetYV4ojUvsGW4+XtXivc96L0Oced7TUIb5BzDKJVHsGH8694R1liSRDlHUMp9jyK8V1m2P2f147DpXpfgK9F94UsiX3PCDA/PIK8DP4Yr0cvqauB5uZ07qM0bhppp7CmmvSZ5SQlKKSlAoBocOlYmoIRFIwyGzkVsvxGx9jWXfkMmDyCK4sa9kd2B6nD3+xrhs4Prk1nCMtME4YBeF9PetnUYkF0DgBj6VmvHlydw44OB3ryGj3E1Yl8AXYsPGT27ELFdxmLk/xj5h/UfjXq5rxCZmsLq2vkGZYJRL1+8Qcn+te2xyLNGksZyjqGU+oIyK9fA1OaHL2PEzKnaoprqNaminMKTFdhwWFBxXK+OnU3GnwluQHcjP0Ga6sCuH8ZsX8QRqvWOBR+JJNY13aDOnBxvVQumKPL3EYJOcVW1xcR5AO4d/arenI3lDGQP61m+IHK9WIfrXItj0t5HMakCy7gnAHX0pmjn/TI1A5J7CprwnyD8wy3HJqHSmCXgw+ORzXPU+G51RPatIcSaRZsMEeUo49hj+lTNWf4WkEmg2pHbcv5Ma0XHNevTd4pnzc42m0RmilNIaoLBRRRQFhtPhA81PrTO9TWozcIO9KXwscF7yLGqtiFRnoua5Ocnz2OcjIxzXR67JtUNnGeMCuWnchdwbnr0rya71PZorQnQnn1ANQ6lIfszqjdsGnWxJO58dOfpUGrFRbyEnCgZOPYVyvY3W5T+GfzTa046GWMdfZq7g1w/wsRzBqsjJsBnVcZ6fLnH613Br28L/BieNjNa8htAoNCitzmsWrfiC4J6FcV5v4mOJXOeCa9IQYtJye/FeW+K3827KJkYNcGLkepgloN0JP3nOcZ/OuvtxunDg52jH1rkNDbYo3MeK6WxlO4Y6N09BXCndHZNWZq3bqsXXAI5rlrNmn8YWQHITc/Psprob0g2o3Z49K5/w8A/jNNxO5LdyoP1A/xp0ta0TOppRkd1SGnEU017h4S1CnLTR1pJpBDDJIf4FLUm7K47dDnZJDLqU8qEH5yBn24/oanu5MqoOFzUFigILHJ9OKfqGwRknqORXnp3bZ7GySOe8RzGLTpkLfMw28V59NsjiYHoa7HX5RLFjGQD2rjb1yFkX5eelZy1Z0QVkT+FpdkpJ5YHp7+te66DFNFodhHckmZYVDZ+n+FeDeGgTM3I3c9egr6DtM/Y7fK7T5S8ZzjgVvhF78vkcOZfZQPUZ61KwqM9a7TzUdr4J/5BUv/Xc/+grXQVz/AIJ/5BUv/XY/+grXQVtHY5p/EwooopkhRRRQAVUt9TsLjULqwt721lvrQKbi2SVWkhDDKl1ByuRyM9amu7iGztZrm5kWOCFGkkduiqBkk/gK8H8G3moab4t8OeKNR0PUrBPEk88F9dzvb+VJ9oYSWYCpKzgqESMb1H3j3OKAPcNE1Wz1zSLPVNLm8+xu4lmhl2su9CMg4YAj8RSvqdomsRaW0uL6WB7lItp5jRlVmzjHBdRjOefrXzx8PdRntPB/hWTwLrFzqmrpol02o6d9va5SFltiYcwElYj5wjUYVdwY53Vfa5s5bnVX8JeIb/WdXHgvUGknj1GW6kS6JhI2fMfKfdzsTbg7eBxQB9CVBc3dtavbpc3EML3EnkwrI4UyvtLbVz1OFY4HOAT2rxfxB42n1O01ubwZrMl/JbeHInLWTmcRyGXDuoGQZFQk+oIwapeI/wDhDrgeG7zT/F2p6hpFtrUBvbuTXrh47QPa3ADGfeDGWbYD8w27sYUOQQD3S1u47qS4SNZ1NvJ5T+bA8YJwDlSwAccj5lyM5Gcg1YrwefW5v7bvYL7Xb+DwiPEf2e5vkv5FEMH9nRPEv2gNujjaUglgwyW5b5jm1oEl1r2p+G9PfWtak0KW71UWtxFfSxSXlrH5flFpVYO4BLBXzkgA55yQD26iuQ+E15c3vgOwkvriW5njlubfzpmLu6x3EkalmPJO1Bknk9a6+gAqrqmo2Wk2Mt7qt5bWVlFjzLi5lWONMkAZZiAMkgfU1arzT4sMdY1nQvDK6Teazav5mo6jaWjQq5hQbIwTK6Lgyurdc/uzjvQB6UrBlDKQVIyCOQRVLT9WstQ0salZzeZZEOfM2MPukhuCM8FT27V4r4f19rjSfDGl+MtVutE07S4ryw1KQ35tHkvLdokhieaJwQWidpMK/wAxHcDmjo2oWKeHtNttf16703QV0ieWwK38lq15cm5mDAsrK0rKojxHznzDlTQB77pl9b6pptpf2Mnm2l1Ck8Mm0ruRgGU4OCMgjg81Zrwaw8UJ4d0O2TUtXewt5/AlidPR5mQSXIWYOYl7yANFnbzjbngCrbavaS+I5YfGnifVNHiTTbCTSVhv5LYXLMuZXUKf38m/ClSG4xxzQB6+2r2XkedDMbmP7R9lY2kbXG2UPsKsIwdu1shicBcHdjBq/Xz3YTWei6VqdvpmsXsOuJ4wWK4tDqszSLbvqY2kxM5wHRhl8fOG5Jya09B1q4l1zR92t6jJ4yl124g1HSGunMcdmHlHNtnYkaxiNlkAyxI+Y7jQB7jRXi3gGS+tpfh3fvq+r3U+tG7ivVu76WaN1WKR1xGzFVKlBggA4JyTXtNAGbrmv6PoEUUuu6tp+mRSttje8uUhDnrgFiMmpdI1bTtasheaPf2moWhJUT2syyoSOo3KSMivOfjHff2b4s+H13/aum6R5d9d/wCm6ku63izaSD5x5kfXOB845I69DFq3iHUJ00u68NeIdP8AEGutDd5h0nItJbdVyXMfmyDzEk8sKd3zFtnyhiygHqK3ds169mtxCbtI1maAOPMVGJCsV6hSVYA9CVPpU9eGWzaRb+OxfadrN5cXF14ZtZNGku9WnU6hcK9x8hBcCU8xkxkEAsTtBJrn9P1zVl8N6zcW/ieCS8XwxfT3kMXiC4vrlbgRBllMTRILR0bcNoK9cYyuaAPpOq9xdx29xbQyLOXuGKIY4HdQQCfnZQQgwOrEAnAHJArxnXmu/D66naW3ifULOG40C3vJLvUbya4WKb7QqFw3zNEGVipKABchgBtzVHSfEN+9zokeh3N9Ip1y5hXbrUmp2t1jT5HVYrhwrSRhwMq2drg88cAHvlFeC+GNbkkh0ptK8Q6pqGqzaHdTeIIJ7ySX7JOIgQxjJxbuJdyhFC5GeDtzXQ/D4XWneIfCEZ1XVr1NY8OSXl2t9eyXAaZGtirqHJCHErj5QARjOSM0Aes0UUUAFFFFABVHWdY0zQ7QXetajZ6dalgnnXc6wpuPQbmIGeDx7Verzr40rcvZ+EVsZYYbo+I7MRSTRGVFb58FlDKWHsGH1oA6bTfGfhzVL+0s9K1qx1Ce6Epi+xyidT5QQyAumVUgSIcEg/NxW/XknjU+ILLxf4bk86zv9ej0bW3tja2rQRvIEtjGuxnkPXA+8c+lcr4e1h2t703ni9I7YaO0t2LHxBcaldpdCSLy5AjRIIH3MU8gEBywXYQDQB77e3cdlHG8yzsHkWICGB5SCxwCQgJA9WPAHJIFWK8W1TWtWGlzSanfXVl4lGu6VBd2UFy4iggaeIKIxkApIpYsccsXQkhBVfQdauJdc0fdreoyeMpdduINR0hrpzHHZh5RzbZ2JGsYjZZAMsSPmO40Ae40V4t4BkvraX4d376vq91PrRu4r1bu+lmjdVikdcRsxVSpQYIAOCck17TQAVR1jWNM0S0+16zqNnp9ruC+ddzrEmT0G5iBmr1eb+L7qz0b4q6HrHiaSK30NNMngtbu5IEFtdtIhO5j8qM0YwGOM7SM9qAO/wBOv7PU7KK8026gu7SUbo57eQSI49QwJBqzXz9d39pHLqep2GpXOj+D9T8U2wW8t7lrWOVfsxFxIrgjEbOoywOCVJB70p1qPz9LS88Tajb+DJPElzBbajJqssRntRYs203O4M8fnhgrlieODwDQB9AUV4Fp+tPJLpEfiLxDqln4HkudT+yanJfy2zXAR0+zrJcgq+3aZihLfPtXJbpWdq/iLUI9B0e41nXrgy/2XJJBYHVptLvbhRcOIbiIqpW4meJU/dP3IP8AFyAe/jV7LzzDLMbeQ3H2VBcRtD50uzftjLgeZ8oJymR8rehxPa3cd1JcJGs6m3k8p/NgeME4BypYAOOR8y5GcjOQa8F8QzxX+tPdeItR1G30uw8YxxtLLqEtsLOF9MHBZHXy/wB4yjIIwXYZ+Zs2p9bm/tu9gvtdv4PCI8R/Z7m+S/kUQwf2dE8S/aA26ONpSCWDDJblvmOQD3iivEdAkute1Pw3p761rUmhS3eqi1uIr6WKS8tY/L8otKrB3AJYK+ckAHPOT3/wmvLm98B2El9cS3M8ctzb+dMxd3WO4kjUsx5J2oMk8nrQB1ssiQxPJK6pGgLM7HAUDqSewrJ0PxRoGvzSxaFrmlanLEu6RLO7jmKDpkhScCpfFP8AyLGr/wDXnN/6Aa8N8GtqelxeBtR1l7aSR/Cy2vhyW2gMSNcPAjfZ7glmLSEImw5Ct8+FB4oA+haK+Yzr2sReE9WubTxRC16vh65lvYofEFxe3K3AVCshjMSC0dSWBQFeuMZXNb+ta1Lbtro8E+IdV1Hw8lrZHUL9L2S9NqzXIWZopGLbX8guzKvCYBABoA99qle6paWMrreSNBGkD3Mk8kbLBHGmNxeXGxcZzgsDgE4wDXiWo6yiW2sx6N4t/wCKVj1KyW3vr3V5/Kndo5DPbC/UvIifLE2/cQrEr3xWXqWoXmu+Gp7G3m1lrafwtrjLA+pSXQuJI5oxGySjaZk5IRmGWRsHIJyAfQovoTeRWyiZnliMyusLtFtBA/1gGwHkYUnJGSAQDVmvAdX1ue1trX/hXms3mox/8Ixf3CCLUJL/AP0hXthkB3bLoGbCnpnAHOC/VtYjj0nxYvgrxNqmo6PHo8Mr3h1GS5a2uzLgBJmYlXZMlkBAXA4GaAPe6K4PwdDLpPxB8Q6Il/qN3Yx6fY3iC+u5Llkld7hHKs5JAYRqdo4B6AV3lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLUtLs9Saza9h802dwt1B8xXZIoIDcHnhjweOaL7SrO+vtOvLqHzLnT5Wmtn3MPLdo2jY4Bwfldhznr64q7RQAUUUUAFFFFABRRRQAUUUUAUtb0qz1zSLzS9Uh8+xu4mhmi3Mu9CMEZUgj8DV2iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb is rotated 90&deg; to the other digits. Thus, abduction and adduction occur in a sagittal plane and flexion and extension occur in a coronal plane. Opposition, the action bringing the tip of the thumb in contact with the pads of the other fingers, is the most complex movement. The components of opposition are abduction and medial rotation at the carpometacarpal joint and flexion of the metacarpophalangeal joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_14_42223=[""].join("\n");
var outline_f41_14_42223=null;
